MicroRNAs regulatory networks in cardiotoxicity

Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie
vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät
der Universität Basel

Von

Caterina Vacchi-Suzzi

aus

Bologna (Italien)

Basel, 2012

Original document stored on the publication server of the University of Basel

edoc.unibas.ch

This work is licenced under the agreement „Attribution Non-Commercial No Derivatives –
2.5 Switzerland“. The complete text may be viewed here:
creativecommons.org/licenses/by-nc-nd/2.5/ch/deed.en
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt, Dr. Philippe Couttet and Prof. Witold Filipowicz.


__________________

Prof. Dr. Martin Spiess
Dekan
“Alle Ding' sind Gift, und nichts ohn' Gift;
allein die Dosis macht, daß ein Ding kein Gift ist“

“All things are poison, and nothing is without poison;
only the dose permits something not to be poisonous.”

(Paracelsus, ca. XVI Century)
Table of Contents

TABLE OF CONTENTS ..................................................................................1

LIST OF FIGURES ....................................................................................5

LIST OF SUPPLEMENTARY FIGURES .....................................................9

LIST OF TABLES .....................................................................................11

LIST OF SUPPLEMENTARY TABLES ....................................................11

FOREWORD ............................................................................................13

SUMMARY ...............................................................................................17

CHAPTER 1: LITERATURE REVIEW ON CARDIAC TOXICITY AND MICRORNAS ..........................................................19

1.1 DRUG DEVELOPMENT AND SAFETY ASSESSMENT .........................................................19

1.1.1 Impact of safety liabilities in drug development .................................................................19

1.1.2 Terminology and definitions in safety assessment ............................................................20

1.1.3 Impact of current strategies for organ toxicity assessment .................................................23

1.1.4 Additional Considerations ...............................................................................................25

1.2 DRUG-INDUCED CARDIAC LIABILITIES .......................................................................25

1.2.1 Common drug-induced cardiovascular safety concerns ......................................................25

1.2.2 Routine cardiac safety studies and regulatory guidelines ..................................................26

1.2.3 Impact and shortcomings of current pre-clinical cardiovascular safety strategy ................27

1.2.4 Reference compounds of cardiac toxicity .........................................................................28

1.2.5 Additional Considerations ...............................................................................................29

1.3 IMPACT OF TRANSCRIPTOMICS IN DRUG SAFETY ASSESSMENT AND BIOMARKER DISCOVERY ..................................................30

1.3.1 Impact of toxicogenomics in drug safety assessment .........................................................30

1.3.2 Experimental approach of genomics studies for organ toxicity assessment ......................31

1.3.3 Data analysis strategy depends on the goal of toxicogenomics studies ...............................31

1.3.4 Toxicogenomics in biomarker discovery ..........................................................................32
CHAPTER 2: PERTURBATION OF MICRO-RNAs IN RAT HEART DURING CHRONIC DOXORUBICIN TREATMENT

2.1 ABSTRACT

2.2 INTRODUCTION

2.3 MATERIALS AND METHODS

2.3.1 Rat in vivo study and histopathology evaluation
2.3.2 Heart tissue RNA extraction ........................................................................................................... 69
2.3.3 Gene expression profiling and analysis ............................................................................................ 69
2.3.4 Amplification of microRNAs via quantitative PCR ........................................................................... 70
2.3.5 Data Analysis .................................................................................................................................... 70
2.3.6 Cell culture and DOX treatment ..................................................................................................... 71
2.3.7 MicroRNA target luciferase reporter assay ..................................................................................... 71
2.3.8 Transfection of HEK 293 .............................................................................................................. 72

2.4 RESULTS ........................................................................................................................................... 72

2.4.1 Doxorubicin induced cytoplasm vacuolation and dysregulation of tissue genomic cardiomyopathy indicators ........................................................................................................................................... 72
2.4.2 Perturbation of rat heart microRNAs during chronic DOX treatment ............................................. 75
2.4.3 MiR-367, miR-215, miR-216b, miR-208b and miR-34c are specifically dysregulated by chronic DOX treatment ........................................................................................................................................ 76
2.4.4 DOX induced up-regulation of miR-216b and miR-367 earlier than tissue lesions as observed by histopathology ........................................................................................................................................ 79
2.4.5 MiR-34c regulates Sipa1 mRNA at the post-transcriptional level and is involved in autophagy process ........................................................................................................................................ 80

2.5 DISCUSSION ..................................................................................................................................... 84

2.6 SUPPLEMENTARY MATERIAL AND METHODS ............................................................................. 88

2.6.1 Histopathology investigations of the heart ...................................................................................... 89
2.6.2 Murine Sipa1 3’-UTR region cloned for reporter assay .................................................................. 89
2.6.3 Murine Tnnt3k 3’-UTR region cloned for reporter assay ................................................................. 90

2.7 SUPPLEMENTARY RESULTS ......................................................................................................... 90

2.7.1 Body and organ weight .................................................................................................................. 90
2.7.2 Hematology and clinical chemistry ................................................................................................ 91
2.7.3 Histopathology scores of cytoplasmic vacuolation in the heart .................................................... 91
2.7.4 Putative targets of microRNAs responding to high dose DOX at 4 weeks ................................. 94
2.7.5 Bias in indexed NGS microRNAs profiling ................................................................................... 97
2.7.6 Effect of DOX 2mg/kg/week and its combination with antidote DZR on microRNAs related to cardiac diseases after 6 weeks ................................................................................................. 100
2.7.7 Early changes in gene expression suggest both structural and functional damage are induced by DOX ........................................................................................................................................ 102
2.7.8 DOX induces expression of anti-tumoral microRNAs .................................................................. 104

CHAPTER 3: HEART STRUCTURE-SPECIFIC GENE EXPRESSION (TRANSCRIPTOMIC) PROFILING REVEALS CONSERVED
MICRORNA-MRNA INTERACTIONS RELEVANT TO CARDIAC PHYSIOLOGY AND FUNCTION

3.1 ABSTRACT

3.2 INTRODUCTION

3.3 MATERIAL AND METHODS

3.3.1 Experimental strategy

3.3.2 Heart tissue dissection

3.3.3 RNA isolation

3.3.4 Gene expression profiling

3.3.5 MicroRNA Next Generation Sequencing

3.3.6 TLDA qPCR

3.3.7 Localization of microRNAs via ISH

3.3.8 Data analysis of gene expression profiles and microRNAs sequencing

3.3.9 Cell culture, transfection and reporter assay

3.4 RESULTS

3.4.1 MicroRNA profiles separate the different structures of the heart as efficiently as mRNAs

3.4.2 Conserved structure-enriched microRNAs and mRNAs across species

3.4.3 Confirmation of microRNAs distribution by in situ hybridization

3.4.4 Integration of gene expression and microRNA profiles at the steady state

3.5 DISCUSSION

3.6 SUPPLEMENTARY MATERIAL AND METHODS

3.6.1 In situ hybridization

3.6.2 Cloned regions of Timp3, Rbm24, Rbm38, Akap2, Tgfbr2 and Csnk2a2

CHAPTER 4: CONCLUDING DISCUSSION

4.1 BRIEF SUMMARY OF RESULTS

4.2 MICRO RNAs TOXICITY/PHARMACODYNAMICS INDICATORS IN THE TISSUE

4.3 HETEROGENEITY OF HEART TISSUE AND CROSS-SPECIES HEART ATLAS

4.4 CARDIAC MICRO RNAs-mRNAs REGULATORY CIRCUITS AND PATHWAYS

4.4.1 Effect of DOX on cardiac remodeling in vivo

4.4.2 Anti-correlation of microRNAs with target mRNAs at the steady state
CHAPTER 5: FINAL REMARKS AND FUTURE DIRECTIONS......155

5.1 MICRO RNAs AS “EARLY” BIOMARKERS OF TOXICITY IN THE TISSUE ......155

5.2 MICRO RNAs AS SOURCE OF CIRCULATING BIOMARKERS OF TISSUE LESIONS ..................................................................................................................155

5.3 NON-CANONICAL REGULATORY CIRCUITS AND TRANSCRIPTIONAL REGULATION OF MICRO RNAs ..........................................................................................................................156

REFERENCE LIST ..........................................................................................................................157

List of Figures

Figure 1-1: Reasons for drug attrition in 1991 and 2000. Rising safety concerns increased the number of drugs withdrawn from market or discontinued (Laverty et al., 2011). Modified from (Kola and Landis, 2004) ............................................................................................................................................................................................................................................19

Figure 1-2: Dose escalation according to NOEL, NOAEL, and LOAEL. Doses used in a toxicity study should be chosen accordingly to observe no effects, no adverse effects, and some adverse effects. NOEL: no effect level; NOAEL: No Adverse Effect Level; LOAEL: lowest observed adverse effect level. Increasing the dose of a substance adverse effects are found. ..................................................................................................................................................................................................................................................23

Figure 1-3: Crucial signaling pathways in the heart and consequences of their activation or inhibition (Force and Kolaja, 2011). Kinases are circled in light yellow ovals. ............................................................................................................................................................................................................................................29

Figure 1-4: Experimental process of Gene Chip hybridization experiments for gene expression determination (Butte, 2002) .........................................................................................................................................................................................................................30

Figure 1-5: MicroRNAs biogenesis. Adapted from (Krol et al., 2010) ..........................................................................................................................35

Figure 1-6: Mechanisms for microRNAs-mediated post-transcriptional activation (Vasudevan, 2011) ..................................................................................................................................................................................................................................................41

Figure 1-7: MicroRNAs detection. Schemes of three kinds of RT-PCR methods: Primer extension (A), stem-loop primer (B), and 3’ adapter ligation (C). Solid-phase amplification of Illumina small RNA libraries (D). Adapted from (Huang et al., 2011) ..................................................................................................................................................................................................................................................44
Figure 1-8: Sensitivity of Taqman single assay RT and qPCR on miR-322 length variants. Shorter microRNAs variant may not be efficiently reverse transcribed by a single microRNAs specific RT primer.

Figure 1-9: Functional role of microRNAs in normal and diseased heart. MicroRNAs are depicted as bulged red ribbons. Arrows indicated activation, while blunted lines indicate inhibition of the downstream elements. Cardiomyocytes and fibroblasts are represented. Adapted from (Small and Olson, 2011).

Figure 1-10: MicroRNAs and genes implicated in cardiac diseases. Different cell types involved in cardiac remodeling are indicated: cardiomyocytes (squared red), fibroblasts (speared beige), and endothelial cells (small pink). Adapted from (Latronico and Condorelli, 2009).

Figure 1-11: MicroRNA-related networks of cytochrome P450 and nuclear receptors (Yokoi and Nakajima 2011).

Figure 1-12: Circulating microRNAs. Mechanisms protecting microRNAs from degradation. EC indicates endothelial cells; HDL, high-density lipoprotein; NPM-1, nucleophosmin-1; SRB1, scavenger receptor class B member 1; BHK, baby hamster kidney (Fichtlscherer et al., 2011).

Figure 2-1: Study design and representative micrograph showing DOX-related vacuolation in the myocardium. (A) Six adult male rats were injected with the indicated doses of vehicle, doxorubicin (DOX), dexrazoxane (DZR), etoposide (EPS) or a combination of DOX and DZR for 2, 4 or 6 weeks. Cardiac tissue was excised and deep frozen for gene expression and microRNA profiling experiments. A representative micrograph of a toluidine blue stained myocardial section of a control (B) and of a DOX treated animal (C). Black arrows indicate sarcoplasmic micro- and macro-vacuolation of cardiomyocytes.

Figure 2-2: DOX 3mg/kg/week altered levels of genomic cardiomyopathy indicators (Ankrd/Carp, Nppb, Myh7 and Myh6). Expression fold change relative to vehicle were represented for DOX 3 mg/kg/week at 2, 4 and 6 weeks time point (n= 6) for (A) Ankrd/Carp, (B) Nppb, (C) Myh7 and (D) Myh6. For each time point and each probe set, vehicle values were averaged and normalized to 1. The same correction was applied to the DOX treated values. Affymetrix probe-set number is indicated in brackets. Error bars represent standard deviation. T-test was performed for vehicle-vs. DOX-treated at each time point. *P<0.05, **P<0.01, ***P<0.005, NS=Non-Significant. (No t-test for #, as n=2).
Figure 2-3: Relative quantification of DOX-responder microRNAs in rat heart across all groups. Relative quantification of (A) miR-208b, (B) miR-215, (C) miR-216b, (D) miR-367 and (E) miR-34c in DOX, DOX + DZR, EPS groups, normalized versus vehicle treated animals. Expression levels were measured by single assay qPCR (n= 3, except #, n= 2). DOX: Doxorubicin, DZR: dexrazoxane, EPS: etoposide; numbers indicate the weekly dose of each compound in mg/kg/week. Empty spaces represent non-sampled animals. The vehicle treated is the first column of each time-point. The animals used in this experiment were distinct from the ones represented in Table 2-1. Error bars represent SD. T-test results are indicated by asterisks for significant DOX-treated groups vs. their own vehicle-treated, unless otherwise specified by horizontal range bars; *P<0.05, **P<0.01, ***P<0.005, NS=Non-Significant).

Figure 2-4: DOX-induced upregulation of miR-216 and miR-367 expression precedes the detection of overt histopathological lesions in cardiac tissue. Blue bars show cumulative vacuolation grade. X axis shows the DOX regimen in mg/kg/week received by the animals at 2 weeks. Y axes report cumulative histopathological scores and microRNA fold change vs. untreated cardiac tissues (normalized at value 1). Path grading = cumulative vacuolation score. FC= fold change. SEM= standard error on the mean.

Figure 2-5: miR-34c directly controls DOX-induced Sipa1 mRNA decrease. (A) Sipa1 mRNA raw expression values decreased in the heart of rats treated with DOX. #, n= 2. (B) DOX treatment for 24h caused a decrease of Sipa1 mRNA and an increase of miR-34c in cardiac myoblast cells (H9c2). (C) H9c2 endogenous Sipa1 mRNA was decreased by transfection of miR-34c mimic, and increased using a miR-34c hairpin inhibitor (HI). Transfection with miR-34c mimic and inhibitor respectively exacerbated and rescued Sipa1 mRNA levels in H9c2 treated with DOX 0.1 and 1µM overnight in comparison to negative controls. (D) Alignment of mammalian miR-34 family. Capital letters indicate mismatch in the sequence. Sipa1 3’-UTR wt and MUT construct: 12 nt surrounding the predicted seed are shown. HEK 293 cells were co-transfected with pmiR-GLO-Sipa1 and the indicated miRNA mimic or a C. elegans negative control mimic. Averaged and normalized Renilla luciferase signal was obtained from 3 independent experiments, each run in quadruplicate. Y axis represents percentual residual luciferase activity in the indicated conditions. Mutant 3’ UTR restores luciferase activity in Sipa1/miR-34c. *P<0.05, **P<0.01, ***P<0.005.
Figure 2-6: Ambra1 expression was induced by DOX treatment in vivo and miR-34c could control its endogenous expression levels in H9c2 cardiac myoblasts. (A) Fold change of Ambra1 probe set in rat heart tissue treated with DOX. Fold change and statistical significance were assessed vs. each vehicle group. n= 4 to 6 (except #, n= 2) (B) Endogenous levels of Ambra1 were measured after miR-34c over-expression (miR-34c mimic) or inhibition (miR-34c HI) in absence of presence of DOX 0.1. Fold change value were normalized vs. the respective negative transfection controls in the untreated condition (n=3). *P<0.05, **P<0.01, ***P<0.005. FC= fold change...

Figure 3-1: Cross-species microRNA/mRNA cardiac atlas. Data sets obtained for rat, dog and/or Cynomolgus monkey are indicated. Inset: a magnified depiction of a papillary muscle...

Figure 3-2: Distribution of microRNAs in rat cardiac structures. (A) Cardiac samples are grouped according to the structure using microRNAs signatures (top 10%) in a hierarchical Euclidean-linkage clustering. (B-C) cardiac structures are separated by microRNAs and mRNA distribution in a principal component analysis. Red circles: myocardial tissue (apex, left and right ventricle, septum, papillary muscle). Blue circles: left and right atrium. Grey circles: cardiac valves. A, apex. LA, left atrium. LV, left ventricle. PM, papillary muscle. RA, right atrium. RV, right ventricle. S, septum. V, valves...

Figure 3-3: Number of microRNAs (A) and mRNAs (B) preferentially expressed in cardiac valves or myocardium across species. Myocardium includes apex, ventricles, septum and papillary muscles. Fold change thresholds were >= 2 for microRNAs in (A), and >=5 from mRNAs in (B).

Figure 3-4: Distribution of miR-1, miR-125b-5p, miR-204 and miR-208b in the cardiac structures. Axes represent fold change vs. apex. A, apex; LA, left atrium; LV, left ventricle; PM, papillary muscle; RA, right atrium; RV, right ventricle; S, septum; V, valve.

Figure 3-5: Localization of miR-204, miR-125b-5p and miR-1 in rat heart. MiR-204 in valves (A-B) and myocardium (C). MiR-125b-5p in valves (D-E) and myocardium (F). MiR-1 in valves (G-H) and myocardium (I). Bar = 50 µm.

Figure 3-6: Rat cardiac disease relevant genes are negatively correlated with putative targeting microRNA. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green
curve represents log2 normalized intensity for the indicated probe set. Black curve represents log2 scaled and normalized microRNA read counts. Three replicates are plotted for each structure...122

Figure 3-7: Anti-correlated microRNA targets are directly inhibited by microRNA over expression. (A-D) Endogenous expression of Timp3, Rbm24, Tgfb2 and Csnk2a2 genes is monitored upon transfection of mimics for miR-1, miR-125b-5p, miR-204, miR-499 and miR-208b in HPASMC cells (A-D). Corresponding luciferase reporter vector are assayed for susceptibility to putative targeting microRNAs, via co-transfection of reporter vectors of interest with the paired microRNA (E-H)...124

Figure 4-1: Percentual representation of selected gene lists in 8 cardiac structures of the heart. LA=left atrium, RA= right atrium. Six gene lists were manually curated and contained in total 222 Affymetrix probe sets...152

Figure 5-1: microRNAs may be earlier predictors of gene expression in toxicogenomics evaluation of drug-induced tissue injury. ..........................156

List of Supplementary Figures

Supplementary figure 2-1: MicroRNA-208a and 208b are regulated similarly as their hosting transcripts upon DOX treatment (Myh6 and Myh7 respectively) (n= 3). (A) Myh6 and miR.208a and (B) Myh7 and miR-208b fold changes vs. control in DOX 3mg/kg/week treated animals........92

Supplementary figure 2-2. Single assay validation of TLDA data. Ten microRNAs among the DOX 3 mg/kg/week 4 weeks dysregulated microRNAs were assayed in the remaining 3 animal tissues at the same dose and in 3 animals for each indicated dose and timepoint (2 and 3 mg/kg for 2 and 4 weeks). All except miR-709 and miR-692 confirmed the trends observed with the LDA-qPCR technique. Fold changes for the given doses are indicated vs. untreated animals. (A) miR-208b. (B) miR-215. (C) miR-216b. (D) miR-218-2*. (E) miR-34c. (F) miR-367. (G) miR-383. (H) miR-692. (I) miR-708. (J) miR-709. ........................................93

Supplementary figure 2-3: Next generation sequencing library with 5’ adapters indexed at their 3’ end. Sequential ligation at the 3’ (green) and the indexed 5’ (pink and grey) adapters to small RNAs (blue) is followed by library reverse transcription and PCR amplification. Only the products
running at 123 nt (red box) are excised from polyacrylamide gel in order to avoid primers duplexes and unspecific PCR products.

Supplementary figure 2-4: Sequenced libraries cluster according to the index sequence (symbols) and not by condition (colors) when adapter indexing is proximal to ligation site.

Supplementary figure 2-5: Variation of levels of microRNAs implicated in cardiac diseases in the heart tissue of rats after a 6 weeks treatment with DOX 2 mg/kg/week alone, or in combination with DZR. Fold change vs. vehicle is indicated for individual animals (n=6). Stars indicate statistical significance vs. vehicle, or otherwise indicated. *P<0.05, **P<0.01, ***P<0.005 (n=6).

Supplementary figure 2-6: Treatment with DOX alters the expression of genes involved in several cellular processes, critical to cardiac function. Fold change is represented by the ratio between averaged DOX vs. vehicle-treated signal intensity values for each probe-set, obtained by microarray genomic profiles. Error bars represent standard deviation. *P<0.05, **P<0.01, ***P<0.005 (n=6).

Supplementary figure 3-1: Cardiac structures are similarly clustered by microRNA and mRNA profiles of dog (A) and Cynomolgus (B), accordingly to their histological characteristics. Red circles: myocardial tissue (apex, left and right ventricle, septum, papillary muscle). Blue circles: left and right atrium. Grey circles: cardiac valves. A, apex. LA, left atrium. LV, left ventricle. PM, papillary muscle. RA, right atrium. RV, right ventricle. S, septum. V, valve.

Supplementary figure 3-2: Correlation of 4 cardiac disease relevant genes with putative targeting microRNA in canine. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 normalized intensity for the indicated probe set. Black curve represents log2 scaled and normalized microRNA read counts. Three replicates are plotted for each structure.

Supplementary figure 3-3: Correlation 4 cardiac disease relevant genes with putative targeting microRNA in Cyno monkey. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 normalized intensity for the indicated probe set. Black curve represents log2 scaled and normalized microRNA read counts. Three replicates are plotted for each structure.
Supplementary figure 3-4: Robustness of microRNA seq and validation with qPCR. Data obtained with miRNAs eq or TLDA cards are compared for each rat cardiac sample. \( r_s \) = Spearman’s rank correlation, \( r \) = Pearson’s correlation.


Supplementary figure 3-6: Gene ontology analysis of all Targetscan putative targets of structure enriched conserved microRNA targets. Targets of conserved myocardial enriched microRNAs (A). Targets of conserved valves enriched microRNAs (B).

Supplementary figure 3-7: Cloning of 3’ UTRs of Timp3, Csnk2a2, Rbm24, Rbm38, Tgfbr2 and Akap2 in pmiR-GLO. Yellow arrows indicate ORFs. Grey arrows identify the region surrounding the microRNA Targetscan targeting site cloned in pmiR-GLO.

List of Tables

Table 1-1: Drug safety impact by target organ. .........................................................24

Table 1-2: List of in silico microRNAs target prediction tools. (Yokoi and Nakajima, 2011) ..................................................................................................................38

Table 1-3: MicroRNAs detection platforms. AQ: absolute quantification; RQ: relative quantification .................................................................................................43

Table 1-4: microRNAs and toxicology. (↑) up-regulation; (↓) down-regulation. (Lema and Cunningham 2010) ..........................................................................................52

Table 1-5: Circulating microRNAs in patients with cardiac disease, adapted from (Fichtlscherer et al. 2011). AMI: acute myocardial infarction; ACS: acute coronary disease; CHF: congestive heart failure; HF: heart failure. .....61

Table 2-1: Chronic DOX treatment (3 mg/kg/ week) alters levels of 25 microRNAs from week 2 onwards .................................................................................................75

List of Supplementary Tables
Supplementary table 2-1: Doxorubicin study design in rats........................................88

Supplementary table 2-2: Atrial and ventricular vacuolation incidence increases with doses of DOX. Microscopic histopathological findings. Severity of lesion is graded by numbers. Low= 1mg/kg/week regimen; Mid= 2 mg/kg/week regimen; High= 3 mg/kg/week regimen .........................91

Supplementary table 2-3: Number of Microcosm predicted targets of 16 out of 25 microRNAs, responding to DOX 3 mg/kg/week after 4 weeks .........................94

Supplementary table 2-4: Barcoded adapters used in preliminary sequencing experiment ..................................................99

Supplementary table 2-5: Literature available on DOX dysregulated microRNAs. When information was available only for the other arm of the microRNAs the mature miRNA name is in bold .................................................104

Supplementary table 3-1: LNA probe hybridization conditions .................................130

Supplementary table 3-2: Rat cardiac structure enriched microRNAs ..................135

Supplementary table 3-3: Monkey cardiac structure enriched microRNAs ........137

Supplementary table 3-4: Canine cardiac structure enriched microRNAs ........140

Supplementary table 3-5: Normalized miRNA seq reads for mir-1, miR-125b-5p, miR-204 and miR-208b in rat myocardium or valves .........................142
Foreword

This thesis work summarizes the main findings I obtained during the last 3 and half years (October 2008 to now), working in the laboratory of Genome Biology of the Discovery and Investigative Safety in the Pre-Clinical Safety department of NIBR. Our section is particularly interested in all aspects of molecular toxicology, in order to better define the safety profiles of drugs before clinical testing. Our department aims at elucidating the mechanisms of drug toxicity, predicting the impact on human subjects, and suggesting translatable safety indicators to monitor the toxic effects in the clinic.

We chose to start working on microRNAs since no previous work specifically covered their role in drug-induced cardiac toxicity, and because of the proven impact of disturbances in microRNAs homeostasis on cardiac physiology.

The main findings were arranged in 2 manuscripts, each covered in the central chapters of this thesis. Chapter 2 illustrates an example of drug-induced cardiac injury, and its impact on expression of microRNAs in rats’ hearts. This manuscript has been submitted to PLoS ONE, and we are currently responding to the reviewers’ questions. At the moment, we are running a few more functional experiments in cardiac myoblasts, and we could not fully incorporate these results in this thesis. Chapter 3 will describe an approach to determine the distribution of mRNAs and microRNAs in different cardiac structures in rat, dog and Cynomolgus monkey, since these are the most used model species in pharmaceutical research, and are still poorly annotated for mRNAs and microRNAs distribution. This manuscript will be submitted in the course of the next days to PLoS Genetics.

Importantly, only the material that was considered sensible for complete publication in peer reviewed journals will be reported in this thesis. With a few exceptions in Chapter 2, techniques validation, incomplete or inconclusive data
will not be shown. This is in line with the guidelines of the University of Basel that accepts “compilative” PhD thesis essentially composed of submitted/accepted manuscripts.

As for every PhD, there are many people whose contributions have been crucial throughout my time in Novartis and that have to be acknowledged here. From the professional side I would like to thank at first Philippe Couttet. As my direct mentor and thesis supervisor he constantly challenged me to develop a critical opinion, always made the time to discuss with me and kept the projects on track. I would also like to thank Olivier Grenet and Jonathan Moggs, who kept a careful eye on the quality of the science and provided strategic steering at all times. My gratitude also goes to Prof. Alex Odermatt for the great exchange of scientific ideas, and also for his impeccable supervision in going through all grad school requirements at the University of Basel.

The most special thanks go to Estelle Marrer, who devoted her personal commitment to this thesis and greatly contributed to the accomplishments obtained in the course of my PhD.

A great “thank you” goes of course to my colleagues from the lab: Magali, Gregory, Sarah, Tulipan and especially Manuela from whom I learnt a lot of tricks that have made my life much easier.

Particular thanks go to Yasmina Bauer, Chiara Buono-Dalton, André Cordier, Valerie Dubost, Bérengère Dumotier, Florian Hahne, Pierre Moulin and Philippe Scheubel, who contributed with their life-long experience on special topics. All the present and past members of the Molecular Toxicology and Molecular Pathology section deserve my special gratitude, as everyone contributed with precious advices and made the time to sit with me throughout the years.

My best acknowledgments go to all co-authors of my two manuscripts: in alphabetical Brian Berridge, Sandrine Bongiovanni, Kevin Gerrish, Hisham Hamadeh, Martin Letzkus, Jon Lyon, Ric Paules, François Pognan, Frank
Staedtler, Martin Vidgeon-Hart contributed to the DOX study manuscript, while Stine Büchmann-Møller, Moritz Frei, Nicole Cheung, Edward Oakeley, Armelle Grevot, Hilde Theil, Magdalena Kalteis, Mark Deurinck, Catherine Boeglen, Robert Stull, Christopher De Benedetto contributed to the cross-species heart atlas project. It was a pleasure to work with all of you, and you commitment to make every project perfect has been refreshing in many occasions.

My thanks also go to Stefan Grzybek, who has dedicated himself to giving a twist to the project, and it is just due to practical choices that his great work is not featured in this thesis. He is definitely a very dedicated and brilliant scientist. I really appreciated working with him.

Great gratitude for impeccable samples logistics goes to Mario Muller, without whom we could not have even started working.

I would like to acknowledge Witek Filipowicz who has made the time to read and correct my thesis despite being in one of the busiest times of his long and inspiring career.

The endeavor of getting a PhD done directly stems from people’s innermost motivations and is indeed a very personal matter. Therefore I was extremely lucky to have at my side Eden, who firmly stood by me when I mostly needed him and patiently carried the burden of an unpredictable life apart from each other for almost 4 years. Without him I would not have made it!

I am feeling incredibly lucky and grateful to my family back in Italy, who has steadily supported me without hesitations in any circumstance.

My deepest respect goes to the lunch/Italian crew and my fellow PhD and post docs here in Novartis: Diego, Davide, Harri, Elaine and Aida. Also, I cannot miss to acknowledge the “involuntary” support I received from my flat mates, Melanie, Sean and of course Chiara. We had long conversations that helped steam out some everyday stress and led to unforgettable moments. With you I shared many chips of life and I hope to have established a lifelong friendship.
Last but not least, I owe a great lot to my fabulous chiropractor Marie Claude. She was always ready to listen and shared many valuable advices and points of view accumulated during her challenging life.

Lastly, thanks to all of those who believed in me and gave me the extra encouragement when I most needed it: this is the product of your contribution and you must be very proud for making all this happen.
**Summary**

A long time and many steps are needed to bring valuable drugs to patients. Drugs not only have to be effective against the disease which they are intended for, but also safe. All drugs cause toxic effects in proportion to the dose (Paracelsus, ca. XVI cent.). Therefore, assessing carefully the optimal dose at the desired benefit/risk ratio (Stevens and Baker, 2009) and characterizing mechanisms of toxicity are essential for maintaining high safety standards. The experimental strategies used to predict drugs’ adverse events are many, and include the use of non-invasive biomarkers that can ideally be translated from test species to humans. In particular, cardiac safety requires special attentions, as it causes the cessation of drug development in over the 30% of cases due to toxic liabilities in Phase III, and over 40% post-approval (Redfern *et al.*, 2011).

In 1993 Victor Ambros, Rosalind Lee and Rhonda Feinbaum (*Lee et al.*, 1993) described for the first time in *C. elegans* the role of short non-coding RNAs, called microRNAs. MicroRNAs pair with target mRNAs via sequence complementarity, and lead to mRNA degradation or translation inhibition (*Filipowicz et al.*, 2008; *Guo et al.*, 2010). MicroRNAs are implicated in many biological processes and in the evolution of the complexity of superior organisms, for review see (Bartel, 2004; Berezikov, 2011). Their role in cardiovascular development and diseases has been supported by an increasing number of publications, for review see (*Kinet et al.*, 2012; *Small and Olson*, 2011). Recently, tissue-specific microRNAs were found in a variety of body fluids following drug-induced tissue injury (*Wang et al.*, 2009). In particular, myocardial necrosis of different etiologies (such as acute coronary syndrome and myocardial infarction) caused an increase of heart enriched microRNAs in plasma/serum of patients, as reviewed by (*McManus and Ambros*, 2011).
This work is aimed at increasing our knowledge about cardiac microRNAs function in different toxicological contexts and across species.

Chapter 1 will give an overview of drug safety assessment focusing on the cardiovascular system, microRNAs biology and their potential as toxicity biomarkers.

In Chapter 2 I will illustrate an example of drug-induced cardiac injury, and its impact on expression of microRNAs in rats’ hearts. Chronic treatment of rats with low amounts of doxorubicin (an anti-tumoral compound) caused myocardial vacuolation in ventricular tissue and a significant increase of specific microRNAs and genomic indicators of cardiomyopathy. We found that Sipa1 could be directly inhibited by miR-34c by using a luciferase assay. Notably, the phenotypic anchoring of microRNAs with histopathological read-outs in the tissue showed that over-expression of miR-216b in the heart preceded the rise of overt lesions.

Chapter 3 will describe an approach to determine the distribution of mRNAs and microRNAs in different cardiac structures in rat, dog and Cynomolgus monkey. We showed that microRNAs could discriminate the different heart structures as good as mRNAs. We also assessed the expected anti-correlation between microRNAs levels and their predicted target mRNAs, and showed that mRNAs of 4 genes implicated in cardiac diseases and muscular development could be inhibited at the post-transcriptional level by 4 distinct microRNAs. We propose that our mRNAs and microRNAs data sets could be used to assess the human relevance of preclinical findings in these 3 species, and to derive potential tissue and circulating biomarkers for drug-induced cardiac injury.

In conclusion, profiling microRNAs have the potential to help biomedical research in bringing drugs to patients, since they can shed light on toxicity mechanisms in the tissues (Taylor and Gant, 2008) and are a source of translatable non-invasive toxicity biomarkers in body fluids.
Chapter 1: Literature review on cardiac toxicity and microRNAs

1.1 Drug development and safety assessment

1.1.1 Impact of safety liabilities in drug development

The rise of safety concerns for patients in the past 10 years increased the attrition rate due to organ toxicity in drug development (Figure 1-1), and today between 25 and 30% of the causes of attrition can be attributed to pre-clinical and clinical toxicity (adverse drug reactions) (Guengerich, 2011).

![Figure 1-1: Reasons for drug attrition in 1991 and 2000. Rising safety concerns increased the number of drugs withdrawn from market or discontinued (Laverty et al., 2011). Modified from (Kola and Landis, 2004).](image)

Safety aspects contribute to decisions during the whole pharmaceutical R&D: from target characterization, to candidate and back-up compounds selection, lead optimization, pre-clinical and clinical phases. Pre-clinical and clinical tests are aimed at balancing predicted risk against expected benefit, and are tightly interconnected.
During all drug development pre-clinical findings influence clinical development and vice versa: animal studies are run after first-in-human stage, to better understand the toxic mechanisms observed, and to mitigate risks. Mandatory pre-clinical safety tests include genotoxicity (mainly in vitro), core safety pharmacology (SP) studies (in vivo cardiovascular SP, in vitro cardiac SP, respiratory SP and central nervous system SP) (Gad, 2008), and repeated dose in vivo toxicity studies. Animal studies that run in parallel with clinical phases include: repeated dose (13-26 weeks), in vivo genotoxicity, reproductive toxicity (segments I, II and III), immunotoxicity and carcinogenicity (2 years).

Factors influencing the definition of safety margins include the indication of the drug, foreseen co-medications and co-morbidities and relevance of the pre-clinical species used, among others. Integrated risk assessment and evaluation of pre-clinical safety profile are strategic elements for taking successful go/no-go decisions.

1.1.2 Terminology and definitions in safety assessment

1.1.2.1 Safety Biomarker

The term “biomarker” has several definitions, depending on the field of use. A drug safety biomarker is an objectively measured parameter that indicates whether a biological process is normal or pathological in response to a therapeutic intervention (Biomarkers Definitions Working Group, 2001).

Regulatory authorities require biomarkers to be:

− Validated, which includes establishing characteristics of the analytical assay, such as accuracy, precision, limit of quantification (LOQ), stability of analyte (Lee et al., 2006).

− Qualified, which includes establishing the physiological, toxicological, pharmacological or clinical significance (Goodsaid and Frueh, 2007).
Ideally, biomarkers developed at the pre-clinical stage should be translatable for human use.

1.1.2.2 Adverse effect

An adverse effect is a harmful and undesired effect resulting from a medication.

1.1.2.3 Toxicity endpoints

A toxic endpoint is a parameter monitored during an *in vivo* study in animal or human, that reflects the toxicity of a compound. Data on endpoints are used to determine the No Observed Adverse Effect Level (NOAEL) and the Lowest Observed Adverse Effect Level (LOAEL). Toxic endpoints include, (but are not limited to):

- In life changes: food/water consumption, weight gain, behavior, reproductive rate, etc.
- Primary immunotoxicity: leukocytes count, hematology, coagulation, globulin and albumin levels, gross evaluation of thymus and spleen, etc.
- Histopathology: macroscopic and microscopic alteration of tissues and cells
- Gene expression changes: transcriptomics and proteomics in affected organs
- Metabolic changes: metabolomics and clinical chemistry
- Organ and tissue function: imaging techniques, hemodynamic, metabolic circulating markers
- Clinical chemistry biomarkers: circulating tissue injury indicators

Endpoints can be validated and qualified to become biomarkers.

1.1.2.4 Adverse vs. non adverse effect

When differences in selected endpoints are observed in a treatment group it is necessary to determine whether these a) are treatment related, and b) they are adverse.
Discriminating factors a):
- There is no obvious dose response
- Findings encountered in “outlier” animals
- Measurement of selected endpoint are inherently imprecise
- Values measured are within normal biological variation (historical control data)
- Lack of biological plausibility

Discriminating factors b)
- There is no alteration in the general function of the test organism or of the organ/tissue tested
- Secondary to other adverse effects
- Adaptive response
- Transient
- Limited severity (magnitude of change)
- Effect is isolated or independent and/or is not a precursor of changes known to progress and establish adverse effects
- A consequence of the experimental model

1.1.2.5 NOAEL: No Observed Adverse Effect Level

The highest exposure level at which there is no statistically significant increases in the frequency or severity of adverse effect between the exposed population and its appropriate control. Some effects may be produced at this level, but they are not considered to be adverse or precursors to adverse effects (Figure 1-2).

1.1.2.6 LOAEL: Lowest Observed Adverse Effect Level

The lowest exposure level at which there is a statistically or biologically significant increase in the frequency or severity of adverse effects between the exposed population and its appropriate control (Figure 1-2).
1.1.2.7 **MTD: Maximum Tolerated Dose**

The highest dose of a pharmacological treatment that will produce the desired effect without unacceptable toxicity (lethality is never an intended endpoint).

![Dose escalation graph](image)

**Figure 1-2**: Dose escalation according to NOEL, NOAEL, and LOAEL. Doses used in a toxicity study should be chosen accordingly to observe no effects, no adverse effects, and some adverse effects. NOEL: no effect level; NOAEL: No Adverse Effect Level; LOAEL: lowest observed adverse effect level.

1.1.3 **Impact of current strategies for organ toxicity assessment**

Hepatic, neurological and cardiovascular adverse drug reactions rank in the top positions of reasons for development interruption or withdrawal due to toxicity, especially during the clinical phase as shown in Table 1-1 (Hamadeh et al., 2002; Redfern et al., 2011; Stummann et al., 2009). It has been proposed that implementation of more predictive tests of liabilities in these organs already in the earliest research phases would significantly lessen the overall compound attrition due to toxicity concerns (Stevens and Baker, 2009).
Table 1-1: Drug safety impact by target organ.

<table>
<thead>
<tr>
<th>Phase</th>
<th>‘Nonclinical’</th>
<th>Phase I</th>
<th>Phase III</th>
<th>Phase III/Approval</th>
<th>Post-Approval</th>
<th>Post-Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information:</td>
<td>Causes of abortion</td>
<td>Serious ADRs</td>
<td>Causes of abortion</td>
<td>ADRs on label</td>
<td>Serious ADRs</td>
<td>Withdrawal from sale</td>
</tr>
<tr>
<td>Sample size</td>
<td>80 CDs stopped</td>
<td>1,015 subjects</td>
<td>82 CDs stopped</td>
<td>1,138 drugs</td>
<td>21,298 patients</td>
<td>47 drugs</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>27%</td>
<td>9%</td>
<td>21%</td>
<td>36%</td>
<td>15%</td>
<td>45%</td>
</tr>
<tr>
<td>Hepatotoxicity</td>
<td>8%</td>
<td>7%</td>
<td>21%</td>
<td>13%</td>
<td>0%</td>
<td>32%</td>
</tr>
<tr>
<td>Haematology/BMT</td>
<td>7%</td>
<td>2%</td>
<td>4%</td>
<td>16%</td>
<td>10%</td>
<td>9%</td>
</tr>
<tr>
<td>Nervous system</td>
<td>14%</td>
<td>28%</td>
<td>21%</td>
<td>67%</td>
<td>39%</td>
<td>2%</td>
</tr>
<tr>
<td>Immunotoxic; photosensitivity</td>
<td>7%</td>
<td>16%</td>
<td>11%</td>
<td>25%</td>
<td>34%</td>
<td>2%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>3%</td>
<td>23%</td>
<td>5%</td>
<td>67%</td>
<td>14%</td>
<td>2%</td>
</tr>
<tr>
<td>Reprotox</td>
<td>13%</td>
<td>0%</td>
<td>1%</td>
<td>10%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>4%</td>
<td>0%</td>
<td>1%</td>
<td>28%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Respiratory</td>
<td>2%</td>
<td>0%</td>
<td>0%</td>
<td>32%</td>
<td>8%</td>
<td>2%</td>
</tr>
<tr>
<td>Renal</td>
<td>2%</td>
<td>0%</td>
<td>9%</td>
<td>19%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td>Genetic tox</td>
<td>5%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Carcinogenicity</td>
<td>3%</td>
<td>0%</td>
<td>0%</td>
<td>1%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Other</td>
<td>0%</td>
<td>0%</td>
<td>4%</td>
<td>16%</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Reproduced with permission of W. Redfern (Redfern et al., 2011). Information collated from published articles and from database BioPrint® (Budnitz et al., 2006; Car, 2006; Krejza et al., 2003; Olson et al., 2000; Sibille et al., 1998; Stevens and Baker, 2009).

The choice of the species to use for in vivo pre-clinical studies is critical, and is conditioned by the relevance to human. It is noted that cardiovascular and oncology disease areas have the highest attrition rate due to poor predictivity of the animal models (Kola and Landis, 2004), and this can be applied to safety testing too. Crucial is to characterize the mechanisms of drug-induced toxicity, the target organ, whether it is an on-target, off-target, idiosyncratic or immunological mediated effect and evaluate the translatability of the findings to the patients. Accumulating data on biological processes and gene/protein expression in model organisms serve as basis for understanding the translatability of toxic findings to human. Of utmost importance is to be aware of similarities
and differences at the molecular level (single genes and pathways) between test species and human. For this purpose genomic techniques are being widely employed to describe molecular mechanisms of pathologies and diseases, and propose novel toxicity/efficacy biomarkers.

1.1.4 Additional Considerations

An earlier and more cost-effective evaluation of the safety profile is essential, in order to make drug development process less cost-intensive, and reduce the attrition of promising compounds at expenses of those at risk of liabilities once in the clinic. The combination of mechanism-based toxicity evaluations and availability of predictive translational biomarkers provides a safer ground for decisions regarding advancing compounds in development.

Knowledge generated by the progress in biological research is constantly taken in consideration throughout drug development, and safety assessment is not an exception. Novel molecular entities, and technologies, should be implemented in safety assessment, to provide new predictive endpoints, elucidation of drug-related molecular events and potential safety/efficacy biomarkers.

1.2 Drug-induced cardiac liabilities

1.2.1 Common drug-induced cardiovascular safety concerns

Drug-induced cardiac liabilities leading to withdrawal and research program discontinuation can be broadly divided into the following classes, according to their pathological outcome (Stummann et al., 2009):

- Arrhythmias: a large spectrum of conditions induced by conduction abnormalities
- Contractility: interference with the ability of muscle fibers to contract (inotropic effects)
– Ischemia: restriction of blood supply to the heart, due to blood vessels (coronary) restrictions
– Secondary toxicity: caused by vascular effects
– Valve toxicity: impairment of valve function to keep unidirectional blood flow between chambers and vessels.

1.2.2 Routine cardiac safety studies and regulatory guidelines

A plethora of morphological, functional and biochemical parameters are used to diagnose classify and characterize these cardiopathies at the pre-clinical and clinical level.

EMEA/CHMP/SWP/488313/2007, ICH S4, ICH S7A and ICH S7B guidelines, issued by the International Conference on Harmonization (ICH), recommend the strategy for the design of cardiac safety pharmacology studies (International Conference for Harmonization, 2011). The requirement for an integrated safety assessment approach include a two-weeks repeated dose toxicity study in a rodent (rat) and a non-rodent species (dog or monkey) followed by histopathology, clinical chemistry parameters and functional endpoints. *In vitro* assays include \( I_{kr} \) (hERG) patch-clamp inhibition assay, ADP studies in cardiac cellular animal preparation to evaluate the effect of the compound on voltage-gated ion channels. Inhibition of \( I_{kr} \), L-type Ca\(^{2+} \) and Na\(^{+} \) currents lead to slower repolarisation and consequent elongation of QT phase in the electrophysiological track. A long QT syndrome (LQTS) is associated to Torsade de Pointes (TdP) and pro-arrhythmic potential of compounds. However, evidences suggest that a long QT measured *in vitro* within \( I_{kr} \) (hERG) assays is not necessarily associated to cardiac liabilities in human (Redfern *et al.*, 2003). Conversely voltage-gated channel alterations are not causally implicated in other compound-induced cardiovascular pathologies, such dilating cardiomyopathy and valvular heart disease. The toolbox of
experimental techniques to tackle each type of cardiovascular toxicity is reviewed in Stumman C. et al. (Stummann et al., 2009).

1.2.3 Impact and shortcomings of current pre-clinical cardiovascular safety strategy

Laverty et al. review the impact of pre-clinical strategies in place to prevent the risk of liabilities in patients (Laverty et al., 2011). Arrhythmic potential (TdP) is tackled thanks to the systematic focus on QT interval in ECG investigations. Ischemic diseases however are often not detected, in part due to the use of young animals in pre-clinical studies and young healthy volunteers in Phase I, which do not represent populations at risk, especially elders with elevated blood pressure and atherosclerosis. It has been proposed that monitoring of T-waves may predict the risk of infarction in population at risk. Myocardial necrosis can be monitored via clinical chemistry endpoints like circulating cardiac troponin I (cTnI), creatinine kinase (CK-MB) and N terminal pro-natriuretic peptide (NT-pro BNP) (Marrer and Dieterle, 2010; Muller and Dieterle, 2009; Wallace et al., 2004). However, these markers are elevated when the damage has already occurred and what are lacking are robust biomarkers to detect and monitor rather the onset of cardiac structural damage or changes in cardiomyocytes homeostasis (Buck et al., 2008). Risk of heart failure can be determined by hemodynamic measurements, such as left ventricle ejection fraction (LVEF) and cardiac contractility. However these techniques are not routinely applied in all companies at the pre-clinical stage. Cardiac valves disorders are rather difficult to observe in animals: the incidence is quite low, no circulating biomarkers exist and only direct histological evaluation can confirm it. However fixed cardiac samples from animal studies for histopathology rarely contain the valves, and only a few slides per organ are evaluated.
Further needs identified by Laverty and colleagues include better understanding of the mechanisms of the drug-induced cardiac injury (DICI) at the cellular and structural level (Laverty et al., 2011).

1.2.4 Reference compounds of cardiac toxicity

The use of compounds with known adverse cardiovascular effects may help to extensively characterize and classify new chemical entities, and establish alternative assays in vitro to be applied very early on during target discovery (Stevens and Baker, 2009).

Drugs belonging to the same pharmacological class, i.e. sharing the same target, tend to have similar liabilities pattern. Increase of focus on kinases as targets for oncology indications in the last 10 years also drag the attention on the safety liabilities of kinase inhibitors. While inhibiting mutated or over expressed kinases in tumors is a very promising strategy, kinases are pivotal genes in sustaining physiological activity in all organs. However, designing compounds that mimic ATP (Type I inhibitors, small molecules) or that target sites adjacent to the catalytical pockets leads to high probability of off-target toxicity. Nevertheless, Type III inhibitors with increased single kinase specificity achieved by target regions of the proteins far from the ATP binding pocket, do not fully prevent kinase mediated cardiotoxicity, as cardiac performances depend on multiple kinase-regulated pathways such as the ATP and Ca^{2+} dependent processes, as illustrated in Figure 1-3 (Force and Kolaja, 2011).

Drugs withdrawn from the market due to valvular dysfunction in the past were all 5-HT2B receptor agonists (serotonin receptors), which is highly expressed in valve leaflets (Bhattacharyya et al., 2009; Elangbam, 2010). These include appetite suppressants (fenfluramine and dexfenfluramine), dopamine agonists indicated for Parkinson’s disease (pergolide and cabergoline) and ergot alkaloids against migraine (methysergide and ergotamine). Highly selective agonists of other serotonin receptor isoforms are devoid of valve liabilities. The mechanism
of 5-HT receptors-induced proliferation implicates downstream activation of G protein coupled/ERK and phospholipase C-β/PKC. TGF-βR and Smad2/4 pathway is also activated. 5-HT2BR expression levels are similar between rat, monkey and human (Elangbam, 2010), suggesting these species are of practical use to establish animal models to predict drug-induced valvular liabilities.

1.2.5 Additional Considerations

It is widely understood that routine cardiac safety assessment is not fully predictive of findings in the clinics, and that mechanistic understanding is essential to distinguish physiological vs. pathological processes. Furthermore, physiological differences across test species and human patients should be clarified and taken in account. Both these aspects have to be taken in consideration for an integrated cardiovascular safety assessment.

Figure 1-3: Crucial signaling pathways in the heart and consequences of their activation or inhibition (Force and Kolaja, 2011). Kinases are circled in light yellow ovals.
1.3 Impact of transcriptomics in drug safety assessment and biomarker discovery

1.3.1 Impact of toxicogenomics in drug safety assessment

Technical advancements of the post-genomic era are supported by high-throughput nucleic acid profiling platforms, such as RNA or DNA based microarray (Figure 1-4) that can quantify transcription changes at the global level, reveal association between diseases and genetic mutations, or characterize the epigenetic changes at the chromatin level. Although next-generation sequencing is becoming more affordable, microarray based profiling are routinely used in drug discovery during the preclinical safety assessment.

![Image of microarray hybridization process]

Figure 1-4: Experimental process of microarray hybridization experiments for gene expression determination (Butte, 2002).

Specific signatures of altered genes can be causally implicated into drugs toxicity in the tissue of interest (Buck et al., 2008; Chen et al., 2008a; Mori et al.,
Goals of toxicogenomics in drug safety assessment screenings are multiple (Van and Sasaki, 2010): 1) formulate hypothesis on the molecular mechanism of undesired phenotypic changes, uncoupling them from the pharmacological effects, 4) give information on the organ structures mostly affected by the drug, 3) support the identification of biomarkers of the pathological process that can be used as screening endpoints for same class and backup compounds and 4) classify compounds in classes based on the toxicity outcome (Ruepp et al., 2005; Steiner et al., 2004).

1.3.2 Experimental approach of genomics studies for organ toxicity assessment

Upon stress stimuli, including xenobiotics exposure, a series of changes take place in the cells, ultimately leading to adaptation or functional impairment of the organ. Molecular alterations precede morphological changes and can be identified early on upon treatment, after only one or two doses of the drug, and in absence of overt toxicity (Hamadeh et al., 2002). Data collection at multiple time points reveals cause-effect relationship between early and later gene expression (Buck et al., 2008).

In a complex toxicity in vivo study including several doses and time points, data analysis still remains the bottle-neck, as the analyst has to take in consideration a plethora of accompanying data (histopathology, clinical pathology, and imaging) to carefully choose the most significant samples set to answer biological questions and enable critical compound prioritization and limit attrition as early as possible.

1.3.3 Data analysis strategy depends on the goal of toxicogenomics studies

A variety of approaches for analysis of large data sets are available, between supervised and unsupervised methods (Butte, 2002). Unsupervised approaches include principal component analysis, clustering and Bayesian networks. Supervised approaches range from the nearest-neighbor analysis and support
vector machine (machine-learning algorithms able to recognize patterns in analyzed data). It is important to decide *a priori* whether the outcome of the analysis is aimed at predicting toxicity only, or at obtaining a mechanistic interpretation of the molecular modifications involved. Gene signatures extracted from the analysis can be long (thousands of genes) in the former case, but must be much shorter (few tens of genes) in the latter case (Natsoulis *et al.*, 2005). In any case, transcriptomics results must be anchored to ancillary data, such as histopathology, in order to establish a temporal evolution of the findings, and propose relevant predictive toxicity indicators that would be noted earlier than overt lesions.

**1.3.4 Toxicogenomics in biomarker discovery**

Transcriptomics analysis can support discovery and validation of molecular indicators (biomarkers) of toxicity 1) in the tissue (pre-clinical only) and 2) in body fluids (pre-clinical and clinical), i.e. if a certain gene is translated to a released protein product. Elevated levels of these molecules can be measured in the peripheral circulation of patients, and specifically reflect leakage of cell content due to tissue injury. Ideally, biomarkers should be translatable across species, including preclinical species, and restricted in expression to the tissue of interest (Decristofaro and Daniels, 2008).

Since the mRNA expression levels may not match in all cases with the level of functional protein translated, proteomics investigations may be needed to confirm the functional outcome of altered gene expression.

**1.3.5 Examples of transcriptomics studies for drug-induced cardiac toxicity (DICI)**

In the case of drug-induced cardiac injury (DICI) histopathological readouts are limited to few qualitative observations (cardiomyocytes degeneration, vacuolation or necrosis) and do not provide explanations of the molecular events causing the injury (Buck *et al.*, 2008), since similar adverse phenotypes can be caused by
different mechanisms. Hemodynamic measurements supported by electro- and echocardiography are operationally intensive and detect the damage when the affected structure is functionally compromised. Therefore transcriptomics investigations bear the great potential of unveiling the mechanistic progression of toxicity. To date the vast majority of literature on toxicogenomics studies available in the public domain regard drug-induced liver toxicity (DILI) (Van and Sasaki, 2010), while cardiovascular toxicants have not received such systematic attention. Two examples of gene expression studies applied to cardiac safety are illustrated below.

Mori and colleagues illustrated the effects on gene expression of 3 known cardiotoxicants: a pesticide (carbofuran), a beta-adrenergic agonist (isoproterenol) and a DNA intercalator (doxorubicin, DOX) (Mori et al., 2010). Several genes were consistently up-regulated after 1 dose only of the three compounds even earlier than histopathological findings, suggesting similar molecular mechanism may be involved in the toxic outcome for all the 3 compounds. These include Spp1, Fhl1, Timp1, Ccl7 and Reg3b genes. However, dosage and administration scheme did not reflect a real accidental exposure situation. Furthermore, those changes may be transient and not be maintained after repeated dosing.

Thompson and colleagues used a different approach and focused on early molecular events induced by DOX that are maintained after repeated administration of low doses in the rats, more closely resembling the clinical setting. The authors determined the gene expression changes after 2 weeks of chronic DOX administration and identified lists of gene significantly altered (Thompson et al., 2009). These were either associated with the cellular response to oxidative stress, encoding mitochondrial proteins or calcium homeostasis. These observations were consistent with the molecular mechanism of proposed DOX-induced cardiac injury due to reactive oxygen species production (Chen et
Further cardiotoxicity aspects associated to anthracyclines chemotherapy are reviewed in the following chapter.

### 1.3.6 Additional Considerations

In addition to transcriptomics, metabolite profiling and proteomics approaches are often used to characterize various aspects toxic liabilities, such as biomarker discovery and characterization of off-target effects upon drug pull-down in protein extracts. The emerging fields of epigenetics and non-coding RNAs are increasingly integrated in mechanistic interpretations of xenobiotics response. Relevance of microRNAs in cardiac physiology and toxicity are reviewed in the next paragraphs.

### 1.4 MicroRNAs biology and function regulation

#### 1.4.1 MicroRNAs biogenesis and function

MicroRNAs are ~22 nucleotides long non-coding RNAs, genomically encoded and conserved throughout evolution in all superior organisms. They are transcribed by DNA Pol II either as independent singular or clustered transcriptional units, or originate from hosting gene during intron splicing (Bartel, 2004; Goymer, 2007; Ruby et al., 2007). Maturation of microRNAs involves sequential steps that include the generation of a primary hairpin, trimmed to a precursor-microRNA by Drosha, which is then exported to the cytoplasm where Dicer cuts the loop, releasing a short double stranded RNA. The duplex is separated to single-stranded RNA filaments, incorporated into an Ago2-RNA Induced Silencing Complex (RISC) (Figure 1-5). Regulation of microRNA expression can take place at all stages of biogenesis, and their function is influenced by several factors such as RISC-complex regulators, RNA binding proteins (RBP) and target mRNA conformation, among others (Krol et al., 2010).
Figure 1-5: MicroRNAs biogenesis. Adapted from (Krol et al., 2010).
Increasing evidences implicate non-coding RNAs as central players of cellular homeostasis by tuning the expression level of hundreds of mRNAs (Lim et al., 2005; Stark et al., 2005; Wang et al., 2011a; Wu and Belasco, 2008). Although microRNAs were initially described as fine regulators of gene expression, it is now believed that single microRNAs can have dramatic effect on genome homeostasis, especially in disease state.

1.4.2 MicroRNAs role in transcriptome homeostasis

MicroRNAs are gene expression inhibitors, acting at the post-transcriptional level by directing the RISC complex to target mRNAs via imperfect pairing with its 3’ untranslated regions (UTR) (Bartel, 2004; Guo et al., 2010). MicroRNAs embedded in the Ago2-miRISC serves as a guiding strand for RISC towards target mRNAs, and exert their inhibitory function inducing translational inhibition, mRNA de-adenylation and decay (Figure 1-5). RISC-mediated microRNAs inhibition requires an almost perfect complementarity between the first 7-8 nucleotides at the 5’ end of the microRNA and the mRNA target, in a region called seed (Grimson et al., 2007). MicroRNA target sequences lie mostly within the 3’ UTR of mRNAs, and multiple sites can often be found. Globally, sites in the coding region appeared to be generally less effective at repressing mRNAs, and accumulating evidences suggest that these may escape evolutionary pressure (Fang and Rajewsky, 2011). The RISC-mediated direct cleavage of the endogenous mRNA is a common mechanism of plant microRNAs, thanks to the almost perfect complementarity with their target. In animals, however, the complementarity is mostly limited to the seed and additional 3’ sites, and mRNAs target decay is induced by a different mechanism. MicroRNAs-loaded RISC recruits factors promoting de-adenylation like CCR4–NOT via GW182-dependent (Chekulaeva et al., 2011). Loss of the poly-A tail causes the mRNA to be degraded (Couttet et al., 1997), consistently with the observation that knock out/in of specific microRNAs revealed a detectable variation in mRNAs dependent on
MicroRNAs inhibit cap-dependent translation at the initiation step via interference with the cap recognition process. Notably microRNAs failed to inhibit IRES-dependent translation, which does not rely on the m7Gppp cap to recruit the translational machinery (Fabian et al., 2010; Filipowicz et al., 2008). Whether microRNAs can inhibit translation at the elongation, as proposed by Maroney and colleagues, and at the termination step is controversial (Maroney et al., 2006).

1.4.3 Finding the targets of specific microRNAs

1.4.3.1 In silico predictions and gene expression analysis

A few rules apply to the interaction between microRNAs and their targets. Pairing at the seed region must be perfect, and comprising at least nucleotides 2 to 8. The presence of bulges and imperfect match in the central portion of the duplex precludes the cleavage of the target mediated by Ago, however additional complementarity at the 3’ end increases the repressive efficiency of the microRNAs, when the seed interaction is below 8 nucleotides (Grimson et al., 2007).

The reduced length and the presence of variable degree of complementarity hinder the possibility of exact target prediction via in silico sequence analysis.

A variety of algorithms exist for identification of microRNAs target genes (Table 1-2). These take into account the degree of complementarity to the miRNA seed sequence, conservation of the microRNA seed element within the target gene across different species, free energy of the miRNA-mRNA duplex binding, and accessibility of the target site. Predictions based on evolutionary conserved seed-matching identified hundreds of potential targets for each microRNA (Lewis et
The extent of false-rate prediction is difficult to assess, and oscillates between 30% and 50% (Alexiou et al., 2009; Thomas et al., 2010).

It has to be kept in mind that the function of individual microRNAs depends on the molecular context: each cell type expresses a limited repertoire of genes that can be under the control of single microRNAs.

Additional *in silico* strategies include the mining of extensive gene expression databases in order to identify mRNAs profiles compatible with microRNAs targeting (Alexiou et al., 2010; Antonov et al., 2009; Le Brigand et al., 2010; van Dongen et al., 2008).

**Table 1-2: List of *in silico* microRNAs target prediction tools. (Yokoi and Nakajima, 2011)**

<table>
<thead>
<tr>
<th>Tool</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>MicroCosm</td>
<td><a href="http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/">http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/</a></td>
</tr>
<tr>
<td>miRanda</td>
<td><a href="http://www.microrna.org/microrna/home.do">http://www.microrna.org/microrna/home.do</a></td>
</tr>
<tr>
<td>miRBase</td>
<td><a href="http://microrna.sanger.ac.uk/">http://microrna.sanger.ac.uk/</a></td>
</tr>
<tr>
<td>miRGator</td>
<td><a href="http://genome.ewha.ac.kr/miRGator/">http://genome.ewha.ac.kr/miRGator/</a></td>
</tr>
<tr>
<td>mirnaviewer</td>
<td><a href="http://cbio.mskcc.org/mirnaviewer/">http://cbio.mskcc.org/mirnaviewer/</a></td>
</tr>
<tr>
<td>RNAhybrid</td>
<td><a href="http://bibiserv.techfak.uni-bielefeld.de/mahybrid/">http://bibiserv.techfak.uni-bielefeld.de/mahybrid/</a></td>
</tr>
<tr>
<td>TargetRank</td>
<td><a href="http://hollywood.mit.edu/targetrank/">http://hollywood.mit.edu/targetrank/</a></td>
</tr>
<tr>
<td>TargetScan</td>
<td><a href="http://www.targetscan.org/">http://www.targetscan.org/</a></td>
</tr>
</tbody>
</table>
1.4.3.2 Experimental identification of microRNAs targets

A variety of experimental approaches have been set up in order to identify the real and biologically relevant targets of microRNAs, as reviewed by Thomson and colleagues (Thomson et al., 2011).

Over expression or knock down of specific microRNAs coupled with microarray analysis allowed to observe the changes induced by that microRNA in model cell lines (Lim et al., 2005). However these strategies have several caveats, in fact not all biologically relevant targets may be expressed in the cell line of choice. The analysis of seed matching sequences in down regulated genes helped to discriminate potential direct from indirect targets, however in most cases it was not assessed whether the observed effects were mediated directly by the microRNA, or were rather a result of unspecific regulation.

Conversely, biochemical approaches involving the co-immunoprecipitation of mRNAs with RISC components combined with over expression of a specific microRNA (cell re-programming) could in principle identify direct microRNAs targets (Hendrickson et al., 2008; Karginov et al., 2007; Matkovich et al., 2011; Tan et al., 2009). However these procedures are difficult to set up and rely on sufficiently stable interactions between the mRNAs and the RISC components.

Cross-linking aided protocols have been developed to overcome this potential drawback, such as the high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation HITS-CLIP (Chi et al., 2009) and the photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) (Hafner et al., 2010). However it is not clear which percentage of the pulled down targets are specific for a single microRNA.

In order to address this problem Orom and Lund have successfully identified the direct targets of miR-10a by using a biotinilated synthetic microRNA as bait for their pull down experiment in (Orom and Lund, 2007) in Drosophila and
human cells. However whether the biotin group had an effect on the microRNA functionality was not elucidated.

**1.4.4 Alternative mechanisms of microRNA function**

Noteworthy, microRNAs not only inhibit gene expression, but also mediate translational activation of a few target genes in specific cell state, such as quiescent cells in G0, germline differentiation, ribosomal protein, HCV RNA etc. (Vasudevan, 2011). These effects can be sequence-dependent (i.e. microRNA-mediated recruitment of activator RNPs), or sequence-independent, (i.e. no direct interaction between the microRNA and the transcriptionally activated/stabilized mRNA). A number of microRNAs were shown to have direct stimulatory activity on the translation of their target mRNAs: miR-122 and miR-10a possess translation activation properties on specific transcripts by pairing at the 5’UTR of respectively HCV and ribosomal genes (Henke et al., 2008; Orom et al., 2008). Others, such as miR-125b and miR-466l mask the binding site for the ARE-decay factor tristetraprolin (TTP) on their respective targets κB-RAS2 and IL10 (Figure 1-6C) (Ma et al., 2010; Murphy et al., 2010). Generic features of direct transcriptional activation mediated by microRNA/mRNA direct interaction include the modification of RNPs recruited by microRNAs/Ago2 complex, such as lack of GW182/PABP complex, recruitment of activator proteins FXR1-iso-a (Figure 1-6A) or interference with regulatory AU-rich elements, shortened or absent polyA (Figure 1-6B) and binding to a 5’UTR site in closer proximity to the cap (Figure 1-6B). MicroRNAs can also act as decoy for repressive proteins and relieve the repression on their targets in a sequence independent manner, such as the case of pre-miR-328 interacting with the RNA inhibitory hnRNP. This rescues the repression of Cebpa mediated by hnRNP in chronic myelogenous leukemia via the miR-328 C-rich cluster, similar to the one present in the 5’ UTR of the Cebpa mRNA, shown in Figure 1-6D (Eiring et al., 2010).
Some non-functional pseudo-genes have been shown to possess a buffer activity on their functional homolog, and accumulating evidences suggest that these conserved microRNA targets sequence would be under evolutionary pressure in order to release the microRNA-mediated inhibition on their homolog gene (Cesana et al., 2011; Poliseno et al., 2010; Sumazin et al., 2011).

MicroRNAs were also found in the nucleus of cells, but their function is at present not fully understood.

The splicing regulator MBNL1 is implicated in myotonic dystrophy (MD), and it has been recently shown to bind to pre-miR-1 in the nucleus and promote its maturation in normal conditions. In diseased conditions, MBNL1 is sequestered
and as a consequence the levels of mature miR-1 are decreased, suggesting that miR-1 could be an effector of the cardiac defects observed in MD patients via its targets (Rau et al., 2011). This also suggests that microRNAs could bind to transcriptional regulators in the nucleus, and have downstream effects on transcriptional gene regulation. Another possibility is that nucleus compartmentalization of either the mature or precursor microRNAs could be a further layer of post-transcriptional regulation of microRNAs activity.

Evidences exist that Ago2 recruitment at the promoter of specific genes, driven by complementarity with guide microRNA, is a functional mechanism in mammals (Li et al., 2006; Younger and Corey, 2011), and was suggested that microRNAs can direct transcriptional activation or inactivation of genes with complementary sequences in their promoters or regulatory regions (Kim et al., 2008; Place et al., 2008). Whether microRNAs-mediated gene regulation at the transcriptional level is a physiological and common layer of gene regulation in animals, similar to the RNAi-induced transcription silencing (RITS) characterized in yeast, is a hypothesis that opens complete new avenues of investigations for the role of non-coding RNAs (Li et al., 2006; Woolcock et al., 2011; Younger and Corey, 2011).

1.4.5 Additional Considerations

In order to minimize the risks and perform predictive experiments, researchers must be confident about the human relevance of the experiments performed in test animals. Unfortunately the test species useful for drug development (rat, canine and non-human primates) are not thoroughly characterized: extensive genomic annotation, detailed proteomics data, gene expression, epigenetic marks and transcription factors profiles are lacking. Given the proven impact of microRNAs in multiple layers of gene regulation, it makes sense to accumulate knowledge on
their role in species of interest for biomedical research and, in our case, in cardiovascular safety.

1.5 MicroRNAs detection and quantification

In the last ten years all high-throughput techniques available for transcriptomics have been adapted for microRNAs detection. These include quantitative PCR (qPCR), hybridization-based techniques and next-generation sequencing (NGS) (Table 1-3).

Table 1-3: MicroRNAs detection platforms. AQ: absolute quantification; RQ: relative quantification

<table>
<thead>
<tr>
<th></th>
<th>Single assay</th>
<th>Whole genome</th>
<th>AQ</th>
<th>RQ</th>
<th>A priori knowledge</th>
<th>Input material</th>
<th>Analysis costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>qPCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-spotted plates</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>yes</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Hybridization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MicroArrays</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>yes</td>
<td>Medium</td>
<td>Low</td>
</tr>
<tr>
<td>Panomics</td>
<td>x</td>
<td>?</td>
<td>x</td>
<td>yes</td>
<td>High</td>
<td>Low</td>
<td>Medium</td>
</tr>
<tr>
<td>Nanostring</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>yes</td>
<td>Low</td>
<td></td>
<td>Low</td>
</tr>
<tr>
<td>Northern blot</td>
<td>x</td>
<td></td>
<td>x</td>
<td>yes</td>
<td>Low</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>ISH</td>
<td>x</td>
<td></td>
<td></td>
<td>yes</td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>NGS</td>
<td>DGE</td>
<td></td>
<td></td>
<td>?</td>
<td>x</td>
<td>Medium</td>
<td>Intense</td>
</tr>
</tbody>
</table>

1.5.1 Quantitative PCR (qPCR)

Advantages of qPCR-based microRNA profiling include relative ease of use, low demands for amount of starting material, high sensitivity, straightforward protocol for sample preparation and data analysis. Since microRNAs are too short to design a regular couple of primers, different strategies illustrated in Figure 1-7A-C can be used to increase the length of the amplicon via ligation, or reverse-transcription. Then, a microRNA specific primer is mixed with a universal primer that recognizes the extended 3’ tail during the PCR reaction. Differentially regulated candidates obtained by high-throughput qPCR can be further confirmed by other means, or justified by biological consistency (i.e. co-regulation with host
genes in the case of intronic microRNAs). However, the specific stem-loop primer used to extend microRNAs length during reverse transcription can fail to recognize length variants (Figure 1-8), decreasing the qPCR sensitivity. When length variants could be present in the sample, the use of a mixture of degenerated RT primers can help to reverse transcribe all microRNAs irrespectively of their 3’ end.

Figure 1-7: MicroRNAs detection. Schemes of three kinds of RT-PCR methods: Primer extension (A), stem-loop primer (B), and 3’ adapter ligation (C). Solid-phase amplification of Illumina small RNA libraries (D). Adapted from (Huang et al., 2011).
1.5.2 Hybridization based techniques

Hybridization-based methods have been used since many years, and microarray technology adapted to microRNAs is offered by a variety of providers (Affymetrix, Agilent, Illumina, Exiqon, Toray). These technologies suffer from unspecificity issues intrinsic of all hybridization-based technologies (non-uniform Tm, normalization strategies, controversial specificity at the single nucleotide level, GC content), exacerbated by the fact that microRNAs are not amenable to multiple probe sets design, differently from mRNAs. Furthermore, the restricted number of microRNAs analyzed in each chip and the lower signal intensity due to inferior labeling efficiency require special attentions during quality control, between-chips normalization and analysis algorithms (Sarkar et al., 2009). Pradervand et al. and Sato et al. tested the performances of different microRNAs microarray providers (Affymetrix, Agilent, Ambion, Exiqon, Invitrogen and Toray) and concluded that Agilent had a superior performance, reproducibility
and comparability within same platform and with other platforms (qPCR and NGS) (Pradervand et al., 2010; Sato et al., 2009).

Sample preparation can be a cause of biases, due to enzyme-based tagging or pre-amplification, and Nanostring and Panomics technologies are promising in that the isolated small RNAs are directly assessed without any further sample preparation step and at high sensitivity. However, these technologies may suffer from specificity issues common to virtually all hybridization-based platforms.

Northern blot is the ultimate and traditional technique for single microRNAs quantification, but it is a targeted approach and requires previous knowledge of the microRNA of interest. It is often used in confirmatory follow-up experiments.

In situ hybridization with either fluorescence or chromogenic detection is used for specific localization of relevant microRNAs within a fixed or frozen tissue section (Nuovo, 2008, 2010; Nuovo et al., 2009; Obernosterer et al., 2007). This technique is still time consuming, requires extensive troubleshooting via optimization of conditions, and cannot be used as absolute quantification method. Furthermore, sample prep conditions (fixation), age of animal, reagents used etc can introduce a potentially high variability of results depending on.

1.5.3 Next-generation sequencing

The current method of choice to investigate small RNA expression is the NGS approach, also called digital expression profiling (DGE). In contrast to other methods, NGS profiling is hybridization-independent, can discriminate microRNA family members with single nucleotide differences, and capture 5′/3′ end variability (for example, isoMirs). Furthermore, sequencing does not require a priori information, and can be used to simultaneously detect known and discover new microRNAs (Linsen et al., 2009). Small RNA NGS is based on high-throughput DNA sequencing of libraries captured and ligated with adaptors necessary for building clusters inside the flow-cells (Illumina), for recognition of the sequencing beads (in the case of SOLiD) and for priming the synthesis (Figure
Mammalian cells express a few hundreds of microRNAs at any given time. This is a relatively small number compared to a standard gene expression profile, and multiplexing of microRNAs samples guarantees a sufficient coverage. This is achieved by indexing (or barcoding) the adapters used for each sample with additional nucleotide sequences that can unequivocally assign the reads, allowing simultaneous analysis of a pool of samples in the same flowcell. However, normalization and data analysis is computationally expensive and requires specific bioinformatics knowledge. Sample preparation is time consuming and requires manual steps, like band excision from gel, which can easily be source of batch-to-batch differences.

1.5.4 Additional Considerations

As reviewed in (Linsen et al., 2009) it is controversial whether qPCR, arrays or NGS are suited for absolute quantification. The extensive sample preparation that includes enzyme based reactions (ligation, reverse transcription, starting material amplification, gel purification) can bias the population of microRNAs measured, as exemplified in the Supplementary Results of Chapter 2. However there is general good concordance of relative expression across the different platforms, and especially between qPCR and NGS, also reported in Chapter 3 (Pradervand et al., 2010).

1.6 MicroRNAs in cardiac physiology and diseases

1.6.1 Implications of cardiac microRNAs in organ development and diseases

MicroRNAs are required for correct cardiovascular development and function, and Dicer conditional deletion causes heavy developmental defects and spontaneous dilated cardiomyopathy mice (Chen et al., 2008b; da Costa Martins et al., 2008; Rao et al., 2009). Among the most abundant microRNAs in the heart,
miR-1 and miR-133 are encoded from the same precursor (miR-1-2/miR-133a-1).

Figure 1-9: Functional role of microRNAs in normal and diseased heart. MicroRNAs are depicted as bulged red ribbons. Arrows indicated activation, while blunted lines indicate inhibition of the downstream elements. Cardiomyocytes and fibroblasts are represented. Adapted from (Small and Olson, 2011).

They are however under the control of transcription enhancers responsive to muscle differentiation factors that include Srf, MyoD and Mef2 (Liu et al., 2008; Liu et al., 2007; Zhao et al., 2007; Zhao et al., 2005).
MiR-1 and miR-133 have opposing effects in the cardiac lineage fate: miR-1 induces differentiation, while miR-133a stimulates proliferation (Ivey et al., 2008). Although their knock-down caused heavy developmental defects, none of the two microRNAs were absolutely required, as 50% of heart-specific knock down mice are viable (Liu et al., 2008; Zhao et al., 2007).

Figure 1-10: MicroRNAs and genes implicated in cardiac diseases. Different cell types involved in cardiac remodeling are indicated: cardiomyocytes (squared red), fibroblasts (speared beige), and endothelial cells (small pink). Adapted from (Latronico and Condorelli, 2009).

Moreover, microRNAs are implicated in cardiac diseases of different etiologies (Catalucci et al., 2009; Kinet et al., 2012; Latronico and Condorelli, 2009).

Several microRNAs have the ability to influence cardiac remodeling through specific effects on signaling pathways (mir-133, mir-1, miR-9, miR-98, mir-199b, miR-23a), sarcomere organization (miR-208a/b, miR-499) and inter-cellular communication (miR-29 and mir-21) (Small and Olson, 2011) (Figure 1-9). Genes that are actively targeted by cardiac microRNAs include regulators of metabolism, electrical conduct, proliferation/hypertrophy and angiogenesis.
MiR-1 was described as a potential arrhythmogenic since it can target connexin 43 (GJA1) (Figure 1-10) and the K+ channel subunit Kir2.1 (KCNJ2), and its deletion ameliorates recovery in post-infarction rodent models (Yang et al., 2007).

Induction of miR-208a was sufficient to induce arrhythmias, and this microRNAs was implicated in cardiac performance and maintenance of conduction via targeting of two regulators of muscle growth and hypertrophy, namely thyroid hormone-associated protein 1 (Thrap1) and myostatin (Mstn) (Figure 1-10). Mir-21 and miR-29 were shown to be induced by fibrotic stimuli (i.e. after myocardial infarction) and mediated extra-cellular matrix (ECM) deposition (Thum et al., 2008; van Rooij et al., 2008).

In addition, genetic polymorphism in pre-mir-499 and pre-miR-196a-2 are associated to human dilated cardiomyopathy (Lu et al., 2008).

1.6.2 Cardiac microRNAs and pathological heart remodeling

Pathological (irreversible) cardiac hypertrophy is caused by a variety of stimuli (i.e. hypertension, valvular heart disease, infarction, obesity, exaggerated pharmacology) and may cause heart failure. The disease progression is complex and involves several stages of molecular and histological remodeling (distinct from physiological hypertrophy due to exercise and pregnancy). At first, hypertrophic growth of cardiomyocytes and thickening of ventricular walls compensate for the increased demands (with or without chambers’ restriction), however sustained pathological stimuli can lead to a functional decompensation due to progressive thinning of the ventricular walls (Hill and Olson, 2008; Hoshijima and Chien, 2002; van Rooij and Olson, 2007). The transition from physiological to pathological is accompanied by re-expression of fetal genes and a switch in myosin isoforms (in rats Myh6 is down-regulated and Myh7 is up-regulated). Interestingly, three microRNAs called myomiRs (miR-208a, miR-208b and mir-499) are co-transcribed within the introns of myosin genes. In
particular, a variety of stressors, including pressure overload and thyroid hormone cause activation of the fetal Myh7 (and miR-208b) transcription in adult rodents in a miR-208a dependent manner (van Rooij et al., 2009). Another cardiac microRNA, miR-133a was linked to cardiac hypotrophy: inhibition of miR-133 via infusion of an antisense construct \textit{in vivo} caused sustained cardiac hypertrophy in rats. The authors identified the GDP-GTP exchange factor RhoA, the kinase Cdc42 and a cardiopoietic nuclear factor Whsc2 as direct targets of miR-133a (Carè et al., 2007) (Figure 1-10).

A calcineurin-dependent transcriptional pathway has been shown to decrease apoptosis in a mice model being therefore beneficial for heart failure recovery (De Windt et al., 2000). However, the calcineurin-dependent nuclear factor NFATc3 can induce the over-expression of the pro-hypertrophic miR-23a upon β-adrenergic hypertrophic stimulation. The knock down of miR-23a was sufficient to relieve the isoproterenol induced enlargement (Lin et al., 2009).

**1.6.3 Additional Considerations**

Accumulating evidences strongly implicate microRNAs as key mechanistic players in cardiac pathways and regulatory circuits in both development and pathogenesis, and suggest microRNAs could be considered as provocative therapeutic targets (van Rooij and Olson, 2007). Interference with regulatory pathways can have multiple faceted effects, and microRNAs can be involved in the tight regulation required for proper homeostasis (i.e. miR-23 and calcineurin pathway mentioned above).

An important caveat in microRNAs research in cardiac diseases is the assumption that disease-related microRNAs would be found either over- or down-regulated in a diseased state. Jentzsch \textit{et al.} performed a functional screening of pro-hypertrophic microRNAs in rat neonatal cardiomyocytes, by transfecting a library of human microRNAs and measuring the cell size by high content microscopy. They found that most of microRNAs that induced cardiomyocytes
hypertrophy (miR-212, miR-365, miR-22, miR-30c, miR-30d) were never found dysregulated in previous works (Jentzsch et al., 2011). This intriguing observation will have to be further confirmed with mechanistic studies, since potentially not all transfected microRNAs could have been be functional in the cells tested and that an isolated cell model often does not recapitulate in vivo findings.

1.7 MicroRNAs in toxicology

MicroRNAs are considered important genome regulators, and their modulation may be prodromal to gene expression changes. This is of particular interest in early detection of toxic liabilities and ultimately to explain the mechanisms of undesired effects in the affected tissues.

Systematic toxicological studies involving microRNAs were performed mainly with hepato- and neuro- toxicants and carcinogens, while cardiac toxicity was not thoroughly investigated. A collection of toxicological studies has been illustrated by Lema and Cunningham (Lema and Cunningham, 2010) (Table 1-4).

Table 1-4: microRNAs and toxicology. (↑) up-regulation; (↓) down-regulation. (Lema and Cunningham 2010)

<table>
<thead>
<tr>
<th>Organism</th>
<th>Toxicant</th>
<th>miRNA</th>
<th>Target</th>
<th>Biologic effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>Wy-14,643, peroxisome proliferator-activated receptor alpha (PPARα) agonist</td>
<td>↑let-7C</td>
<td>Transcription factor, c-myc</td>
<td>Hepatocyte proliferation</td>
<td>Shah et al. (2007)</td>
</tr>
<tr>
<td>Mouse</td>
<td>Ethanol</td>
<td>↓miR-21, -335, -153</td>
<td>Notch-receptor ligand, Jagged-1, brain-specific regulator of RNA stability, ELAVL2 (embryonic-lethal abnormal vision, Drosophila-like 2)</td>
<td>Induction of cell cycle and stem cells maturation</td>
<td>Sathyan et al. (2007)</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), environmental contaminant</td>
<td>↑let-7, miR-15, -16, -26, -181; ↓miR-10b</td>
<td>Cell cycle regulators</td>
<td>Regulation of tumor pathogenesis</td>
<td>Zhang and Pan (2009)</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hexahydro-1,3,5-</td>
<td>↑miR-206, -30,</td>
<td>Brain-derived</td>
<td>Neurotoxicity</td>
<td>Zhang and Pan</td>
</tr>
<tr>
<td>Organism</td>
<td>Toxicant</td>
<td>miRNA</td>
<td>Target</td>
<td>Biologic effect</td>
<td>Reference</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>-------</td>
<td>--------</td>
<td>----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Rat</td>
<td>Tamoxifen</td>
<td>↑miR-294</td>
<td>Transcriptional repressor genes</td>
<td>Altered gene expression</td>
<td>Izzotti et al. (2009)</td>
</tr>
<tr>
<td>Rat</td>
<td>Cigarette smoke</td>
<td>↓let-7c, miR-34c, -222</td>
<td>Genes involved in stress response and cell proliferation</td>
<td>Carcinogenesis</td>
<td>Izzotti et al. (2009)</td>
</tr>
<tr>
<td>Rat</td>
<td>Acetaminophen; Carbon tetrachloride</td>
<td>↑miR-298, -370</td>
<td>Thioredoxin reductase 3</td>
<td>Hepatotoxicity</td>
<td>Fukushima et al. (2007)</td>
</tr>
<tr>
<td>Rat</td>
<td>4-(methyltritosamino)-1-(3-pyridyl)-1-butanone (NNK), tobacco carcinogen</td>
<td>↓miR-126</td>
<td>Cytochrome P450 (CYP) 2A3</td>
<td>Tumorigenesis</td>
<td>Kalscheuer et al. (2008)</td>
</tr>
<tr>
<td>Human</td>
<td>1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), major vitamin D metabolite</td>
<td>↑miR-125b</td>
<td>Endogenous vitamin D receptor (VDR)</td>
<td>Augmentation of the antitumor effects of 1,25(OH)(2)D(3)</td>
<td>Mohri et al. (2009)</td>
</tr>
<tr>
<td>Human</td>
<td>Sodium arsenite</td>
<td>↓miR-210</td>
<td>Cellular methyl-donor pool</td>
<td>Alterations of genomic methylation</td>
<td>Marsit et al. (2006)</td>
</tr>
<tr>
<td>Human</td>
<td>Cigarette smoking</td>
<td>↑miR-218</td>
<td>Transcription factor, MAFG (v-maf musculoaponeurotic fibrosarcoma oncogene homolog G)</td>
<td>Expression of MAFG targets</td>
<td>Schembri et al. (2009)</td>
</tr>
<tr>
<td>Human</td>
<td>5-fluorouracil (5-FU), antineoplastic drug</td>
<td>↑miR-200b</td>
<td>Protein tyrosine phosphatase (PTPN12)</td>
<td>Inactivation of oncogenes products (c-Abl, Src or Ras)</td>
<td>Rossi et al. (2007)</td>
</tr>
</tbody>
</table>

1.7.1 MicroRNAs role in cytochrome toxicity

Cytochromes and nuclear receptors are pivotal genes in pharmacodynamics and toxicology. Recent works suggest a number of these genes may be regulated by microRNAs (Figure 1-11) (Yokoi and Nakajima, 2011). MiR-27b, miR-298, miR-
24, miR-34a and miR-148a were implicated in either direct or Hnf4/Pxr-mediated regulation of Cyp3a4 (Pan et al., 2009; Takagi et al., 2010; Takagi et al., 2008). Interestingly, Cy1b1 and RXRα were also found to be modulated by miR-27b (Ji et al., 2009a; Tsuchiya et al., 2006). Cyp2e1, the most abundant cytochrome in human liver, is over expressed in diabetes and obesity and down-regulated by insulin treatment. The capability of miR-378 to decrease Cyp2e1 was first described by Mohri and colleagues, and is likely to have toxicological relevance (Mohri et al., 2010). Cyp2a3 is responsible for the metabolic activation of the nicotine-derived pro-carcinogen nitrosamine ketone (NNK) α-hydroxylation. Kalscheuer and colleagues found that one of the microRNAs down regulated by NNK chronic administration in rat lungs, miR-126*, was also directly targeting Cyp2a3 (Kalscheuer et al., 2008), suggesting the implication of miR-126* in NNK carcinogenic potential. Cy24a1 and vitamin D receptor are involved in calcium homeostasis of solid tumors and are directly inhibited by miR-125b, which is itself modulated in a variety of tumors (Komagata et al., 2009; Mohri et al., 2009).

Figure 1-11: MicroRNA-related networks of cytochrome P450 and nuclear receptors (Yokoi and Nakajima 2011).
1.7.2 Xenobiotics-induced carcinogenesis

MicroRNAs expression was found altered upon xenobiotics administration, including cigarette smoke, tamoxifen, acetaminophen, ethanol, hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), dioxin, arsenite and carbon tetrachloride (Fukushima et al., 2007b; Izzotti et al., 2010; Marsit et al., 2006b; Pogribny et al., 2007; Sathyan et al., 2007; Schembri et al., 2009; Yoshioka et al., 2011; Zhang and Pan, 2009), however the impact of such changes on toxicity was often not investigated.

Carcinogenesis is a common toxic outcome of xenobiotics exposure (Pogribny et al., 2007). Pparα signaling has been implicated in hepatocytes proliferation and tumor development. Shah and colleagues reported that let-7c was down regulated by administration of a PPARα agonist. Let-7c modulated c-myc cascade by directly inhibiting the c-myc oncogene via 3’UTR targeting. Thus let-7c appeared to be critical in PPARα-induced liver proliferation (Shah et al., 2007).

Arsenic is known to induce bronchial epithelium carcinoma, via not completely understood mechanism. Wang et al. found that miR-200b was heavily down-regulated in epithelial cells undergoing arsenic-induced epithelial-to-mesenchimal transition (EMT). Re-expression of miR-200b relieved the carcinogenic phenotype in vitro and tumorigenicity of arsenic exposed cells in a xenograft model (Wang et al., 2011c).

Another cause of malignant bronchial epithelial cells transformation is exposure to benzopyrene. Silencing of miR-106a suppressed benzopyrene-induced cell proliferation, promoted apoptosis and cell cycle arrest. Retinoblastoma1 (Rb1) was confirmed as miR-106a target by luciferase assay. These results suggest miR-106a may work as an oncogene in chemical carcinogen transformation (Jiang et al., 2011).
1.7.3 Additional Considerations

As for transcriptomics, confirming causal implication of microRNAs in tissue injury requires careful in vivo study design. Drug-induced expression changes of microRNAs should be monitored at early stages, before overt histopathological readouts are present. Also, dosing scheme and duration should mimic foreseen applications in patients. Including several time points and a washout phase can help observing microRNAs being affected earlier than others, or that persist altered even after discontinuation from the treatment.

Noteworthy, lack of extensive characterization of microRNAs expression in different cell types and their multiplicity of downstream effects, hinder the possibility to build up cell type or functional lists of microRNAs, as it is instead possible with regular genes (expression atlas and gene ontology). Systematic target discovery/validation and detailed expression profiling of tissues cell types will enable a direct interpretation of changes in a network of microRNAs and mRNAs.

In conclusion, the implication of microRNAs in cardiotoxicity is still to be investigated.

1.8 Circulating microRNAs: from intercellular signaling and organ injury biomarkers

1.8.1 The discovery and function of microRNAs in body fluids

In recent years, microRNAs were detected and characterized in several cell-free fractions of mammalian blood, including vesicles (exosome, microparticles and apoptotic bodies), but also in protein associated fractions, and globally called circulating microRNAs (Figure 1-12).
1.8.1.1 **Exosomes, microparticles and apoptotic bodies**

The presence of microRNAs in extracellular exosomes (50-90 nm) was first described by Valadi and collaborators in 2007 (Valadi et al., 2007). The same study revealed the extreme stability and resistance of cell-free microRNAs to enzymatic degradation. Further studies identified microRNAs in microparticles (>100 nm) and apoptotic bodies. In fact, studies conducted on mammalian cell lines suggest that extracellular and intracellular microRNAs pools are clearly distinct, since preponderant cytoplasmatic microRNAs are not the most abundant in the respective supernatant (Collino et al., 2010; Ohshima et al., 2010; Pigati et al., 2010). Furthermore respiratory chain inhibitors (i.e. rotenone) alter the microRNAs release kinetic pointing to a potential energy-dependent microRNAs secretion pathway (Wang et al. 2010b).

Microvesicles are important mediators of cell-to-cell communications, as they contain protein and chemokines (Ratajczak et al., 2006). In general, release of microRNAs form both exosomes and microparticles appear to be an actively regulated process, raising the possibility that vesicle-enclosed microRNAs may work as long-distance inter-cellular communication and regulation (Kosaka et al., 2010). Several studies documented how monocyte-secreted microvesicles contain high levels of miR-150, and can deliver it to different cells and inhibit miR-150 target c-Myb (Xiao et al., 2007; Zhang et al., 2010). Pegtel et al. found that an Epstein-Barr virus specific microRNA could accumulate in non-infected MoDC cells when co-cultured with EBV-infected B cells, and that this process is mediated by exosome transfer (Pegtel et al. 2010). Recently, Hergenreider et al. showed how vesicles encapsulated miR-143/145 cluster produced by HUVEC can control targets in co-cultured human smooth muscle cells, opening new avenues for atherosclerosis treatment (Hergenreider et al., 2012).

In addition to secreted vesicles, pools of microRNAs reflecting their cellular origin are also found in apoptotic bodies. Notably, miR-126 contained in
endothelial cells apoptotic bodies could mediate CXCL12 production in recipient vascular cells, thus mitigating atherosclerosis via incorporation of stem cell antigen-1 positive progenitor cells in atherosclerotic plaques (Figure 1-12) (Zernecke et al., 2009).

1.8.1.2 Membrane-free microRNAs complexes

More recent works proposed that microRNAs are present in membrane-free fraction, mainly in association with protein complexes or high-density lipoproteins (HDL). Ago2/miRNA complexes were identified in cell culture media (Turchinovich et al., 2011) and plasma (Arroyo et al., 2011). Protein-associated microRNAs originate mainly from cell death by-products and are stable in the bloodstream. This is partially attributed to further association of particle-free microRNAs to nucleophosmin (NPM1). Intrestingly, specific microRNAs, such as miR-16 and miR-92a, preferentially associated with vesicle fractions, while others, like let-7a, rather co-purified with protein complexes (Wang et al., 2010c). Human HDL was shown to contain microRNAs. Native HDL could incorporate microRNAs and deliver genetic material to recipient cells. RhoB and Efna1 mRNAs were decreased upon HDL-mediated miR-223 delivery in human cultured hepatocytes. HDL-microRNAs transfer was dependent on the known HDL receptor scavenger receptor class B type I (SR-BI). Furthermore, HDL obtained from familial hypercholesterolemia (FH) patients, contained a pattern of microRNAs that differed from control subjects, raising the possibility of using HDL-associated microRNAs as diagnostic markers (Vickers et al., 2011).
1.8.2 **Circulating microRNAs as tissue injury biomarkers**

Circulating microRNAs have been proposed to be non-invasive, sensitive and specific tissue injury biomarkers, thanks to their relative stability in the bloodstream and the easiness of quantification via qPCR. Upon injury of different etiologies (infectious, pharmacological, etc.) microRNAs are released in the circulation in apoptotic bodies, or in protein complexes, where are usually stable (Laterza *et al.*, 2009). A number of microRNAs are expressed in a tissue specific manner and can be relatively stable if released in body fluids. Profiling of circulating microRNAs as indicators of drug-induced tissue injury may help to reinforce histopathology and clinical chemistry endpoints. However not very
many microRNAs are known to be strictly tissue specific. MiR-122 is mostly expressed in the liver, miR-124 in the brain and miR-133a in heart and skeletal muscle (Laterza et al., 2009). Furthermore tissues are constituted by a heterogeneous population of cells assembled in distinct histological structures, characterized by different molecular expression.

### 1.8.2.1 Biomarkers of cardiovascular diseases

A growing field for application of circulating microRNAs as tissue injury biomarkers concerns the cardiovascular system, summarized in Table 1-5 (Fichtlscherer et al., 2011). Myonecrosis associated with acute myocardial infarction, acute coronary syndrome and viral myocarditis caused increase of miR-1, miR-133, miR-499 and/or miR-208 in the plasma of patients, as documented by several publications (Adachi et al., 2010; Ai et al., 2010; Cheng et al., 2010; Corsten et al., 2010; D'Alessandra et al., 2010b; De Rosa et al., 2011; Kuwabara et al., 2011; Wang et al., 2010b; Widera et al., 2011). Notably, miR-208 is the most cardiac specific microRNA, since its expression is restricted to the myocardial tissues, whereas miR-1, miR-133 and miR-499 are also expressed in skeletal muscles (Ji et al., 2009b). Furthermore, miR-208 was released in blood of rats after coronary artery ligation, while miR-1, miR-133a and miR-499 were increased in the circulation of sham operated animals, in respect to non operated animals (Wang et al., 2010b). None of the usual cardiac microRNAs was released in the circulation of patients suffering from congestive heart failure (CHF) (Adachi et al., 2010). However, in one case researchers observed an increase of circulating miR-423-5p in a 30 CHF patients cohort (Tijsen et al., 2010). Conversely, acute heart failure was associated with detectable increase of miR-499, reflecting a myocardial damage (Corsten et al., 2010).
Table 1-5: Circulating microRNAs in patients with cardiac disease, adapted from (Fichtlscherer et al. 2011). AMI: acute myocardial infarction; ACS: acute coronary disease; CHF: congestive heart failure; HF: heart failure; CAD: coronary artery disease

<table>
<thead>
<tr>
<th>Clinical Study Cohort</th>
<th>Groups and Numbers of Patients Studied</th>
<th>Major Findings</th>
<th>Association/Correlation</th>
<th>RNA Isolation</th>
<th>miRNA Detection</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI</td>
<td>33 pts with AMI</td>
<td>miR-208a, miR-1, miR-133a, miR-499↑</td>
<td>ROC curve: miR-208a shows highest sensitivity and specificity, comparable to TnI</td>
<td>Plasma, TRI Reagent BD, Spiking with cel-miR-39</td>
<td>qPCR TaqMan (ABI)</td>
<td>(Wang et al. 2010a)</td>
</tr>
<tr>
<td>AMI</td>
<td>33 pts with STEMI</td>
<td>miR-1, miR-133a, miR-133b, miR-499-5p↑</td>
<td>Time course of upregulated miR associated with TnI</td>
<td>mirVana PARIS isolation kit (Ambion, Austin, TX)</td>
<td>qPCR TaqMan (ABI) (normalized to miR-17)</td>
<td>(D'Alessandra et al. 2010)</td>
</tr>
<tr>
<td>AMI unstable angina</td>
<td>9 pts with STEMI, 5 pts with unstable angina</td>
<td>miR-499↑ in STEMI (within 48 h)</td>
<td>Correlation with CKMB</td>
<td>Vana PARIS Kit (Ambion) Spiking with small RNA</td>
<td>qPCR TaqMan (ABI)</td>
<td>(Adachi et al. 2010)</td>
</tr>
<tr>
<td>AMI</td>
<td>93 pts with AMI</td>
<td>miR-1↑</td>
<td>Association with QRS duration</td>
<td>mirVana PARIS (Ambion) protocol</td>
<td>qPCR</td>
<td>(Ai et al. 2010)</td>
</tr>
<tr>
<td>AMI</td>
<td>31 pts with AMI, 20 healthy controls</td>
<td>miR-1↑</td>
<td>Association with CKMB levels</td>
<td>mir Isolation Kit (RNA Bioscience)</td>
<td>qPCR, primer ABI, Roche Light cycler</td>
<td>(Cheng et al. 2010)</td>
</tr>
<tr>
<td>AMI</td>
<td>29 pts with ACS, 42 pts without ACS</td>
<td>miR-1, miR-133↑</td>
<td>Correlation with TnT</td>
<td>TRIzol LD (Invitrogen)</td>
<td>qPCR, TaqMan (ABI)</td>
<td>(Kuwabara et al. 2011)</td>
</tr>
<tr>
<td>AMI</td>
<td>32 pts with AMI, 36 pts with chest pain but normal angiogram</td>
<td>miR-208b, miR-133a, miR-499↑ miR-223↓</td>
<td>miR-208b and miR-499 correlate with TnT</td>
<td>mirVana PARIS kit (Ambion)</td>
<td>qPCR, MiScript primers (Qiagen), BR SYBR Green (Quanta Biosciences)</td>
<td>(Corsten et al. 2010)</td>
</tr>
<tr>
<td>ACS</td>
<td>444 pts with ACS</td>
<td>miR-133a and miR-208b associated with risk of death</td>
<td>miRNAeasy RNA isolation kit (Qiagen, Inc.)</td>
<td>qPCR, TaqMan (ABI)</td>
<td>(Widera et al. 2011)</td>
<td></td>
</tr>
<tr>
<td>Clinical Study Cohort</td>
<td>Groups and Numbers of Patients Studied</td>
<td>Major Findings</td>
<td>Association/ Correlation</td>
<td>RNA Isolation</td>
<td>miRNA Detection</td>
<td>Reference</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>---------------</td>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ACS</td>
<td>7 pts non-CAD</td>
<td>In pts with ACS: miR-133, miR-499, miR-208↑</td>
<td>Transcoronary gradients document cardiac release of miR-133 and miR-499</td>
<td>miRNeasy RNA isolation kit (Qiagen, Inc.)</td>
<td>qPCR, TaqMan (ABI)</td>
<td>(De Rosa et al. 2011)</td>
</tr>
<tr>
<td></td>
<td>31 pts stable CAD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19 pts ACS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>30 pts with heart failure</td>
<td>miR-423-5p↑</td>
<td>ROC showing that miR-423-5p is a predictor of heart failure</td>
<td>mirVana PARIS kit (Ambion)</td>
<td>qPCR High Resolution Melting Master (Roche)</td>
<td>(Tijsen et al. 2010)</td>
</tr>
<tr>
<td></td>
<td>20 pts with dyspnea (non-HF)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>39 healthy controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>15 pts CHF (II and III)</td>
<td>miR-499 below detection limit of the PCR in CHF pts and healthy controls</td>
<td></td>
<td>mirVana PARIS kit (Ambion)</td>
<td>qPCR TaqMan (ABI)</td>
<td>(Adachi et al. 2010)</td>
</tr>
<tr>
<td></td>
<td>10 healthy controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>33 pts with ischemic HF</td>
<td>miR-126↓</td>
<td>miR-126 negatively correlated with age, BNP and NYHA class</td>
<td>mirVana PARIS kit (Ambion)</td>
<td>qPCR TaqMan (ABI)</td>
<td>(Fukushima et al. 2007)</td>
</tr>
<tr>
<td></td>
<td>17 controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute HF</td>
<td>33 pts with acute HF</td>
<td>Acute Heart failure: miR-499↑</td>
<td></td>
<td>mirVana PARIS kit (Ambion)</td>
<td>qPCR, MiScript primers (Qiagen), BR SYBR Green (Quanta Biosciences)</td>
<td>(Corsten et al. 2010)</td>
</tr>
<tr>
<td></td>
<td>34 controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral myocarditis</td>
<td>14 pts with acute viral myocarditis</td>
<td>Acute viral myocarditis: miR-208, miR-499↑</td>
<td>Course of viral myocarditis</td>
<td>mirVana PARIS kit (Ambion)</td>
<td>qPCR, MiScript primers (Qiagen) BR SYBR Green (Quanta Biosciences)</td>
<td>(Corsten et al. 2010)</td>
</tr>
<tr>
<td></td>
<td>20 pts post-viral myocarditis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 aged-matched controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1.8.1 Technical aspects of microRNAs quantification in body fluids

Technically speaking, microRNAs quantification in plasma/serum is affected by high variability. Many factors, including withdrawal protocol, preparation of samples, age of the subject, diet and plasma components can alter the outcome of microRNAs profiling from human samples (Kim et al., 2012). Obtaining plasma from whole blood requires addition to the test tubes of anti-coagulant agents, such as heparin, EDTA, Na-citrate or NaF/KOx. These can have inhibitory effect on either the RNA isolation or reverse transcription and qPCR (Kim et al., 2012). Insufficient blood centrifugation, inaccurate supernatant withdrawal and hemolysis can lead to confounding cellular microRNAs to be co-purified and quantified. Therefore, standardized methods and accurate removal of contaminants (proteins, lipids and enzyme inhibitors) from body fluids is essential for quantification of microRNAs by qPCR.

1.9 Contribution to the field

In this thesis I will illustrate our strategies to generate data that can support elucidation of the molecular mechanisms of cardiac function and drug-induced cardiomyopathy. First, we identified a microRNAs signature altered by an anti-tumoral agent known for its cardiotoxicity (doxorubicin), and proposed a link with concomitant transcriptome variation, and we could identify a novel direct microRNAs-mRNAs interaction (miR-34/Sipa1). Second, we have uncovered the spatial distribution of microRNAs and mRNAs in 8 cardiac structures of rat, dog and Cynomolgus monkey, with a level of detail never achieved before in these model species. A subset of microRNAs with a patterned expression across cardiac structures was further characterized and 3 novel targets relevant for cardiac biology were validated (Timp3, Rbm24, Csnk2a2).
Ideally, our findings will contribute to develop more predictive safety models for drug development, especially for cardiac toxicity, as much needed in the field (Stummann et al., 2009).
Chapter 2: Perturbation of microRNAs in rat heart during chronic doxorubicin treatment

2.1 Abstract

Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) is limited by adverse effects of these compounds on the cardiovascular system, ultimately causing heart failure. Despite extensive investigations into the effects of doxorubicin on the cardiovascular system, the molecular mechanisms of toxicity remain largely unknown. MicroRNAs are endogenously transcribed non-coding 22 nucleotide long RNAs that regulate gene expression by decreasing mRNA stability and translation and play key roles in cardiac physiology and pathologies. Increasing doses of doxorubicin, but not EPS (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. Furthermore, the lowest dosing regime (1 mg/kg/week for 2 weeks) led to a detectable increase of miR-216b in the absence of histopathological findings or alteration of classical cardiac stress biomarkers. In silico microRNA target predictions suggested that a number of doxorubicin-responsive microRNAs may regulate mRNAs involved in cardiac tissue remodeling. In particular miR-34c was able to mediate the DOX-induced changes of Sipa1 mRNA (a mitogen-induced Rap/Ran GTPase activating protein) at the post-transcriptional level and in a seed sequence dependent manner. Our results show that integrated heart tissue microRNA and mRNA profiling can provide valuable early genomic biomarkers of drug-induced cardiac injury as well as novel mechanistic insight into the underlying molecular pathways.
2.2 Introduction

Doxorubicin (DOX), a potent drug used in cancer chemotherapy, intercalates with DNA and stabilizes a ternary complex with Topoisomerase II (Top2) thus preventing replication of DNA and subsequent cell proliferation (Momparler et al., 1976).

Despite its beneficial therapeutic effects, acute administration of high DOX doses causes severe kidney damage, whilst toxic cardiomyopathy is observed when DOX is chronically administered for several weeks at doses devoid of severe nephrotoxicity (Bardi et al., 2007; Chen et al., 2007; Jones et al., 2006; Storm et al., 1989). The exact mechanism of its cardiac toxicity remains largely unknown. In a clinical setting, the occurrence of DOX-induced cardiomyopathy is mitigated by prophylactic treatment with dexrazoxane (DZR), a Top2 inhibitor and iron-chelating agent which limits the amount of metal ions interacting with DOX and thus reduces oxidative stress (Jones et al., 2006). The cardioprotective mechanism of DZR is at present not fully understood (Hasinoff and Herman, 2007).

Administration of DOX ranging from 1 to 3 mg/kg/week to rats during several weeks recapitulates the cardiac symptoms observed in humans (Gianni et al., 2008; Herman and Ferrans, 1998). Similarly, combined treatment with DZR lessens the cardiac symptoms in rats treated with DOX (Thompson et al., 2009).

MicroRNAs are a class of genomically encoded non-translated short RNAs, about 22 nucleotides long, discovered in plants in 1993 (Lee et al., 1993). They are evolutionarily conserved throughout higher eukaryotes, from C.elegans to human, and their function is exerted via the mammalian RNA interference machinery (He and Hannon, 2004). They play a role in the post-transcriptional regulation of target genes, via imperfect base complementarities, and control gene expression mainly via translation inhibition and mRNA degradation (Filipowicz
et al., 2008; Guo et al., 2010; Wu and Belasco, 2008). MicroRNAs are involved in a diverse range of physiological and pathological processes including organism development (Marson et al., 2008), cancer (Croce, 2009) and immunity (Cullen, 2006; Rodriguez et al., 2007; Umbach and Cullen, 2009). In particular, microRNAs are key players in the development, physiology and pathology of the heart (Latronico and Condorelli, 2009; Thum et al., 2007; van Rooij et al., 2006). MicroRNAs have been shown to be differentially expressed in response to various signals resulting in post-transcriptional regulation of their predicted target genes. This extra level of regulation is critical during heart development and important in the cardiac response to stress (Callis et al., 2009; van Rooij et al., 2007).

Recent studies investigating DOX-induced changes in gene expression at the mRNA level in rat cardiac tissue have successfully identified genomic biomarkers whose molecular functions are consistent with proposed toxicity mechanisms (Thompson et al., 2009). However the emerging importance of microRNAs for the regulation of cardiac physiology and pathologies (Latronico and Condorelli, 2009; Thum et al., 2007; van Rooij et al., 2006), together with their potential to provide novel insight into mechanisms of xenobiotics-induced toxicity (Taylor and Gant, 2008), suggest that the integration of mRNA and microRNA profiling may provide new opportunities for elucidating mechanisms of DOX-induced cardiotoxicity.

In the present study, we report that the chronic myocardial toxicity induced by DOX in rats was associated with the modulation of microRNAs, and some of these can be phenotypically anchored to histopathology findings. Alteration of miR-216b could be detected earlier than overt myocardial damage. Furthermore, by integrating DOX-inducible microRNAs with mRNA profiles generated from the same cardiac tissue samples, the putative target genes of the DOX-induced microRNA signature were highlighted, including a number of genes that have not previously been described in DOX-induced cardiomyopathy. Finally, evidence for
the direct targeting of Sipa1 mRNAs by miR-34c was provided for the first time, and this microRNA-mRNA interaction could potentially play a role in the molecular response to DOX in the rodent heart.

2.3 Materials and methods

2.3.1 Rat in vivo study and histopathology evaluation

This in vivo study was conducted in compliance with the Animal Welfare Act, and the Office of Laboratory Animal Welfare, after review and approval by the Covance site (Vienna, Virginia) Institutional Animal Care and Use Committee. Doxorubicin (Adriamycin, Lot No. 86G23FY, CAS# 23214-92-8), a generous gift from Adria Laboratories Inc. (Columbus, OH, USA), etoposide (ETOPOPHOS® Lot No. 5E04155, CAS# 117091-64-2) was purchased from Bristol-Myers Squibb (Princeton, NJ, USA) and dexrazoxane (Zinecard® Lot No. ADR074B, CAS# 24584-09-6) purchased from Pharmacia/Pfizer (Kalamazoo, MI, USA) were administered once weekly as follows: 11 week old male Crl:CD(SD) rats received DOX or EPS via intravenous injection once a week for 2, 4, or 6 weeks according to Supplementary table 2-1 at a dose volume of 2 mL/kg. Animals in the DZR groups were given a 10 mL/kg intraperitoneal injection of DZR followed (30±2 minutes later) by a 2 mL/kg IV injection of 0.9% sodium chloride or DOX. The intravenous (iv) route of administration for DOX and EPS and the intraperitoneal (ip) route for DZR respectively, were selected to match the clinical route of administration in humans. More details are provided in the Supplementary Material and Methods and in a forthcoming publication from Gerrish et al. The experimental strategy is summarized in Figure 2-1.
2.3.2 Heart tissue RNA extraction

Total RNA was obtained from 50-100 mg frozen cardiac tissue homogenized in Trizol, according to manufacturer instructions (Invitrogen, Life Technologies, Carlsbad, CA). Long and short RNA fractions were separated via affinity resin column during clean up, according to the manufacturer instructions (miRNeasy Mini Kit, Qiagen, MD). Short RNA was quantified by absorbance at 260 nm using a Nanodrop (Thermo Scientific, Wilmington, DE), and the quality and integrity were determined using Small RNA chips (Agilent Technologies, Santa Clara, Ca) and stored at -80°C until analysis.

2.3.3 Gene expression profiling and analysis

GeneChip experiment was conducted in the BMD Genechip laboratories (Novartis, BS) on Rat Genome Rat230 2.0 Array (Affymetrix, Inc.). Target preparation was performed with a starting amount of approximately 1 µg of total RNA unless otherwise specified using the Affymetrix GeneChip HT One-Cycle Target Labelling and control reagent according to manufacturer’s instruction (Affymetrix, Inc.). cRNA size distribution (before and after fragmentation) was confirmed by agarose-gel electrophoresis. An amount of biotinylated cRNA of approximately 10 µg for each sample was hybridized for approximately 16 hours at 45°C on an array. The array was washed and stained on Affymetrix Fluidics Workstation 450 and scanned on Affymetrix Scanner 3000 according to manufacturer’s technical manual. The scanned image was converted into numerical values of the signal intensity (Signal) and into categorical expression level measurement (Absolute Call) using the Affymetrix MAS 5.0 software. The software scaled the average intensity of each chip to a target intensity of 150. The Genechip data will be uploaded in ArrayExpress.
2.3.4 Amplification of microRNAs via quantitative PCR

Using the Taqman Low Density Array (TLDA) technology (Applied Biosystems, Life Technologies, Carlsbad, CA), about 500 rodent microRNAs were profiled without any pre-amplification step, using 700 ng of small RNA according to the manufacturer instructions (Applied Biosystems, Life Technologies, Carlsbad, CA). Sufficient RNA amount for the TLDA cards was obtained for 3 out of 6 animals receiving DOX 3 mg/kg/week for 4 weeks, and for 6 out of 6 receiving DOX 3 mg/kg/week for 2 weeks. An arbitrary cut-off at 35 Ct was set in order to exclude microRNAs out of the linear range of detection. Mammalian snRNA U6 was used as housekeeping gene for its expression was not affected by DOX treatment. In order to confirm the results of the TLDA, a subset of microRNAs were quantified using single Taqman assays in the 3 remaining animals treated with DOX 3 mg/kg/week for 4 weeks. All procedures were carried out according to manufacturer instructions (Applied Biosystems, Life Technologies, Carlsbad, CA) using a 7900HT Fast Real-Time PCR System.

2.3.5 Data Analysis

MicroRNA data obtained from the TLDAs were quality checked and analyzed using Statminer plugin (Integromics, Madrid, Spain) for TIBCO Spotfire (TIBCO Software, Palo Alto, CA). Average fold changes and standard deviations were calculated and plotted using GraphPad Prism 5.00 (GraphPad Software, San Diego California USA). Lists of putative targets for each DOX regulated microRNA were obtained from Microcosm (Griffiths-Jones et al., 2008). Raw intensity values for each probe set were generated using RMA algorithm, using Genespring GX 7.3 (Agilent Technologies, Santa Clara, CA). Gene lists were filtered for raw expression (>80 raw signal in at least 50% of arrays) and anti-correlation with the microRNA (absolute fold change >1.3 or 1.5 in animals receiving DOX 3 mg/kg for 4 weeks versus control treated). Candidates passing
this cut-off were used to build networks of up- or down-regulated genes with their putative cognate microRNAs. P values were generated via unpaired, two-tailed Student t-test and were considered significant below 0.05. Phenotypic anchoring and Spearman correlation analysis were realized by using TIBCO Spotfire (TIBCO).

2.3.6 Cell culture and DOX treatment

HEK 293 (CRL-1573, ATCC) and rat myoblastic cells H9c2 (CRL-1446, ATCC) were cultured in MEM and DMEM respectively, supplemented with 10% v/v heat-inactivated fetal bovine serum (Invitrogen). DOX was purchased from Sigma, diluted in DMSO to a stock concentration of 10 mM and stored at -20°C. DOX treatment of H9c2 cells (n= 3) was independently repeated 3 times (total of 9 replicates). DOX was added cells transfected with microRNA reagents after 4 hours, buy replacing transfection medium with fresh growth medium supplemented with DOX at the indicated concentrations.

2.3.7 MicroRNA target luciferase reporter assay

Two-hundred nucleotides surrounding the microRNA predicted seed site in the 3’-UTRs of either murine Tnni3k or Sipa1 were synthesized (GeneArt, Invitrogen, Carlsbad, CA) and cloned into a pmiR-GLO vector (Promega, Madison, WI) downstream of the luciferase gene via a XbaI-SacI restriction site to generate the pmiR-GLO-Sipa1 wt expression vector. The pmiR-GLO expression vector contains both the luciferase and the Renilla genes under the control of different promoters. Complete insert sequences are listed in Supplementary Material and Methods section. Stratagene “Quick change” kit was used to introduce a 6 nt mutation in the miR-34c predicted seed site to generate the pmiR-GLO-Sipa1 mutant and the pmiR-GLO-Tnni3k mutant expression vectors.
Sipa1 mutagenesis Primer1: 5’- CTG CGC TGA GGC GCG TCT TAG GGA ATT CCC CTC TTC CCA GCC CAT TTG -3’. Sipa1 mutagenesis Primer 2: 5’-CAA ATG GGC TGG GAA GAG GGG AAT TCC CTA AGA CGC GCC TCA GCG CAG -3’.

2.3.8 Transfection of HEK 293

HEK 293 cells were plated in 24 wells plates 24 hours prior to co-transfection in antibiotic-free medium. Cells (2x 10^5 per well) were co-transfected with the reporter constructs (20ng/well) and synthetic mmu-miR-34a, b or c (40 or 80 nM) mimics (Dharmacon, Lafayette, CO) in serum-free medium, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). A C. elegans microRNA mimic with no affinity for mammalian targets was used as negative control. Dual-GLO Luciferase Assay System (Promega, Madison, WI) was used to assess luciferase relative luminescence, according to manufacturer instructions.

2.4 Results

2.4.1 Doxorubicin induced cytoplasm vacuolation and dysregulation of tissue genomic cardiomyopathy indicators

Male rats were treated with DOX according to the scheme reported in Figure 2-1A. Macro-and micro-vesicular vacuolation of individual cardiac myocytes was observed in atria and ventricles of DOX-treated animals. Representative histopathological image is shown in Figure 2-1B and C. Atrial and ventricular vacuolation occurred with increasing frequency and severity over time, with or without continued weekly exposure to drug (Supplementary table 2-2). The vacuoles could be caused by autophagic vesicles accumulation (Kobayashi et al., 2010); however, a hierarchical clustering using the expression of 31 autophagy-related genes could not discriminate between vehicle and DOX treated cardiac samples (data not shown). Given the small proportion of
cardiomyocytes undergoing vacuolation within the whole tissue it is possible that the expression changes of a large list of genes would be diluted by background signals. The treatment of DOXO at 1, 2 or 3 mg/kg/week for 2, 4 and 6 weeks showed a statistically significant increase of Ambra1 mRNA, a positive autophagy regulator (Fimia et al., 2007) but did not affect the level of other markers (Figure 2-6A).

Figure 2-1: Study design and representative micrograph showing DOX-related vacuolation in the myocardium. (A) Six adult male rats were injected with the indicated doses of vehicle, doxorubicin (DOX), dexrazoxane (DZR), etoposide (EPS) or a combination of DOX and DZR for 2, 4 or 6 weeks. Cardiac tissue was excised and deep frozen for gene expression and microRNA profiling experiments. A representative micrograph of a toluidine blue stained myocardial section of a control (B) and of a DOX treated animal (C). Black arrows indicate sarcoplasmic micro- and macro- vacuolation of cardiomyocytes.
The administration of DOX at 3 mg/kg/week induced time-dependent changes in the expression of mRNAs that have previously been associated with molecular responses underlying cardiac pathologies (de Bold et al., 1996; Dorn et al., 1994; Mikhailov and Torrado, 2008) (Figure 2-2).

Figure 2-2: DOX 3mg/kg/week altered levels of genomic cardiomyopathy indicators (Ankrd/Carp, Nppb, Myh7 and Myh6). Expression fold change relative to vehicle were represented for DOX 3 mg/kg/week at 2, 4 and 6 weeks time point (n= 6) for (A) Ankrd/Carp, (B) Nppb, (C) Myh7 and (D) Myh6. For each time point and each probe set, vehicle values were averaged and normalized to 1. The same correction was applied to the DOX treated values. Affymetrix probe-set number is indicated in brackets. Error bars represent standard deviation. T-test was performed for vehicle- vs. DOX-treated at each time point. *P<0.05, **P<0.01, ***P<0.005, NS=Non-Significant. (No t-test for #, as n=2).
A significant increase of Ankyrin repeat domain 1 (Ankrd1/Carp), natriuretic peptide precursor type B (Nppb) and myosin heavy chain 7 (Myh7/β) mRNA and a significant decrease of myosin heavy chain 6 (Myh6/α) mRNA was observed in the groups treated with DOX at 3 mg/kg/week. Together, these genomic cardiomyopathy indicators were significantly altered between 2 and 4 weeks of treatment and remained altered after 6 weeks of treatment.

Furthermore, they were not affected by EPS and DZR alone (data not shown). It is important to note that only two out of six animals survived 6 weeks dosing of DOX 3 mg/kg/week.

### 2.4.2 Perturbation of rat heart microRNAs during chronic DOX treatment

Expression profiles of 518 rodent microRNAs were generated by using a low density array qPCR platform (TLDAs). Approximately 370 microRNAs gave a measurable signal below the arbitrary cut-off set at 35 qPCR cycle times (Ct), with no major distinction between controls and treated samples. The administration of 4 weekly doses of DOX 3 mg/kg/week led to increased levels of 17 microRNAs and decrease levels of 8 microRNAs (p-value below 0.05) (Table 2-1). Notably, a subset of those was consistently modulated at the earlier 2 weeks time point (fold change > 1.5 are italicized in Table 2-1).

<table>
<thead>
<tr>
<th>DOX 3mg/kg/week</th>
<th>2 weeks</th>
<th>4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FC</td>
<td>P value</td>
</tr>
<tr>
<td>*mmu-miR-367 #</td>
<td>4.58</td>
<td>1.97E-01</td>
</tr>
<tr>
<td>*mmu-miR-215 #</td>
<td>1.11</td>
<td>9.41E-01</td>
</tr>
<tr>
<td>*mmu-miR-216b #</td>
<td>42.58</td>
<td>4.54E-03</td>
</tr>
<tr>
<td>*mmu-miR-383 #</td>
<td>2.22</td>
<td>5.69E-01</td>
</tr>
<tr>
<td>*mmu-miR-692 #</td>
<td>1.79</td>
<td>5.16E-01</td>
</tr>
</tbody>
</table>

Table 2-1: Chronic DOX treatment (3 mg/kg/week) alters levels of 25 microRNAs from week 2 onwards.
Variation of cardiac microRNA levels versus vehicle are reported for animals treated with DOX 3 mg/kg/week for 2 and 4 weeks. Values were calculated via the relative quantification (ΔΔCt) method by using the mammalian U6 snRNA as a normalizer. MicroRNAs showing same trend at 2 and 4 weeks are italicized. # indicates microRNAs selected for further analysis. Significant P values (<0.05) are in bold. FC= fold change.

<table>
<thead>
<tr>
<th>MicroRNA</th>
<th>FC 1-week</th>
<th>P-value 1-week</th>
<th>FC 2-week</th>
<th>P-value 2-week</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu-miR-135b</td>
<td>1.74</td>
<td>1.07E-01</td>
<td>12.69</td>
<td>4.04E-02</td>
</tr>
<tr>
<td>mmu-miR-667</td>
<td>1.49</td>
<td>3.08E-01</td>
<td>7.19</td>
<td>1.45E-02</td>
</tr>
<tr>
<td>mmu-miR-298</td>
<td>-1.44</td>
<td>1.83E-01</td>
<td>3.67</td>
<td>1.69E-02</td>
</tr>
<tr>
<td>mmu-miR-145*</td>
<td>1.60</td>
<td>8.87E-02</td>
<td>3.42</td>
<td>1.09E-02</td>
</tr>
<tr>
<td>mmu-miR-208b #</td>
<td>1.09</td>
<td>7.94E-01</td>
<td>3.23</td>
<td>3.05E-03</td>
</tr>
<tr>
<td>mmu-miR-21*</td>
<td>1.16</td>
<td>7.36E-01</td>
<td>3.21</td>
<td>4.26E-02</td>
</tr>
<tr>
<td>mmu-miR-877</td>
<td>1.55</td>
<td>1.79E-01</td>
<td>2.74</td>
<td>2.33E-02</td>
</tr>
<tr>
<td>mmu-miR-709 #</td>
<td>1.04</td>
<td>8.38E-01</td>
<td>2.51</td>
<td>7.28E-03</td>
</tr>
<tr>
<td>mmu-miR-708 #</td>
<td>1.11</td>
<td>7.08E-01</td>
<td>2.34</td>
<td>1.57E-02</td>
</tr>
<tr>
<td>mmu-miR-31</td>
<td>-1.02</td>
<td>9.68E-01</td>
<td>2.32</td>
<td>3.95E-02</td>
</tr>
<tr>
<td>mmu-miR-34c #</td>
<td>1.02</td>
<td>9.55E-01</td>
<td>2.25</td>
<td>3.06E-02</td>
</tr>
<tr>
<td>rno-miR-29b-2*</td>
<td>-1.10</td>
<td>6.84E-01</td>
<td>2.01</td>
<td>3.41E-02</td>
</tr>
<tr>
<td>mmu-miR-218-2* #</td>
<td>1.03</td>
<td>9.79E-01</td>
<td>-8.61</td>
<td>3.45E-03</td>
</tr>
<tr>
<td>mmu-miR-434-5p</td>
<td>-3.21</td>
<td>3.29E-01</td>
<td>-6.14</td>
<td>4.81E-02</td>
</tr>
<tr>
<td>rno-let-7e*</td>
<td>1.49</td>
<td>6.00E-01</td>
<td>-3.95</td>
<td>1.84E-02</td>
</tr>
<tr>
<td>mmu-miR-337-5p</td>
<td>-2.86</td>
<td>2.30E-01</td>
<td>-3.76</td>
<td>4.37E-02</td>
</tr>
<tr>
<td>mmu-miR-335-3p</td>
<td>1.43</td>
<td>1.33E-01</td>
<td>-2.52</td>
<td>3.47E-02</td>
</tr>
<tr>
<td>mmu-miR-384-3p</td>
<td>1.07</td>
<td>7.52E-01</td>
<td>-2.38</td>
<td>4.32E-02</td>
</tr>
<tr>
<td>mmu-miR-221</td>
<td>1.37</td>
<td>1.15E-01</td>
<td>-2.08</td>
<td>1.85E-02</td>
</tr>
<tr>
<td>rno-miR-1*</td>
<td>-1.16</td>
<td>8.05E-01</td>
<td>-2.01</td>
<td>3.29E-02</td>
</tr>
</tbody>
</table>

2.4.3 MiR-367, miR-215, miR-216b, miR-208b and miR-34c are specifically dysregulated by chronic DOX treatment

A subset of ten microRNAs whose expression was altered by chronic DOX treatment was selected based on their lowest p-values (Table 2-1) and evaluated their expression profile in additional individual animals from the same DOX treatment groups (originating from the same in vivo study) using single Taqman
assays (Supplementary figure 2-2). Five of these microRNAs (miR-208b, miR-215, miR-216b, miR-34c and miR-367) displayed a consistent dose-dependent response to DOX at 2 and 4 weeks and were thus chosen as candidates for further expression profiling across the larger in vivo study treatment groups including co- treatment of DOX with DZR and treatment with EPS only (Figure 2-3).

Following two weeks treatment with DOX alone, a slight up-regulation of miR-208b, mir-216b and miR-367 was observed in the heart of most animals. Following 4 weeks of treatment with DOX alone, the level of all five microRNA candidates were significantly increased and dose dependency was observed for miR-208b, miR-215, miR-216b and miR-367. Following 6 weeks of treatment with DOX alone, the levels of miR-208b, miR-215, miR-216b and miR-367 were significantly increased. Dose dependency was difficult to assess at the 6 week time point since only 2 animals survived in the high dose group.

Following treatment with DZR alone for 2 and 6 weeks, none of the five candidate microRNAs was affected. After treatment with the combination of DOX at 2 mg/kg/week and DZR at 50 mg/kg/week, the level of miR-208b, miR-216b and miR-367 was either slightly increased or not affected. For all five candidate microRNAs, the level was lower when compared to the group of animals treated for 2 weeks with DOX alone at 2 mg/kg/week. Following 6 weeks of treatment with the same DOX/DZR combination, the level of miR-208b, miR-216b and miR-367 was increased. However, this level was lower for miR-208b and miR-216b when compared to the group of animals treated 6 weeks with DOX alone at 2 mg/kg/week and higher for miR-367.

Following 2 and 6 weeks of treatment with EPS, the expression level of the 5 microRNA candidates was minimally affected and considered as non statistically significant since no dose and time dependency was observed (although these
changes might still be biologically relevant). Together, these data suggested that the variation of these five microRNAs was DOX-specific.

Figure 2-3: Relative quantification of DOX-responder microRNAs in rat heart across all groups. Relative quantification of (A) miR-208b, (B) miR-215, (C) miR-216b, (D) miR-367 and (E) miR-34c in DOX, DOX + DZR, EPS groups, normalized versus vehicle treated animals. Expression levels were measured by single assay qPCR (n= 3, except #, n= 2). DOX: Doxorubicin, DZR: dextrazoxane, EPS: etoposide; numbers indicate the weekly dose of each compound in mg/kg/week. Empty spaces represent non-sampled animals. The vehicle treated is the first column of each time-point. The animals used in this experiment were distinct from the ones represented in Table 2-1. Error bars represent SD. T-test results are indicated by asterisks for significant DOX-treated groups vs. their own vehicle-treated, unless otherwise specified by horizontal range bars; *P<0.05, **P<0.01, ***P<0.005, NS=Non-Significant).

In summary, chronic treatment with DOX at 3 mg/kg/week for 2 weeks led to increases in miR-208b, miR-216b and miR-367, with fold change intensities comparable to those shown by genomic cardiomyopathy indicators (Ankrd/Carp,
Nppb, Myh7 and Myh6) (Figure 2-2 and Table 2-1), suggesting that microRNAs may enhance the predictivity of established genomic indicators of drug-induced cardiomyopathy (e.g. myosin genes, troponins, natriuretic peptides) when assessing the potential for drug-induced cardiotoxicity.

### 2.4.4 DOX induced up-regulation of miR-216b and miR-367 earlier than tissue lesions as observed by histopathology

We then compared the variation of DOX-specific microRNA perturbations with the severity of cardiac tissue lesions induced by drug (cytoplasm vacuolation) in order to evaluate their sensitivity. Increasing doses of DOX led to higher cumulative vacuolation grading with time (Supplementary table 2-2), as well as progressively larger fold changes for microRNAs miR-208b, miR-216b and miR-367 versus vehicle. Notably, treatment with DOX 1 mg/kg/week during 2 weeks did not cause any detectable vacuolation, but showed a statistically significant increase of miR-216b (Figure 2-4). Treatment with DOX at 2 and 3 mg/kg/week for 2 weeks showed a statistically increase of miR-216b and miR-367 (Figure 2-4). Interestingly, we observed that miR-208b profile across treatment groups had the best statistically significant correlation score in comparison to the severity of vacuolation (Spearman R squared = 0.76, p= 4.45E-04) (Supplementary table 3). Therefore miR-208b may be implicated in the pathology mechanism of the vacuolation. These data suggest that DOX-induced perturbations of cardiac microRNA expression can precede overt tissue histopathology and that specific microRNAs may be useful as genomic indicators of drug-induced cardiac toxicity.
Figure 2-4: DOX-induced upregulation of miR-216 and miR-367 expression precedes the detection of overt histopathological lesions in cardiac tissue. Blue bars show cumulative vacuolation grade. X axis shows the DOX regimen in mg/kg/week received by the animals at 2 weeks. Y axes report cumulative histopathological scores and microRNA fold change vs. untreated cardiac tissues (normalized at value 1). Path grading = cumulative vacuolation score. FC= fold change. SEM= standard error on the mean.

2.4.5 MiR-34c regulates Sipa1 mRNA at the post-transcriptional level and is involved in autophagy process

Out of the 7804 mRNA targets for DOX-inducible microRNAs predicted by Microcosm, 132 (1.7%) mRNAs showed the expected profile of anti-correlated expression relative to its putative targeting microRNA (>1.5 fold change at DOX 3mg/kg/week for 4 weeks vs. vehicle) (Supplementary table 2-3). Since this low prediction rate could have been obtained by statistical chance, the putative microRNA-mRNA interaction of miR-34c/Sipa1 was selected for further
experimental evaluation. Treatment with DOX at 1, 2 and 3 mg/kg/week showed a dose-dependent decrease of signal-induced proliferation-associated 1 (Sipa1) and a dose-dependent increase of miR-34c (Figure 2-5A). Similarly, the treatment of H9C2 rat myoblasts with DOX at 0.1 and 1µM for 24h showed a decrease of Sipa1 mRNA and an increase of endogenous miR-34c (Figure 2-5B). The transfection of miR-34c mimics in H9c2 showed a statistically significant decrease of Sipa1 mRNA, as the transfection of miR-34c hairpin inhibitor (HI) showed a statistically significant increase of Sipa1 mRNA (Figure 5C). Notably miR-34c over-expression exacerbated Sipa1 down-regulation induced by DOX, while the transfection with mir-34c hairpin inhibitor significantly rescued the expression (Figure 2-5C), suggesting that miR-34c is mediating the DOX-induced regulation of Sipa1. Finally, to confirm whether the regulatory effect of miR-34c on the levels of Sipa1 mRNA was direct, 2 luciferase-based reporter expression vectors (pmiR-GLO-Sipa1 WT and mutated) were generated by cloning a 200 nucleotide region surrounding the predicted microRNA seed from each of their 3’-UTR regions downstream of a firefly luciferase reporter gene. The co-transfection of the Sipa1 reporter with miR-34c in HEK 293 cells showed a significant decrease in the luciferase signal. This decrease was observed to a lower extent with other members of the miR-34 family (Figure 2-5D) suggesting that miR-34c interacted directly and specifically with the 3’-UTR of Sipa1.

We have also used the rat myoblast H9c2 cell line to assess the DOX-induced autophagy process through the regulation of Ambra1 mRNA. Transfection of miR-34c mimics showed a statistically significant increase of Ambra1 mRNA. Transfection of miR-34c hairpin inhibitor showed a statistically significant decrease of Ambra1 mRNA. Treatment with DOX at 0.1 µM for 16h in the presence of miR-34c mimics showed a statistically significant increase of Ambra1 mRNA. Treatment with DOX at 0.1 µM for 16h in presence of miR-34c hairpin
inhibitor showed a statistically significant decrease of Ambra1 mRNA when compared to the presence of miR-34c mimics.

Figure 2-5: miR-34c directly controls DOX-induced Sipa1 mRNA decrease. (A) Sipa1 mRNA raw expression values decreased in the heart of rats treated with DOX. #, n= 2. (B) DOX treatment for 24h caused a decrease of Spa1 mRNA and an increase of miR-34c in cardiac myoblast cells (H9c2). (C) H9c2 endogenous Sipa1 mRNA was decreased by transfection of miR-34c mimic, and increased using a miR-34c hairpin inhibitor (HI). Transfection with miR-34c mimic and inhibitor respectively exacerbated and rescued Sipa1 mRNA levels in H9c2 treated with DOX 0.1 and 1µM overnight in comparison to negative controls. (D) Alignment of mammalian miR-34 family. Capital letters indicate mismatch in the sequence. Sipa1 3’-UTR wt and MUT construct: 12 nt surrounding the predicted seed are shown. HEK 293 cells were co-transfected with pmiR-GLO-Sipa1 and the indicated miRNA mimic or a C. elegans negative control mimic. Averaged and normalized Renilla luciferase signal was obtained from 3 independent experiments, each
run in quadruplicate. Y axis represents percentual residual luciferase activity in the indicated conditions. Mutant 3’ UTR restores luciferase activity in Sipa1/miR-34c. *P<0.05, **P<0.01, ***P<0.005.

The extent of Ambra1 mRNA regulation is slight but comparable between the *in vivo* systems and the H9c2. Treatment with DOX in H9c2 didn’t affect the level of miR-208b ruling out a potential implication of miR-208b with autophagy in this cellular model. Therefore miR-34c is directly implicated in the DOX-induced modulation of Sipa1 mRNA regulation.

![Graph A](image1.png)

![Graph B](image2.png)

Figure 2-6: Ambra1 expression was induced by DOX treatment *in vivo* and miR-34c could control its endogenous expression levels in H9c2 cardiac myoblasts. (A) Fold change of Ambra1 probe set in rat heart tissue treated with DOX. Fold change and statistical significance were assessed vs. each vehicle group. n= 4 to 6 (except #, n= 2) (B)
Endogenous levels of Ambra1 were measured after miR-34c over-expression (miR-34c mimic) or inhibition (miR-34c HI) in absence of presence of DOX 0.1. Fold change value were normalized vs. the respective negative transfection controls in the untreated condition (n=3). *P<0.05, **P<0.01, ***P<0.005. FC= fold change.

2.5 Discussion

In the present study 25 microRNAs were found to be dysregulated by pharmacological intervention with DOX in the rat heart. A subset of microRNA candidates were further investigated and associated to their putative targets.

The chronic weekly intravenous administration of DOX was designed to trigger cardiomyopathy symptoms within a 6 week time-frame allowing us to identify mRNAs and microRNAs that are altered in the early stages of the drug-induced cardiac remodeling. Cardiac toxicity at a cumulative dose of 12 mg/kg (3 mg/kg/week for 4 weeks) was confirmed by histopathological lesions and altered expression of genomic indicators associated to contraction performance (Myh6, Myh7) and heart failure (Ankrd1/CARP, Nppb) (Figure 2) (Caulfield and Wolkowicz, 1990; de Bold et al., 1996; Dorn et al., 1994; Mikhailov and Torrado, 2008; Suzuki et al., 1998). In most of the cases the dysregulation of these genes reached a significantly higher level between 2 and 4 weeks of the DOX 3 mg/kg/week dosing regimen. Additionally, 2 weeks treatment with DOX at 2 mg/kg/week onward caused cytoplasm vacuolation to occur with increasing severity.

We profiled hundreds of microRNAs via TLDAs in the heart of rats that showed clear signs of toxicity (DOX 3mg/kg for 4 weeks), and found that 25 microRNAs were dysregulated with p-values below 0.05. Seven out of 25 microRNAs (miR-367, miR-216b, miR-383, miR-692, miR-135b, miR-145*, miR-877, miR-434-5p and miR-337-5p), were already modulated after 2 weeks of DOX at 3 mg/kg/week (Table 2-1). Comparable changes for many of these
microRNAs were confirmed in additional animals, and a subset of five microRNAs (miR-208b, miR-215, miR-216b, miR-367 and miR-34c) and were largely unaffected by the direct Top2 inhibitor etoposide (EPS) (Figure 2-3). However DOX-induced up regulation of these microRNAs was not lessened by co-treatment with DZR, suggesting that these were not involved in the molecular pathways triggered by DZR.

It is noteworthy that miR-21 and miR-146a, previously linked to DOX-induced apoptosis in cardiomyocytes in vitro (Horie et al., 2010; Wang and Li, 2010a) or by single administration of a high dose of DOX in vivo (Horie et al., 2010), were not among the microRNAs regulated by our chronic DOX dosing regime in Sprague Dawley rats. Similarly, miR-1 and miR-133, known to have alternative effects on oxidative stress-induced apoptosis in myocytes (Xu et al., 2007), the former being pro-apoptotic and the latter anti-apoptotic, were not altered in the present study. These discrepancies may derive from several key differences in the model systems and study designs used. Importantly, primary cells or cell lines treated in vitro are not comparable to the whole cardiac tissue when exposed to metabolized systemic DOX and the work of Horie et al. explores the acute effect of a single high dose of DOX, which contrasts to the chronic regimen administered here. Our present study describes global changes in microRNAs during chronic drug-induced cardiac toxicity, in a way that closely resembles the safety signals observed in a clinical setting.

In our study miR-215, part of the miR-192/miR-215 cluster, and miR-34c, involved in DNA damage mediated proliferation arrest (Braun et al., 2008; Cannell et al., 2010; Georges et al., 2008; He et al., 2007), were up-regulated, consistent with the pharmacological effect of DOX. However miR-215 and miR-34c were not significantly up-regulated by EPS administration, suggesting that this compound may not trigger a p53 response under these experimental conditions.
Interestingly miR-215, up regulated by DOX in this study, was also linked to p53 mediated cell cycle arrest [37,38], consistent with the pharmacology of DOX and partially replicating expression changes of miR-34c upon treatment, thus strengthening the biological relevance of our findings and consistency with previously published mechanisms (Cannell et al., 2010).

MicroRNA-208b, encoded from the intron 28 of rat Myh7, is associated to maintenance of myocardial performance together with 2 other myomirs, i.e. miR-208a/miR-499, which play a pivotal role in the myosin balance (van Rooij et al., 2009). Consistent with previous work, the DOX-induced expression of miR-208b parallels the modulation of expression of its host gene Myh7 (Supplementary figure 2-1B) and occurs in parallel to the appearance of vacuolation (Supplementary table 3). The concomitant decrease of miR-208a and Myh6 levels upon DOX treatment (Supplementary figure 2-1A) further support the importance of the regulatory role of myomiRs-myosin interactions in the myosin switch, which is associated with progressive structural changes and pathological cardiac remodeling (van Rooij et al., 2009).

Of particular interest is the predictive potential of microRNAs as early tissue indicators of drug-induced cardiac lesions. The lowest dose of DOX tested in our study (1 mg/kg/week for 2 weeks) did not cause detectable tissue vacuolation (Supplementary table 2-2). However, miR-216b was already up-regulated (>1.5 fold) under these conditions, and miR-367 concomitantly increased at the earliest time point (2 weeks) in the different treatment groups. Treatment with DOX at all doses and time points was associated with sustained up-regulation of these microRNAs, together with miR-208b and miR-215 at later time points. Further studies will be needed to investigate the potential of circulating microRNAs as indicators of DOX-induced cardiac injury.

In order to gain further insight into the cellular processes that may be modulated upon DOX-induced cardiac toxicity, high confidence target mRNAs of
DOX-dysregulated microRNAs were identified by using the Microcosm prediction tool (Supplementary table 2-3 and Supplementary table 2-3). In particular, only the genes that had an anti-correlated change of expression at the mRNA level vs. the cognate microRNA were retained. The screening for putative targets of microRNAs in DOX treated animals, revealed that a number of DOX-responsive microRNAs may regulate mRNAs involved in cardiac tissue remodeling (data not shown), but we also speculated that the Sipa1 mRNA transcripts could be targeted by miR-34c directly. Sipa1 gene product is an activator of Rap GTPase and can influence proliferation rate and metastatic potential in various types of malignancies (Crawford et al., 2006; Minato and Hattori, 2009; Shimizu et al., 2011). Moreover cAMP-mediated Rap signaling, and its modulators, played a role in significant aspects of cardiovascular physiology, including cardiomyocytes contraction and hypertrophy (Jeyaraj et al., 2011). Importantly, Sipa1 mRNA showed an anti-correlated pattern with miR-34c in H9c2 cells treated with DOX 1 µM during 24h (Figure 2-5B). Reporter assay experiments further support that Sipa1 mRNA is a target of the miR-34 family, in particular miR-34c (Figure 2-5D). In addition, our observations in H9c2 myoblast cell line suggest that miR-34c could be involved in the stimulation of the positive autophagy regulator Ambra1, also in presence of DOX. In fact, miR-34c over expression increased the endogenous levels of Ambra1 mRNA in H9c2 cells (both with and without DOX). Vice versa transfection of a miR-34c-directed hairpin inhibitor showed a statistically significant decrease of Ambra1 mRNA level. However, the functional relevance of this finding in autophagy regulation and the exact mechanism of this regulation will have to be elucidated. Further studies, such as gain- or loss-of-function in vivo investigations, will be required to elucidate the functional significance of altered Sipa1 expression for cardiac responses to DOX. Immunochemistry staining of autophagy markers like Ambra1 in heart tissues will also be required to elucidate the functional involvement of
miR-215, miR-216b, miR-367, miR-208b and miR-34c in the DOX-induced autophagy process since they seem to be specifically associated to vacuoles appearance.

In conclusion, 25 microRNAs implicated in DOX-induced cardiac toxicity \textit{in vivo} were identified. Among them, miR-216b, which was significantly regulated before overt toxicity, has the potential of a genomic indicator of cardiac toxicity. Our study also provides the basis for understanding the global role of microRNAs in DOX-induced cardiac remodeling and toxicity, and provides evidence the direct miR-34c/Sipa1 functional interaction for the first time.

\textbf{2.6 Supplementary Material and Methods}

**Supplementary table 2-1: Doxorubicin study design in rats.**

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of animals</th>
<th>Doxorubicin (mg/kg/week)</th>
<th>Dexrazoxane (mg/kg/week)</th>
<th>Etoposide (mg/kg/week)</th>
<th>Dose duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Control</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>2 DOX Low</td>
<td>6 Male</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>3 DOX Mid</td>
<td>6 Male</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>4 DOX High</td>
<td>6 Male</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>5 EPS Low</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>6 EPS High</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>7 DZR</td>
<td>6 Male</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>8 DZR + DOX Mid</td>
<td>6 Male</td>
<td>2</td>
<td>50</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>9 Control</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>10 DOX Mid</td>
<td>6 Male</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>11 DOX High</td>
<td>6 Male</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>12 Control</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>13 DOX Low</td>
<td>6 Male</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>14 DOX Mid</td>
<td>6 Male</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>15 DOX High</td>
<td>6 Male</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>16 EPS Low</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>17 EPS High</td>
<td>6 Male</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>18 DZR</td>
<td>6 Male</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>19 DZR + DOX Mid</td>
<td>6 Male</td>
<td>2</td>
<td>50</td>
<td>0</td>
<td>6</td>
</tr>
</tbody>
</table>
2.6.1 Histopathology investigations of the heart

At necropsy, the heart was oriented with the left ventricle uppermost (i.e. aorta stem pointing towards operator) and then cut in half longitudinally. Each heart was longitudinally bisected from base to apex along the middle of the ventricular free walls to reveal right and left ventricles; right and left atria; both atrioventricular valves and the root of the aorta. One half of the bisected heart was placed in 4% formaldehyde/1% glutaraldehyde while the other half was flash-frozen for other studies. The fixed hemi-sections of heart were processed for methylmethacrylate plastic embedment, sectioned at 1-2 µm, stained with toluidine blue and examined histologically. Figure 2-1 shows representative histologic cardiac sections with evidence of cardiomyocellular injury, more specifically microvesicular vacuolation typical of doxorubicin cardiomyopathy (Bertinchant et al., 2003; Herman et al., 1985) (Figure 2-1B and C). Vacuolar changes in ventricular and atrial cardiomyocytes were recorded separately and semi-quantitatively graded using a simple cardiomyopathy scoring method based on the frequency and severity of observed changes on a four step arbitrary scale from minimal to marked (1=Minimal, 2=Mild, 3=Moderate and 4=Marked).

2.6.2 Murine Sipal 3’-UTR region cloned for reporter assay

Wild type:

5’-

cgttcaatctgaatctggacctttgcctggcccctcagagcaactgggtcatactagtgcccttcctcag
gacctttccctgcgctgaggcgcgtcttagcactgccccctcttcccagcccatttggtggctaatgcctgtccctgttt
gtaaatatcctgttaagaaaaaggagacactcagagttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
gacttctcctgagcgcgtcttagGGAATTcccctttccagccatatttggtgcaatgctggctaatgcctgtccc
 tgtttgtaatatcctgtaaagaaagagagcatcagaggttttttttttcatggcaggctacttcca
 ttataatgctctgccctctgaggtctcttcaagtcgtcttgcttattctgcgctcacgtaattcccttctacaggggtaggct
 ttcaagtgtcagacgacgatgacgacgatagatttagttgatatttaaaggtccttaattgcctgggggtggggttcaagtctgtgtagat

2.6.3 Murine Tnni3k 3'-UTR region cloned for reporter assay

Wild type:
5’- ccaggtctgacatacacaoagacagtgcagcagctgattttcccaatgcacctgagctctcgatggcaggctacttcca
attataatgctctgccctctgaggtctcttcaagtcgtcttgcttattctgcgctcacgtaattcccttctacaggggtaggct
ttcaagtgtcagacgacgatgacgacgatagatttagttgatatttaaaggtccttaattgcctgggggtggggttcaagtctgtgtagat

2.7 Supplementary Results

2.7.1 Body and organ weight

Treatment with DOX caused dose-dependent decreases in mean body weight and weight gain in animals dosed with 2 or 3 mg/kg/week. Treatment with combination of DOX and DZR similarly induced a significant decrease in mean body weight gain. The changes in mean body weight and body weight gain appear to directly correlate with decreases in mean food consumption. A similar decrease was not noted in animals that received DZR or EPS alone, indicating that the decrease in mean body weight gain was attributable to DOX. Of the animals that survived to scheduled euthanasia and necropsy, the overall, significantly decreased heart weight parameters indicated a progressive, irreversible DOX-related toxic effect at dose levels of 2 or 3 mg/kg/week. Decrements in heart weight parameters were mitigated when DZR was given in conjunction with DOX illustrating protective properties of DZR (data not shown). More details will be given in a forthcoming publication by Gerrish et al.
2.7.2 Hematology and clinical chemistry

Dose and time dependent alterations in hematology and serum chemistry were caused by DOX once weekly for 2, 4, or 6 weeks. There were minimal alterations in the clinical pathology from rats given DZR or EPS only (data not shown). In general, many of the alterations in rats given DOX in combination with DZR were of much smaller magnitude suggesting that it alleviates many of the side effects of DOX. More details will be given in a forthcoming publication by Gerrish et al.

2.7.3 Histopathology scores of cytoplasmic vacuolation in the heart

DOX-induced cardiomyopathy is characterized by sarcoplasmic micro- and macro-vacuolisation of the heart atrium and ventricle. These are generally categorized as minimal, mild, moderate and marked. In order to visualize the histopathological diagnoses we combined the pathology scores from the individual animals in each treatment group.

Supplementary table 2-2: Atrial and ventricular vacuolation incidence increases with doses of DOX. Microscopic histopathological findings. Severity of lesion is graded by numbers. Low= 1mg/kg/week regimen; Mid= 2 mg/kg/week regimen; High= 3 mg/kg/week regimen.

<table>
<thead>
<tr>
<th>Treatment/Dose/Duration</th>
<th>Control 2 wks 6</th>
<th>Dox Low 2 wks 6</th>
<th>Dox Mid 2 wks 5</th>
<th>Dox High 2 wks 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrial vacuolation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>minimal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mild</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>marked</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vacular vacuolation</td>
<td>minimal</td>
<td></td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>mild</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>marked</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment/Dose/Duration</td>
<td>Control 4 wks 6</td>
<td>Dox Mid 4 wks 6</td>
<td>Dox High 4 wks 6</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Atrial vacuolation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>minimal</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>mild</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

91
There is a progressive increase in the cumulative pathology score in the hearts from DOX-treated animals (Supplementary table 2-2).

Supplementary figure 2-1: MicroRNA-208a and 208b are regulated similarly as their hosting transcripts upon DOX treatment (Myh6 and Myh7 respectively) (n= 3). (A) Myh6 and miR.208a and (B) Myh7 and miR-208b fold changes vs. control in DOX 3mg/kg/week treated animals.
Supplementary figure 2-2. Single assay validation of TLDA data. Ten microRNAs among the DOX 3 mg/kg/week 4 weeks dysregulated microRNAs were assayed in the remaining 3 animal tissues at the same dose and in 3 animals for each indicated dose and timepoint (2 and 3 mg/kg for 2 and 4 weeks). All except miR-709 and miR-692 confirmed the trends observed with the LDA-qPCR technique. Fold changes for the given doses are indicated vs. untreated animals. (A) miR-208b. (B) miR-215. (C) miR-216b. (D) miR-218-2*. (E) miR-34c. (F) miR-367. (G) miR-383. (H) miR-692. (I) miR-708. (J) miR-709.
### 2.7.4 Putative targets of microRNAs responding to high dose DOX at 4 weeks

Supplementary table 2-3: Number of Microcosm predicted targets of 16 out of 25 microRNAs, responding to DOX 3 mg/kg/week after 4 weeks.

<table>
<thead>
<tr>
<th>Up-regulated</th>
<th>Predicted</th>
<th>Raw&gt;80</th>
<th>cutoff f FC 1.3</th>
<th>cutoff f FC 1.5</th>
<th>Gene symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu-miR-367</td>
<td>762</td>
<td>411</td>
<td>31</td>
<td>12</td>
<td>Alb, Igfbp5, Serpinf1, Cryl1, Itga6, Pros1, Sdc2, Dclk1, Man2a1, Marcks, Itgae Igtp</td>
</tr>
<tr>
<td>rno-miR-215</td>
<td>429</td>
<td>226</td>
<td>18</td>
<td>6</td>
<td>Dpp4, Bst2, Pdp2, Pcbd1, Pc, Man2a1</td>
</tr>
<tr>
<td>hsa-miR-216b</td>
<td>707</td>
<td>336</td>
<td>21</td>
<td>9</td>
<td>Gbp2, Cryl1, Map2k6, Afap111, Hrasls, Tmod4, Pxmp2, Pqlc1, Hfe2</td>
</tr>
<tr>
<td>mmu-miR-383</td>
<td>443</td>
<td>226</td>
<td>25</td>
<td>12</td>
<td>Cdh11, Slc25a25, Pdia4, Cryl1, Pllp, Fn1, Dtx3l,</td>
</tr>
<tr>
<td>gene product</td>
<td>target gene 1</td>
<td>target gene 2</td>
<td>target gene 3</td>
<td>target gene 4</td>
<td>target gene 5</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Abhd14b</td>
<td>Ccl5</td>
<td>Cd302</td>
<td>Ros1</td>
<td>Igtp</td>
<td></td>
</tr>
<tr>
<td>Sord</td>
<td>Casp12</td>
<td>Angpt1</td>
<td>Ugdh</td>
<td>Actr3b</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-135b</td>
<td>345</td>
<td>172</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-667</td>
<td>651</td>
<td>337</td>
<td>20</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-298</td>
<td>410</td>
<td>204</td>
<td>11</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-208b</td>
<td>572</td>
<td>399</td>
<td>11</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-877</td>
<td>325</td>
<td>163</td>
<td>15</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>mu-miR-708</td>
<td>333</td>
<td>158</td>
<td>18</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>gene product</th>
<th>target gene 1</th>
<th>target gene 2</th>
<th>target gene 3</th>
<th>target gene 4</th>
<th>target gene 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sord</td>
<td>Casp12</td>
<td>Angpt1</td>
<td>Ugdh</td>
<td>Actr3b</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-135b</td>
<td>345</td>
<td>172</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-667</td>
<td>651</td>
<td>337</td>
<td>20</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-298</td>
<td>410</td>
<td>204</td>
<td>11</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-208b</td>
<td>572</td>
<td>399</td>
<td>11</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-877</td>
<td>325</td>
<td>163</td>
<td>15</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>mu-miR-708</td>
<td>333</td>
<td>158</td>
<td>18</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>gene product</th>
<th>target gene 1</th>
<th>target gene 2</th>
<th>target gene 3</th>
<th>target gene 4</th>
<th>target gene 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sord</td>
<td>Casp12</td>
<td>Angpt1</td>
<td>Ugdh</td>
<td>Actr3b</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-135b</td>
<td>345</td>
<td>172</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-667</td>
<td>651</td>
<td>337</td>
<td>20</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-298</td>
<td>410</td>
<td>204</td>
<td>11</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-208b</td>
<td>572</td>
<td>399</td>
<td>11</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-877</td>
<td>325</td>
<td>163</td>
<td>15</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>mu-miR-708</td>
<td>333</td>
<td>158</td>
<td>18</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>gene product</th>
<th>target gene 1</th>
<th>target gene 2</th>
<th>target gene 3</th>
<th>target gene 4</th>
<th>target gene 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sord</td>
<td>Casp12</td>
<td>Angpt1</td>
<td>Ugdh</td>
<td>Actr3b</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-135b</td>
<td>345</td>
<td>172</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-667</td>
<td>651</td>
<td>337</td>
<td>20</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-298</td>
<td>410</td>
<td>204</td>
<td>11</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-208b</td>
<td>572</td>
<td>399</td>
<td>11</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-877</td>
<td>325</td>
<td>163</td>
<td>15</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>mu-miR-708</td>
<td>333</td>
<td>158</td>
<td>18</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>miRNA</td>
<td>Gene Assignment</td>
<td>Gene Count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------</td>
<td>------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rno-miR-31</td>
<td>Slc25a25, Crlyl1, Pfkbfb1, Cp, Wfde1c1, Ttc7</td>
<td>485 233 27 12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rno-miR-34c</td>
<td>Col3al, Serpinfo1, Cie4n-2, Pdia4, Mt1a, Fkbp4, Ttr, Prelp, Faim3, Wfde1c1, Adfp, Pce</td>
<td>532 276 24 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fxyd3, Stard10, Crlyl1, Itga6, Ppm1j, Nr1d1, Mecr, Marcks, Nid2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Down-reg</td>
<td>Srpk3, Eef2k, Lrrfip1, Ecm1, Cdc25b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rno-miR-337</td>
<td>Lrrc48, Max, Ppm1b, Lrrfip1, LOC497978</td>
<td>395 193 15 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rno-miR-335</td>
<td></td>
<td>444 238 20 10</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Raw gene expression was filtered to be higher than 80 in at least 50% of the conditions at the cumulative dose of 12 mg/kg. The absolute fold change anti-correlated to the cognate microRNA was used to further reduce the lists at 2 different stringencies. Number of genes passing these filters is indicated for each signature-microRNA for which prediction was available.

### 2.7.5 Bias in indexed NGS microRNAs profiling

In order to obtain information on the whole microRNAs population, we prepared cDNA libraries of small RNA samples isolated from the cardiac tissue of at least 5 animals per treatment condition.

As mentioned, the reduced size of the cellular microRNAs repertoire allows sequencing of multiple samples in the same run (multiplexing). We initially attempted pooling small RNA samples ligated with 5’ adapters carrying the indexed sequence (barcode) 3’ end, (grey oligo sequence in Supplementary figure
2-3, Supplementary table 2-4). However, the composition of the sequenced libraries was biased by the index used, as showed by a principal component analysis in Supplementary figure 2-4. Samples prepared from the animals belonging to different pharmacological treatment groups clustered by the “barcode” sequence and not by the condition, possibly due to sequence “preferences” of the ligase or polymerase enzymes used in the sample preparation, which resulted in apparently enhanced or depleted read counts of a number of microRNAs. We therefore proceeded to profiling microRNAs using TLDA cards, as described in the coming paragraphs.

**Supplementary figure 2-3:** Next generation sequencing library with 5’ adapters indexed at their 3’ end. Sequential ligation at the 3’ (green) and the indexed 5’ (pink and grey) adapters to small RNAs (blue) is followed by library reverse transcription and PCR amplification. Only the products running at 123 nt (red box) are excised from polyacrylamide gel in order to avoid primers duplexes and unspecific PCR products.

More recently validated protocols for multiplexing were released by sequencing suppliers, thanks to the increased read length and improved chemistry that allowed paired-end runs for microRNAs applications. In this case the
“barcode” sequence is at the 5’ of the adapter and is read during a second round of sequencing in the opposite direction. This strategy did not lead to any anomaly in the clustering of samples (data not shown).

Supplementary table 2-4: Barcoded adapters used in preliminary sequencing experiment.

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence : (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barcode 1</td>
<td>5’GUUCAGAGUUCUACAGUCCGACGAUCAAAC</td>
</tr>
<tr>
<td>Barcode 2</td>
<td>5’GUUCAGAGUUCUACAGUCCGACGAUCACCC</td>
</tr>
<tr>
<td>Barcode 3</td>
<td>5’GUUCAGAGUUCUACAGUCCGACGAUCAGGC</td>
</tr>
<tr>
<td>Barcode 4</td>
<td>5’GUUCAGAGUUCUACAGUCCGACGAUCAUUC</td>
</tr>
<tr>
<td>Barcode 5</td>
<td>5’GUUCAGAGUUCUACAGUCCGACGAUCACCC</td>
</tr>
<tr>
<td>Barcode 6</td>
<td>5’GUUCAGAGUUCUACAGUCCGACGAUCCCGC</td>
</tr>
</tbody>
</table>

Libraries of small RNA samples were prepared using 6 different adapters. The 3 sub-terminal nucleotides (bold) were read within a multiplexed sequencing experiment and used to assign each read to the samples of origin.

Supplementary figure 2-4: Sequenced libraries cluster according to the index sequence (symbols) and not by condition (colors) when adapter indexing is proximal to ligation site.
2.7.6 Effect of DOX 2mg/kg/week and its combination with antidote DZR on microRNAs related to cardiac diseases after 6 weeks

MicroRNAs involved in cardiac diseases include miR-1, miR-15 family, the myomiRs (miR-208a/b and miR-499), miR-21 and miR-29. Of particular interest miR-21 and miR-29b as fibrotic tissue remodeling is one of the most characterized outcomes of cardiac stress induced by anthracyclines (Jones et al., 2006; Migrino et al., 2008). Members of the miR-15/16 family were implicated in cardiac remodeling, including angiogenesis and post-ischemic injuries (Hullinger et al., 2012).

Treatment with DOX 2 mg/kg/week (medium dose) significantly altered the levels of miR-208b, miR-21 and miR-1. However only for miR-208b this change was conspicuous (>2 folds vs. vehicle) and relieved by co-treatment with the antidote DZR. DOX treatment did not lead to significant alteration of miR-499 and miR-15a/miR-16, while a small increase was observed in the co-treatment group, but not in the DZR alone group. Neither treatment significantly altered miR-208a. No DOX-related effect was detected in the case of miR-29b, but a small decrease was caused by the treatment with DZR alone (Supplementary figure 2-5).

In conclusion, among the microRNAs tested, the variation of miR-208b measured in the cardiac tissue was a conspicuous and specific change induced by DOX, and also reflected the protective effect of DZR.
Supplementary figure 2-5: Variation of levels of microRNAs implicated in cardiac diseases in the heart tissue of rats after a 6 weeks treatment with DOX 2 mg/kg/week alone, or in combination with DZR. Fold change vs. vehicle is indicated for individual animals (n=6). Stars indicate statistical significance vs. vehicle, or otherwise indicated. *P<0.05, **P<0.01, ***P<0.005 (n=6).
2.7.7 Early changes in gene expression suggest both structural and functional damage are induced by DOX

Changes in expression level of genes implicated in glycolysis/gluconeogenesis, Nrf2-mediated oxidative stress, mitochondrial activity, ion homeostasis, carbohydrate metabolism and proliferation were among the early changes induced by DOX in SH rats by Thompson and colleagues in 2009 (Thompson et al., 2009). In our study, DOX 3mg/kg/week caused decrease of Ryr2, Gpd2 and Igfbp5 transcripts, and an increase of Hmox1, Pfkp and Scn1a from week 2 onwards (Supplementary figure 2-6). Ryanodin receptor 2 (Ryr2) plays a major role in calcium homeostasis, and intracellular ion disturbances are linked to heart failure and arrhythmias (Lehnart et al., 2009; Yano et al., 2005a; Yano et al., 2005b). The decrease of mRNA levels of glycerol-3-phosphate dehydrogenase 2 (Gpd2), part of the glycerol phosphate shuttle in mitochondria, and of insulin-like growth factor binding protein 5 (Igfbp5), associated with cell proliferation and cancer (Akkiprik et al., 2008), might suggest a loss of myofibrillar functionality and regeneration potential.

Also, higher levels of phosphofructokinase (Pfkp) level contribute to the impairment of carbohydrate metabolism efficiency caused by chemically-induced oxidative stress (Janero et al., 1994), after 4 doses of DOX 3mg/kg.

Sodium channel, voltage-gated, type I, alpha (Scn1a) is a neuronal sodium channel isoform and its expression level was previously characterized by Xi et al. in a model of failing heart in rodents, and found increased upon pressure overload (Xi et al., 2009). Scn1a transcript levels are increased by DOX in the present study, which implies a disruption of the physiological action potential that resembles the failing heart.

In our study DOX 3 mg/kg/week induced changes in expression level of genes implicated in these processes from week 2 onwards (Supplementary figure 2-6).
Supplementary figure 2-6: Treatment with DOX alters the expression of genes involved in several cellular processes, critical to cardiac function. Fold change is represented by the ratio between averaged DOX vs. vehicle-treated signal intensity values for each probe-set, obtained by microarray genomic profiles. Error bars represent standard deviation. *P<0.05, **P<0.01, ***P<0.005 (n=6).

The behavior of such a gene-signature suggests that both metabolic and structural functions are deeply compromised by the DOX treatment, as described by previous works.
2.7.8 **DOX induces expression of anti-tumoral microRNAs**

Consistently with the pharmacological action of DOX, and according to the characterization of some microRNAs based on previous works, there is a general signature of block of proliferation as suggested by the 4 anti-tumoral microRNAs up-regulated (miR-215, miR-216b, miR-31 and miR-708), the 2 p53 transcriptional responders also up-regulated (miR-34c and miR-215) and 1 downregulated onco-miR (miR-221) as shown in Supplementary table 2-5.

**Supplementary table 2-5: Literature available on DOX dysregulated microRNAs. When information was available only for the other arm of the microRNAs the mature miRNA name is in bold**

<table>
<thead>
<tr>
<th>Early regulated at both 2 and 4 weeks</th>
<th>Function</th>
<th>Selected publications</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu-miR-367</td>
<td>Expressed in embryo, inhibits Ryr3 gene</td>
<td>(Suh et al., 2004; Zhang et al., 2011)</td>
</tr>
<tr>
<td>mmu-miR-216b</td>
<td>Tumor suppressor, targets κ-Ras</td>
<td>(Deng et al., 2011)</td>
</tr>
<tr>
<td>mmu-miR-383</td>
<td>Role in spermatogenesis</td>
<td>(Lian et al., 2009)</td>
</tr>
<tr>
<td>mmu-miR-145*</td>
<td>80 papers on miR-145 and inhibition of cells growth, in smooth muscle cells</td>
<td>(Rangrez et al., 2011)</td>
</tr>
<tr>
<td>mmu-miR-877</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>mmu-miR-135b</td>
<td>Placental µRNA, detectable in plasma, involved in prostate cancer, miR-135a downreg in DMD, osteogenic differentiation</td>
<td>(Chim et al., 2008; Greco et al., 2009; Schaap-Oziemlak et al., 2010; Wang et al., 2008)</td>
</tr>
<tr>
<td>mmu-miR-692</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Down-regulated**

| mmu-miR-434-5p | - | - |
| mmu-miR-337-5p | - | - |

**Late regulated at 4 weeks only**

<table>
<thead>
<tr>
<th>Up-regulated</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu-miR-208b</td>
</tr>
<tr>
<td>miRNA</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>mmu-miR-21*</td>
</tr>
<tr>
<td>mmu-miR-298</td>
</tr>
<tr>
<td>mmu-miR-31</td>
</tr>
<tr>
<td>mmu-miR-34c</td>
</tr>
<tr>
<td>mmu-miR-708</td>
</tr>
<tr>
<td>mmu-miR-709</td>
</tr>
<tr>
<td>rno-miR-29b-2*</td>
</tr>
<tr>
<td>mmu-miR-215</td>
</tr>
<tr>
<td>mmu-miR-667</td>
</tr>
<tr>
<td>mmu-miR-218-2*</td>
</tr>
<tr>
<td>mmu-miR-221</td>
</tr>
<tr>
<td>mmu-miR-335-3p</td>
</tr>
<tr>
<td>mmu-miR-384-3p</td>
</tr>
<tr>
<td>rno-let-7e*</td>
</tr>
<tr>
<td>rno-miR-1*</td>
</tr>
</tbody>
</table>
Chapter 3: Heart structure-specific gene expression (transcriptomic) profiling reveals conserved microRNA-mRNA interactions relevant to cardiac physiology and function

3.1 Abstract

MicroRNAs are short non-coding RNAs that regulate gene expression at the post-transcriptional level and play key roles in heart development and cardiovascular disease. Here, we have characterized the expression and distribution of microRNAs across 8 cardiac structures (left and right ventricles, apex, papillary muscle, septum, left and right atrium and valves) in rat, canine and Cynomolgus monkey using miRNA-seq. Conserved microRNA signatures enriched in specific heart structures across these species were identified for cardiac valve (miR-let-7c, miR-125b, miR-127, miR-199a-3p, miR-204, miR-320, miR-99b, miR-328 and miR-744) and myocardium (miR-1, miR-133b, miR-133a, miR-208b, miR-30e, miR-499-5p, miR-30e*). The relative abundance of myocardium- (miR-1) and valve-enriched (miR-125b-5p and miR-204) microRNAs was confirmed using in situ hybridization. Potential microRNA-mRNA interactions were explored using anti correlation expression analysis in matched samples and microRNA target prediction algorithms. These included miR-1/Timp3, miR-125b/Rbm24, miR-204/Tgfbr2 and miR-208b/Csnk2a2, for which respective post-transcriptional inhibition was confirmed by over-expression in human pulmonary smooth muscle cells and in a luciferase reporter assay. In conclusion, we have generated a high-resolution heart structure-specific mRNA/microRNA expression atlas for three mammalian species relevant to biomedical research and uncovered novel microRNA regulatory circuits that provide novel insight into cardiac physiopathology.
3.2 Introduction

MicroRNAs are ~22 nucleotides long non-coding RNAs, genomically encoded and conserved throughout evolution in all superior organisms. MicroRNAs are regulators of gene expression, acting mainly at the post-transcriptional level, by directing the RISC complex to target mRNAs via imperfect complementarity (Fabian et al., 2010) which mediates inhibition of translation and mRNA decay. The expression levels of many genes can be influenced by microRNAs (Lim et al., 2005). However, the lack of perfect complementarity between microRNAs and their target mRNAs jeopardizes the prediction of the targets, and in silico prediction tools need further optimization (Thomas et al., 2010).

During development, cellular microRNA pools are highly dynamic, tuned by temporal and spatial cues (Martinez et al., 2008; Mendell, 2008; Shkumatava et al., 2009; Stark et al., 2005) and accumulating evidences implicate microRNAs in numerous physiological and pathological processes, as well as responses to xenobiotics, including drug-induced cardiotoxicity (Fukushima et al., 2007a; Izzotti et al., 2010; Lema and Cunningham, 2010; Marsit et al., 2006a; Pogribny et al., 2007; Sathyan et al., 2007; Schembri et al., 2009; Yokoi and Nakajima, 2011; Zhang and Pan, 2009). In particular, several microRNAs preferentially expressed in different types of muscles (miR-1, miR-133, and the myomiRs miR-208, miR-208b and miR-499, among others) play a pivotal role in maintenance of cardiac function (Catalucci et al., 2009; Small and Olson, 2011), and the ablation of microRNAs-RISC machinery can have dramatic effects on cardiac development (Chen et al., 2008b; da Costa Martins et al., 2008; Hauck et al., 2008a).

Notably, drug-induced cardiac toxicity, which is often irreversible, ranks among the most frequent reasons for compound attrition due to safety liabilities during pharmaceutical development. Histopathological read-outs, the golden
standard in safety assessment, often do not provide mechanistic explanations. These can be addressed by detection of drug-induced toxic events at earlier stages by genomic profiling, which also helps generating mechanistic hypotheses. In principle, given the central role played by microRNAs in post-transcriptional regulation, a change in the level of a specific microRNA may be prodromal to expression change of a target gene, suggesting that integrated mRNAs/microRNAs expression profiling can improve the understanding of drug-induced events at the molecular levels and translatable to the clinical context.

Although the sequences conservation of microRNAs across species has been thoroughly studied, systematic data on the degree of similarity of microRNAs distribution within complex organs and/or tissues across mammalian species are still lacking. Availability of an expression atlas can help to address the role of microRNAs pool in gene expression homeostasis in specific cell types and tissue structures at the steady state, revealing novel relevant regulatory circuits, and also be a potential source for circulating lesion markers.

In this work, we generated ad hoc data sets of matching microRNA and mRNA profiles from 8 cardiac structures, including apex, left and right ventricular walls, papillary muscle, septum, left and right atrial walls and cardiac valves, from 3 preclinical mammalian species relevant to human biology (Rattus norvegicus, Canis familiaris, and Macaca fascicularis). We identified highly expressed microRNAs that can cluster apart the different cardiac structures and found that a number of microRNAs showed a specific pattern of expression conserved in the 3 analyzed species, with particular emphasis on the cardiac valves. By comparing mRNAs with microRNAs expression across the cardiac structures, we could identify genes that had highly anti-correlated expression pattern with their predicted targeting microRNA. Among these, we confirmed that miR-1, miR-208b, miR-204 and miR-125b could directly modulate genes relevant for
cardiac/muscle physiopathology (i.e. Timp3, Csnk2a2, Tgfbr2, Akap2 and Rbm24).

Our data provide a large, comprehensive and homogenous amount of cross-species information for hypothesis-generation on the role of microRNAs, and can be further used to 1) identify microRNAs signatures characteristics of cardiac structures, 2) further elucidate microRNAs/mRNAs interactions relevant for cardiac physiology and 3) propose novel tissue injury specific indicators.

3.3 Material and methods

3.3.1 Experimental strategy

Different cardiac structures were dissected by hand from at least 3 Wistar rats, Beagle dogs and Cynomolgus monkeys (Cyno), as indicated in Figure 3-1. Small (<200 nt) and long RNA was isolated from the very same samples. Messenger RNAs transcriptome was generated via Affymetrix Gene Chip technology from all available samples (Figure 3-1). Based on the mRNAs profiles, we sub-selected the 3 samples from each structure that had the lowest cross-contamination with neighboring regions, and proceeded with microRNAs next-generation sequencing (miRNA seq) (Figure 3-1). Sequencing reads were mapped to miRBase, version 17, containing 1424 human, 720 murine and 383 canine entries. In parallel, rat microRNAs were also profiled using a TLDA qPCR approach. On average, a Spearman correlation of 0.835 ± 0.016 was observed when comparing the TLDA with the miRNA seq data set, confirming the reliability of the miRNA seq approach (Supplementary figure 3-4).
3.3.2 Heart tissue dissection

Hearts were obtained from naïve adult male Wistar rats, during necropsy. Following brief infusion with saline, a first cut was made parallel to the auricles, adjacent to the level of the atria; both portions were again rinsed with saline, in order to remove most of the blood. Cardiac valves (mitral and tricuspid) were dissected at first, followed by atria, septum, ventricles and apex. All tissues were snap frozen in liquid nitrogen and stored at -80°C until RNA isolation. Similar procedure was carried out for male adult Beagle dogs and female adult Cynomolgus monkeys (*Macaca fascicularis*).
3.3.3 RNA isolation

Cardiac frozen tissue, sectioned and snap frozen as described in the previous section, was homogenized in Qiazol reagent according to manufacturer instructions. Organic extraction of RNA was achieved by adding chlorophorm and high speed centrifugation at 4°C. RNA-containing upper aqueous phase was mixed with 1 volume of 70% EtOH and loaded into RNeasy minispin columns and briefly spuned at room temperature according to miRNeasy mini kit instructions (Qiagen). The content of this filter-column was then processed to obtain total RNA, while the first flow through, enriched in <200 nt RNA (small RNA fraction) was then processed through an RNeasy Clean-up column, according to manufacturer instructions (Qiagen, MD). Small RNA was eluted in 15 µl of nuclease free water, quantified via 260nm absorbance and quality checked using the Bioanalyzer small RNA chips.

3.3.4 Gene expression profiling

Processing of total RNA and Gene Chip experiments were conducted as recommended by the manufacturer (Affymetrix, Santa Clara, CA). Messenger RNAs isolated from rat, canine and Cynomolgus were hybridized on 3’IVT arrays Rat230_2, Canine_2 and HG-U133_Plus_2 respectively.

HPASMC cells endogenous genes expression was obtained using Taqman assays for the corresponding human transcript, according to manufacturer instructions. Briefly 300 ng of RNA were reverse transcribed to cDNA using the High Capacity Reverse Transcription kit. Two µl of cDNA were used in a 20 µl qPCR reaction in 7900HT machines (all Applied Biosystems, Life Technologies, Carlsbad, CA), 18S was used as reference housekeeping gene.

3.3.5 MicroRNA Next Generation Sequencing

Indexed miRNA sequencing libraries were prepared from 100 ng small RNA using TruSeq Small RNA Sample Preparation Kits (Illumina). After PCR
amplification multiplexed libraries were generated by equimolary pooling of individual libraries. The multiplexed libraries were size selected on 6% TBE-PAGE gels (Invitrogen). The libraries were loaded on HiSeq Single Read Flow Cells v1.5 using TruSeq Single-Read Cluster Generation Kits (v2). The sequencing runs were done on HiSeq 2000 instruments.

3.3.6 TLDA qPCR

Three-hundreds and eighty rodent microRNAs were profiled using the Taqman Low Densitiy Array (TLDA) technology (Applied Biosystems, Life Technologies, Carlsbad, CA) according to the manufacturer instructions (Applied Biosystems, Life Technologies, Carlsbad, CA). Mammalian snRNA U6 was used as housekeeping gene.

3.3.7 Localization of microRNAs via ISH

Detection of microRNA by ISH was performed using double-digoxigenin labeled miRCURY LNA™ probe provided by Exiqon A/S (Vedbaek, Denmark).

ISH on rat heart tissue section was done using the fully automated instrument Ventana Discovery Ultra® (Roche Diagnostics, Rotkreuz, Switzerland). All chemicals were also provided by Roche Diagnostics except the “microRNA ISH optimization kit” provided by Exiqon A/S. Briefly, formalin fixed paraffin embedded sections were de-paraffinized and rehydrated under solvent-free conditions (EZprep solution) and pretreated by enzymatic digestion (Proteinase K at 12 µg/ml for 16 minutes at 37°C). Hybridization was performed adding to each slide 50 nM of DIG-LNA probe diluted in the Exiqon hybridization buffer and incubated for 3 hrs. After hybridization, sections were washed on stringency conditions (see Supplementary table 3-1 for details).

DIG-label LNA probe detection was performed using an Alkaline Phosphatase-conjugated Sheep anti-digoxigenin antibody (Roche Diagnostics) diluted 1/500 in antibody diluent. Antibody incubation was carried out for 30 min at 37°C
followed by chromogenic detection using BlueMap™ Kit with a substrate incubation time of 6 hrs.

Counterstaining using ISH nuclear fast red was performed for 2 min. Sections were mounted in Glycerol-gelatin mounting medium (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and post-mounted using Pertex™.

**3.3.8 Data analysis of gene expression profiles and microRNAs sequencing**

The generated “.cel” files were loaded in Genespring 11.5.1 (Agilent Technologies, Santa Clara, CA) and further processed according to the standard RMA workflow. Expression data were analyzed at the gene level. Preferentially enriched gene lists were generated by retaining the top 10th percentile most expressed genes in all replicates of at least one structure. Genes that were 5 fold more expressed in one cardiac structure vs. the median of all the remaining were retained.

Illumina NGS reads were aligned to the respective miRBase v.17 (Griffiths-Jones et al., 2008) reference sequences for the different species and to the in-silico computed sequences of their precursor molecules using the Bowtie short readaligner (Langmead et al., 2009). The miRNA abundance was quantified using an in-house NGS analysis pipeline, normalized to robust estimates of the individual sequencing library sizes. MicroRNAs hierarchical Euclidean centroid-linkage clustering and distance matrix were plotted using MeV package (Saeed et al., 2006). The normalized read counts were averaged per structure and the top 10th percentile most expressed microRNAs in at least one structure were compared across the other data sets of the same species in order to determine those preferentially expressed in each structure (average expression fold change >2, top 10th percentile expressed). All mRNA expression values were computed using the standard Bioconductor RMA normalization and quantification algorithm (Gautier et al., 2004). The mouse miRNA target predictions were extracted from TargetScan (Version 5.2) (Grimson et al., 2007) and translated to the rat and dog
genomes by homology mapping based on the ENSEMBL gene orthology predictions. These were systematically plotted against the corresponding microRNA across cardiac samples in order to generate a Spearman correlation scores from -1 to +1. Genes expressed at a lower level in samples enriched with their targeting microRNAs, and vice versa, obtained a more negative score and will be referred to as anti-correlated.

The degree of correlation between qPCR and miRNAseq profiles was obtained by computing Pearson and Spearman correlation factors (r and rs respectively) for each sample pair and for the microRNAs detected by both technologies.

Gene set enrichment analysis (GSEA) was performed using Ingenuity Pathways Analysis 8.8 (Ingenuity® Systems).

**3.3.9 Cell culture, transfection and reporter assay**

Human pulmonary artery smooth muscle cells (HPASMC, Lonza CC-2581 lot# 7F33558) were cultured according to supplier instructions. The day of transfection, cells were trypsinized, rinsed with HEPES, and resuspended in 500 µl Nucleofector solution (Lonza, CH) supplemented with 50 nM of microRNA-mimics (Dharmacon, Lafayette, CO) according to Amaxa transfection protocol A-033. After 24 h, cells were lysed in Qiazol to retrieve RNA.

Regions of interest of mRNAs 3’UTR (Supplementary figure 3-7 and Supplementary Material and Mehtods) were cloned by synthesis in pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI). Target seeds were mutated using QuikChange II Site-Directed Mutagenesis Kits (Agilent Technologies, Santa Clara, CA). Primers were designed according to manufacturer instructions.

Hek293 cells were cultured according to supplier instructions. Cells (2x 10^5 per well, in 24-wells plates) were co-transfected with 5 ng of pmiR-GLO reporter construct of interest and synthetic microRNA mimics (40 nM) (Dharmacon, Lafayette, CO) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). A C.
elegans mimic with no affinity for mammalian targets was used as negative control. Dual-GLO Luciferase Assay System (Promega, Madison, WI) was used to obtain the luciferase/Renilla relative luminescence, according to manufacturer instructions. Data were averaged for n=4 in 3 independent experiments.

3.4 Results

3.4.1 MicroRNA profiles separate the different structures of the heart as efficiently as mRNAs

Between 260 and 340 unique mature microRNAs were found expressed (normalized counts >10) in each cardiac structure in the different species. A hierarchical Euclidean linkage clustering showed that microRNAs profile can group the samples in at least 3 distinct clusters, comprising the two ventricles, apex, septum and papillary muscles (myocardium), the 2 atria (atria) and the cardiac valves (Figure 3-2A) with a threshold of > 7.5. Similarly, principal component analysis of microRNAs and mRNAs data sets showed that individual samples from these 3 main structures grouped together (Figure 3-2B and C). In fact valvular profiles were clearly separated from atrial and ventricular profiles. Conversely, expression profiles from ventricles, septum, papillary muscles and apex were virtually indistinguishable from each other and therefore pooled together for further analysis under the name of “myocardium”. This was consistent with the cell type composing these structures, where cardiomyocytes are predominant. Similarly, left and right atria profiles were evaluated together in further analysis based on the similarity of their profiles.
Figure 3-2: Distribution of microRNAs in rat cardiac structures. (A) Cardiac samples are grouped according to the structure using microRNAs signatures (top 10%) in a hierarchical Euclidean-linkage clustering. (B-C) cardiac structures are separated by microRNAs and mRNA distribution in a principal component analysis. Red circles: myocardial tissue (apex, left and right ventricle, septum, papillary muscle). Blue circles: left and right atrium. Grey circles: cardiac valves. A, apex. LA, left atrium. LV, left ventricle. PM, papillary muscle. RA, right atrium. RV, right ventricle. S, septum. V, valves.
The clusters obtained were reproducible and consistent across several individuals, suggesting that the structure-specific signatures were robust enough and were not affected by inter-individual differences (Supplementary figure 3-1).

3.4.2 Conserved structure-enriched microRNAs and mRNAs across species

For each species, we identified microRNAs that were preferentially expressed in each of the 3 described major cardiac structures (valves, myocardium or atria), by a two step procedure. At first we retained only the microRNAs in top 10\textsuperscript{th} percentile most expressed for each structural cluster. Secondly, we further compared the expression of each highly expressed microRNAs across structures, retaining those that were preferentially enriched in one structure only (see Data Analysis section in Material and Methods for details). In this way, we obtained lists of microRNAs likely to play a role in gene expression homeostasis in cardiac valves, myocardium or atria. These lists are available as supplementary information (Supplementary table 3-2, Supplementary table 3-3, Supplementary table 3-4). The 3 cardiac structures could still be discriminated in the 3 species by a hierarchical clustering when using these limited microRNAs signatures (data not shown). The commonly called heart-specific microRNAs were indeed amongst the most expressed microRNAs in the myocardium, but were present to a much lower extent in valves and atria. Applying a similar analytical process, structure-enriched messenger RNAs were also identified (see Data Analysis section in Material and Methods for details).

In an attempt to determine the degree of conservation of cross-species structure-specific distribution of microRNAs, we found that 9 unique microRNAs were highly enriched in the cardiac valves of rat, canine and Cynomolgus monkey (miR-let7c, mIR-125b, miR-127, mir-199a-3p, miR204, miR-320, miR-99b, miR-328 and miR-744) (Figure 3-3A), 7 in the myocardium (miR-1, mir-133a, miR-133b, miR-208b, miR-30e, miR-499-5p, miR-30e*)(Figure 3-3A). At the messenger mRNA level, 4 (S100a4, Inhba, Mfap4 and Cdh11) and 1 (Myl2)
mRNAs were found to be expressed consistently in cardiac valves or myocardium respectively of rat, canine and monkey (Figure 3-3B).

A. microRNA

![Diagram of microRNA expression]

B. mRNA

![Diagram of mRNA expression]

Figure 3-3: Number of microRNAs (A) and mRNAs (B) preferentially expressed in cardiac valves or myocardium across species. Myocardium includes apex, ventricles, septum and papillary muscles. Fold change thresholds were >= 2 for microRNAs in (A), and >=5 from mRNAs in (B).

A few microRNAs were selected for further analysis and their expression relative to apex is shown in Figure 3-4. Mir-1 is highly expressed in almost all structures, but to a much lower extent in the valves, in all species. MiR-208b is more specific of the myocardium structures, and is almost absent in the atria of rat and canine as well as in the valves of all species. MiR-125b-5p and miR-204 are enriched in the valves of all 3 species while less abundant in all other structures. Notably, mir-125b-5p expression is not restricted to the valves in dog, as for rat and Cynomolgus monkey.
Figure 3-4: Distribution of miR-1, miR-125b-5p, miR-204 and miR-208b in the cardiac structures. Axes represent fold change vs. apex. A, apex; LA, left atrium; LV, left ventricle; PM, papillary muscle; RA, right atrium; RV, right ventricle; S, septum; V, valve.

3.4.3 Confirmation of microRNAs distribution by in situ hybridization

Relative expression obtained by ISH for miR-1, miR-125b-5p and miR-204 were consistent with the distribution patterns observed by miRNAs seq and qPCR.
MiR-1, miR-204 and miR-125b were detected in rat cardiac tissue by *in situ* hybridization (ISH). Representative micrographs are shown in Figure 3-5. Coherently with our miRNAs seq data signal for miR-1 was more intense in the myocardium than in the valves (Figure 3-5G, H and I), and staining for miR-204 and 125b-5p was more intense in the valves than in the rest of the heart (Figure 3-5A to F).

MiR-1 showed an intense and uniform staining in the ventricle, while was weakly detectable in cardiac valves (Figure 3-5 G, H and I and Supplementary table 3-5). The signal for miR-204 appeared more intense at the level of endothelial cells in the valves (Figure 3-5 A and B). However, specificity of miR-204 for endothelial cells will have to be investigated further via ISH in other endothelial cells-rich tissues. Mir-204 was weakly expressed in myocardial tissue, and the staining was almost undetectable (Figure 3-5 C). Similarly to miR-204, also miR-125b-5p showed a more intense signal in the cardiac valves than in the myocardium (Figure 3-5 D, E and F). MiR-125b-5p was strongly expressed in the myocardium but was more preponderant in the cardiac valves according to expression data (Supplementary table 3-5). While signals for miR-1 and miR-125b-5p were strong, miR-204 was at the limit of detection, consistently with its relative abundance as observed by miRNAseq and qPCR (Supplementary table 3-5). Several attempts of staining for miR-208b were unsuccessful, possibly due to the low expression level of miR-208b (Ct value ~27 in rat myocardium).

In conclusion, the results of the *in situ* hybridization correlate well with the relative distribution of microRNAs observed using the miRNA seq/TLDA approach and suggest that the precise dissection of the rat heart successfully allowed the isolation of expression profiles from individual structures.
Figure 3-5: Localization of miR-204, miR-125b-5p and miR-1 in rat heart. MiR-204 in valves (A-B) and myocardium (C). MiR-125b-5p in valves (D-E) and myocardium (F). MiR-1 in valves (G-H) and myocardium (I). Bar = 50 µm.

3.4.4 Integration of gene expression and microRNA profiles at the steady state

MicroRNAs targets were obtained from Targetscan (human database was used for Cyno microRNAs). Spearman correlation scores for the distribution of each
microRNA and their predicted mRNAs targets were calculated across all samples, in order to identify avoidant expression profiles.

![Figure 3-6](image)

**Figure 3-6:** Rat cardiac disease relevant genes are negatively correlated with putative targeting microRNA. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 normalized intensity for the indicated probe set. Black curve represents log2 scaled and normalized microRNA read counts. Three replicates are plotted for each structure.

Expression profiles of four microRNAs interesting for their distribution pattern (miR-1, miR-125b, miR-204 and miR-208b) and 4 respective predicted target mRNAs that show anti-correlated distribution in rat are shown in Figure 3-6. Interestingly Timp3, Rbm24, Tgfbr2 and Csnk2a2 were already reported to be
implicated in cardiac physiology and/or muscular differentiation (Bujak and Frangogiannis, 2007; Hauck et al., 2008b; Jin et al., 2010; Kandalam et al., 2010; Limana et al., 2011; Litchfield, 2003; Miyamoto et al., 2009). The sequence of the microRNAs predicted binding site is conserved across species, reinforcing the hypothesis that the interactions could be relevant for heart biology (Supplementary figure 3-5). Expression profiles of miR-1/Timp3 and miR-125b-5p/Rbm24 were also anti-correlated with microRNAs expression in the canine heart (Supplementary figure 3-2) and Cynomolgus monkey (Supplementary figure 3-3). Expression profiles of miR-204/Tgfbr2 in canine and Cynomolgus monkey as well as miR-208b/Csnk2a2 in Cynomolgus monkey were instead positively correlated. Human Timp3 was found down-regulated upon miR-1 over expression in HeLa cells by Lim and colleagues (Lim et al., 2005), although it was not investigated whether the effect was directly mediated by the microRNAs at the post-transcriptional level by a direct reporter assay. Interestingly, Tgfbr2 was shown to be directly targeted by miR-204 in human epithelial cells (Wang et al. 2010a), providing us with a suitable positive control for further confirmatory experiments.

Transfection of miR-1 in HPASMC caused a decrease of about 50% of both the endogenous Timp3 mRNAs level (Figure 3-7A) and of the corresponding rodent Timp3 3’UTR reporter assay in HEK 293 (Figure 3-7E). Interestingly, we demonstrated that only one out of 2 predicted binding sites was active: seed mutation of site 1 (pmiR-GLO-Timp3-S1-MUT), but not site 2 (pmiR-GLO-Timp3-S2-MUT), could rescue expression of reporter gene luciferase, suggesting that site 2 is not involved in the regulation of this gene by miR-1. Notably, Limana et al. previously reported that the site 2, but not site 1, was targeted by miR-206, which has identical 5’ seed to miR-1, whilst site 1 did not respond to miR-206 over expression. Additional interactions mediated by the 3’ end of the microRNA were crucial for alternate miR-1/206 regulation of Timp3, beyond the
canonical 5’ seed, suggesting an alternative effect of highly related microRNAs in different cell types or tissues.

Figure 3-7: Anti-correlated microRNA targets are directly inhibited by microRNA over expression. (A-D) Endogenous expression of Timp3, Rbm24, Tgfbr2 and Csnk2a2 genes is
monitored upon transfection of mimics for miR-1, miR-125b-5p, miR-204, miR-499 and miR-208b in HPASMC cells (A-D). Corresponding luciferase reporter vector are assayed for susceptibility to putative targeting microRNAs, via co-transfection of reporter vectors of interest with the paired microRNA (E-H).

Notably, miR-206 was not detected in any of the cardiac structures of any of the 3 species investigated in this study, in accordance to what reported by Rao et al. (Rao et al., 2009), while it is expressed in the skeletal muscles (data not shown).

Transfection of miR-125b-5p in HPASMC significantly reduced Rbm24 levels by 25% (Figure 3-7B), consistently with the effect observed with the 3’UTR reporter assay in HEK 293 (Figure 3-7F). Mutation of the predicted target site rescues luciferase gene activity. The function of Rbm24 and Rbm38 stabilize the mRNAs of myogenin and p21, respectively, in skeletal muscle (Jin et al., 2010; Miyamoto et al., 2009). The levels of their mRNAs increase during myoblastic differentiation, while at the same time miR-125b-5p expression drop (Ge et al., 2011). Interestingly, Rbm38 is also anti-correlated to miR-125b in our cardiac samples, and has a predicted miR-125b targeting site in its 3’UTR. However only Rbm24 is directly affected by miR-125b co-transfection in the luciferase assay (Figure 3-7F), while luc-Rbm38 signal was unaffected (data not shown).

Transfection of mir-204 significantly decreased the level of Tgfbr2 mRNA by 20% in both HPASMC (Figure 3-7C) and in co-transfection with the corresponding Tgfbr2 3’ UTR luciferase reporter assay (Figure 3-7G).

MiR-208b over expression lowered Csnk2a2 mRNA level in HPASMC by 25% (Figure 3-7D), and co-transfection with the reporter assay caused a 50% inhibition of luciferase activity in HEK cells (Figure 3-7H). Although the 3 myomiRs miR-208a/miR-208b/miR-499 are almost identical at the seed sequence, miR-499 was much less potent at inhibiting luc-Csnk2a2 than miR-
208a/miR-208b, suggesting a functional role of 3’ compensatory interaction between the microRNA and the target in this case (Figure 3-7D and H).

In summary, we have verified that 4 genes important for the cardiac/muscular physiology are post-transcriptionally regulated by miR-1, miR-125b-5p, miR-204 and miR-208b, and the respective anti-correlated profiles suggest that these microRNAs are responsible for the homeostasis of these transcripts across tissues and species.

3.5 Discussion

The tissue-specific deletion of Dicer in murine myocardial lineage causes lethality, demonstrating the pivotal role played by microRNAs in cardiovascular development (Chen et al., 2008b). In particular, miR-1 and miR-133, which are abundant microRNAs in the heart, are implicated in cardiovascular development and myocardial lineage differentiation, as they tightly control expression of muscle genes and repress ”unwanted” gene levels, through a network of target transcription factors (Ivey et al., 2008; Liu et al., 2008; Schlesinger et al., 2011; Zhao et al., 2007). Noteworthy, miR-1, miR-133, mir-30, miR-208a, miR-208b, mir-499, miR-23a, miR-9 and miR-199a were shown to be functionally involved in cardiovascular diseases such as heart failure and hypertrophy (Latronico and Condorelli, 2011; Thum et al., 2007; van Rooij et al., 2009; van Rooij et al., 2006; van Rooij et al., 2007), and have been proposed as therapeutics or disease related drug targets (Montgomery et al., 2011; van Rooij and Olson, 2007). However one of the issues of studying the function of specific genes/microRNAs in the cardiac organ is the heterogeneity of cell type and morphological composition. In order to have a better understanding of the significance of different microRNA in the physiology of distinct heart structures we have generated a comprehensive heart structure-specific transcriptomic resource for
three mammalian species that should facilitate the investigation of microRNA/mRNA regulatory interactions in cardiac physiopathology mechanisms and may also enhance the identification of cardiac tissue injury biomarkers.

Conserved microRNA signatures were identified in valves (miR-let-7c, miR-125b, miR-127, miR-199a-3p, miR-204, miR-320, miR-99b, miR-328 and miR-744) and in ventricular-specific regions of the myocardium (miR-1, miR-133b, miR-133a, miR-208b, miR-30e, miR-499-5p, miR-30e*) of Wistar rat, Beagle dog and Cynomolgus monkey. The putative targets of conserved valvular and myocardial microRNAs found in this study are significantly enriched in genes implicated in Gene Expression Regulation, Cellular and Organism Development according to gene ontology terms enrichment (Supplementary figure 3-6), suggesting that they may play important roles in defining the molecular identity of heart-specific structures through direct post-transcriptional regulation of mRNA targets and their downstream effects on gene regulatory proteins. Conversely, microRNAs that exhibit a dissimilar heart-structure specific distribution across species are likely to be of high interest for translational science applications including the drug cardiosafety assessment.

Here we have focused on the characterization of four microRNAs, including myocardial specific miR-1 and miR-208b and valve enriched mir-204 and miR-125b-5p, based on their distinct heart-structure-specific distribution patterns and known roles in cardiac physiology, disease and pathological remodeling. Numerous putative microRNA targets were found to have an anti-correlated distribution with these 4 microRNAs across cardiac tissues supporting the biological relevance of predicted microRNA-mRNA interactions. We demonstrated that miR-1 could directly control Timp3 expression at the post-transcriptional level. Timp3 is a regulator of adult myogenesis implicated in the fibrotic pathological remodeling of infarcted heart, and atrial fibrillation (Barth et
Interestingly, Timp3 has 2 predicted sites for miR-1/206 family and despite miR-1 and miR-206 (an already known regulator of Timp3) having identical seed sequence, miR-206 targets specifically the second site (Limana et al., 2011), while miR-1 specifically targets the first site (Figure 3-7E). These observations suggest that duplication of targeting sites may be a strategy for redundant regulation in cardiac cell types having different microRNA repertoires. RNA binding motif proteins 24 and 38 (Rbm24 and Rbm38) play a role in muscle differentiation (Jin et al., 2010; Miyamoto et al., 2009) and carry a miR-125b-5p targeting site. Interestingly, the function of miR-125b in controlling proliferation/differentiation switches was characterized in a number of cell types, such as immune system and muscular cells (Ge et al., 2011; Le et al., 2011; Lee et al., 2005; Murphy et al., 2010; Rossi et al., 2011). We found that miR-125b-5p over-expression could lower Rbm24, but not Rbm38, levels in HPASM cells, and that the down-regulation was directly mediated by the microRNAs as verified via luciferase reporter assay. The direct relationship between the RNA regulatory protein Rbm24 and miR-125b-5p reinforces the key responsibilities of this microRNA in cell fate switches. TGF-β receptor 2 (Tgfbr2) has been functionally connected to cardiovascular diseases (Barth et al., 2005; Bujak and Frangogiannis, 2007; Kato et al., 2009; Wang et al., 2010a) and miR-204 was observed to directly inhibit Tgfbr2 mRNA in a direct manner both in HPASM cells and in a luciferase assay, thus extending the potential roles for miR-204 in cardiac pathogenesis. Casein kinase 2a2 (Csnk2a2) and miR-208ab have both previously been implicated in cardiovascular pathologies (Eom et al., 2011; Hauck et al., 2008b; van Rooij et al., 2007) and we have shown here for the first time that they are inter-related based on the striking anti-correlation between their expression profiles in cardiac tissues. Additional predicted targeting sites for miR-221/222, implicated in muscular development (Cardinali et al., 2009; Davis et al., 2005; Kandalam et al., 2010; Limana et al., 2011; Liu et al., 2010).
2009; Liu et al., 2009b), were also found in Timp3 and Rbm24 3’ UTRs (Supplementary figure 3-7), however the corresponding luciferase reporter assays were unaffected when miR-221 mimic was co-transfected in Hek 293 cells (data not shown) suggesting that miR-221/222 could not directly regulate these genes at the post-transcriptional level.

MicroRNAs can easily be quantified in body fluids using assays that are fully translatable across species based on the sequence conservation (Wang et al., 2009) and numerous publications support the use of tissue-specific microRNAs in the peripheral circulation as marker of tissue injury (Starkey Lewis et al., 2011; Wang et al., 2010b; Wang et al., 2009; Wang et al., 2011b). Furthermore, heart ventricular microRNAs (miR-1, miR-133 and miR-499) were found to be increased in the plasma of patients with myocardial infarction, and might represent an alternative to the classical cTnI cardiac injury biomarkers (Cheng et al., 2010; Corsten et al., 2010; D'Alessandra et al., 2010a; Wang et al., 2010b; Wang et al., 2011b). MicroRNAs involved in drug-induced cardiac injury may also provide earlier safety endpoints as their expression change could be prodromal to the corresponding target gene/protein variations. Here, for the first time, we describe conserved valve-enriched microRNAs that may help to monitor or predict valvular disease and drug-induced valvular injury, for which no translational circulating biomarkers currently exist (Bhattacharyya et al., 2009).

The identification of microRNAs that are highly specific for a cell type or morphological structure is challenging, as most of them are ubiquitous, but this may be overcome by measuring a signature of several microRNAs. This strategy can help to discriminate between closely related tissues (such as skeletal vs. cardiac muscle), or isolate the signal of an under-represented structure in global genomics analyses.

In conclusion, data presented here provided a valuable resource to investigate potential roles of specific microRNAs as conserved regulators of cell homeostasis
and tissue pathological remodeling. Our data sets can be further analyzed to answer different open questions, such as cell type specific genes/microRNAs distribution, involvement of microRNAs in genome plasticity, disease and cellular homeostasis and co-regulation between intronic microRNAs and their hosting transcripts. One important future direction is to obtain suitable clinical samples for the extension of this molecular atlas to human heart-specific structures. A similar transcriptomic atlas strategy can also be extended to other heterogeneous organs in order to characterize potential tissue structure-specific specific mechanisms and biomarkers.

3.6 Supplementary Material and Methods

3.6.1 In situ hybridization

Supplementary table 3-1: LNA probe hybridization conditions

<table>
<thead>
<tr>
<th>Probe Name</th>
<th>Reference number</th>
<th>Hybridization temperature</th>
<th>Stringency washes</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-204</td>
<td>18098-15</td>
<td>55°C</td>
<td>0.5x SSC at 37°C (3x times)</td>
</tr>
<tr>
<td>hsa-miR-125b</td>
<td>18022-15</td>
<td>57°C</td>
<td>0.5x SSC at 37°C (3x times)</td>
</tr>
<tr>
<td>rno-miR-1</td>
<td>41336-15</td>
<td>47°C</td>
<td>2.0x SSC at 37°C (3x times)</td>
</tr>
</tbody>
</table>

3.6.2 Cloned regions of Timp3, Rbm24, Rbm38, Akap2, Tgfbr2 and Csnk2a2

Relative position of cloned stretches is shown in Supplementary figure 3-7. Mutations are in indicated in bold.

Timp3 WT 5’-3’ (Murine NM_011595.2):

AGTTTAATCTTTTTTTTTTTTTTTTTTGTGGATGGGAATTGTGACATTTC
CAAGTTGACTTTTTTTTTTTTTTTTTTTTTATCTGAACAGATTATGGGTATTTTATCCTC
TATTAGTATATATCATCGTTTTTTTTTACCTCCACTTTAGAAACACAGTTACCAGT
TGAGTATTTCACCTGTTTCACCTACTGTATAATTTAAATCATTTATGTA
GCTGAGACACTTTTGATACTTCAATTATATCGAGAAACCCCTCTAGA
AGGAATGTATTTGTTGCTAAAATTTTGTAGCAGCTTTACAGTTTTCCCTC
CATGTGA

Timp3 S1-S2 MUT 5’-3’ (Murine NM_011595.2):
AGTTTAATCTTTTTTTCTTTTGTGTTTGATGGGAAATTGTGTGTGAAG
GAAGTTTGACCTTTTTTTATTATCTGAACAGATTATGGGTATTATCCTCTC
TATTAGTATCATATCGTTTTGTAAAGGTCTTTTAGAAACACAGTTACCAG
TTGAGTATTTTCACCTGTTACTTTACTGTATAATTTAAAAATCATTATGT
AGCTGAGACACTTTGTATGACTTCAATTATATCGAGAAACCCCTGAAG
AAGGAATGTATTTGTTGCTAAAATTTTGTAGCAGCTTTACAGTTTTCCCTC
CATGTGA

Rbm24 WT 5’-3’ (Rat NM_001191100):
AGGACACGATGGCAGGGGTACCCATGGGACTTCACTTTTGTATGGG
GATTTTTATTTTTTTTGCTTTTTTTATAGTGATCCAGGGAAGCAAACCTGC
CTTTTCCAAGTTAGAAACAGCTACGTGAAATCTAGCTGAACCAGGGAAT
ACGGAGTCTCTCTAAAGGAAGGAACCTTTAGAAGTGACACTGTAATAATTAT
GTATTCATCTCATGGCATAAGTTATTACAGTACGGTCTAGATGTACATAT
TAAATATAAACCTATTCAACTAAAGATGTTGGCTTTGGAATTATTAAAT
TTCTTATATGTGC

Rbm24 MUT 5’-3’ (Rat NM_001191100):
GAGAGGACACGATGGCAGGGGTACCCATGGGACTTCACTTTTGTAT
GGGGATTTTTATTTTTTTTGCTTTTTTTATAGTAGTACGCCCTTAGCAAAC
TGCTTTTTCCAAGTTAGAAACAGCTACGTGAAATCTAGCTGAACCAGGG
AATACGGAGTCTCTAAGGAAGGAACTTTAGAAGTGACACTGTAATAATTAT
TTATGTTATCTCATGGCATAAGTTATTACAGTACGGTCTAGATGTACGC
ATATAAAATATACCTATTCAACTAAAGATGTTGGCTTTGGAATTATTAAAT
TTATTTATATGTGC

Rbm38 WT 5’-3’ (Rat NM_001108965.1):
CACCCAGCCCCCATTTGTCACTGTACCAGTCTGGAGCATGACCTAG
CTGCACAGGGAGAAGGTCACCTGTACCAGTCTGGAGCATGACCTAG
TGGGCATCTCTGCGAGCATGGGCTGCCCACAGGGCTGGGCAGTGGGTC
CTCCACACCTACCTACGGAGCCAGTGTAGGCACTCCACAGCATGC
CTGTTAGTCAAGGCCTGGAGGACAGAGGGAGTAATGTTATAATAATAT
TTTATTGAAATGTTCTGATTATAAAAAAAAAATAACTTGTTTTCTTTAAAG
G
Akap2 WT 5’-3’ (Human NM_001004065):
ATTGTGTGTTTGTAAAATGTGTATGTTCATGAGTAAGGGGTGTGTGTG
TGTGTGATATTTAAAAATTCCAGAGGCTGGACCTGGGACTTCGGGTTGTAACAGGT
AATTTCCCTCCAGAGCTGTGTGCTGGGCATTCCAGAGGTCAGGAGTAATTTTC
TTTTTTATGAAAAAGGGATATAAAAAGGCACCAGGCTGGATGCACTTTTGT
AATATTAAGTTGACCTAACAAGGTATTTGCATGAGTCACAATTACAAA
GTTTTGAGCGGTTTTTGTAATTTGACATTTAGGAGAGTGCTCCTATTTATT
CTCATACCTTTAC

Akap2 MUT 5’-3’ (Human NM_001004065):
ATTGTGTGTTTGTAAAATGTGTATGTTCATGAGTAAGGGGTGTGTGTG
TGTGTGATATTTAAAAATTCCAGAGGCTGGACCTGGGACTTCGGGTTGTAACAGGT
AATTTCCCTCCAGAGCTGTGTGCTGGGCATTCCAGAGGTCAGGAGTAATTTTC
TTTTTTATGATACTTTACTTTATGAAAAAGGGATATAAAAAGGCACCAGGCTGGATGCACTTTTGT
AATATTAAGTTGACCTAACAAGGTATTTGCATGAGTCACAATTACAAA
GTTTTGAGCGGTTTTTGTAATTTGACATTTAGGAGAGTGCTCCTATTTATT
CTCATACCTTTAC

Tgfbr2 WT 5’-3’ (Human NM_001024847):
CTCATCTTGCTTTCTCATCAGCATAAAACTGGAATGTAGTGTGTCAGAGGAT
ACTGTTGGCCTTTTGTGGTTATGTTTTTTTTTTTTTTTTTTTTTTTATCAAGAAAAAGA
CCAAAGGAATAACATTTCGGTAGTTCTCCTAAAAATACACTGACTTTTTTCACTA
CTATACATAAAAAGGGAGTTTTATTTTTATGGAACACTTCAGTCGTA
CTCATGTATTAAATAGGAATGTGAATGCTATATACTCTTTTTATATCA
AAAGTCTCAAGCACTTATTTTTATTCTATGCATTGTTTGTCTTTTACATA
AATAAAA

Tgfbr2 MUT 5’-3’ (Human NM_001024847):

CTCACCTCTGGGTATACAGCATAAATCTGGAATGTAGTGTCAGAGGAT
ACTGTGGCCTTGGTTTTGTTTATGTTTTTTTTTCTTATTCAAGAAAAAGA
CCAAGGAATAACATTTGCTAGTTCTCTAAAATACTGACTTTTTTTCTCTA
CTATACATTTCCCTTAACTTTTATTCTTTTATGGAACACCTCAGCTGTA
CTCATGTATTTAAAATAGGAATGTGAATGCTATATACTCTTTTTATATCA
AAAGTCTCAAGCACTTATTTTTATTCTATGCA

Csnk2a2 WT 5’-3’ (Rat NM_001107409):

CTTCTACCCGCTGGTGAAGGAGCGACTCCCAGCCTTGCTGCTGAGAAC
ACCGTGCTTTCCAGTTGCTCACCAGCAGCATGAAGCCTGGGAAT
CGACGGTCTGTGTCGGTTCTCAGGAGATCAGTCCCCGAGAGC
CAGACACAAAATGTGGGCAAGATTCTGCGCAACAGGAACTAGACCCC
GAAGGGCGAGGCCACACGGTAAATCAGACCTCACTTTCCAATGTAAG
AGGTTTACATGCCTTTG

Csnk2a2 MUT 5’-3’ (Rat NM_001107409):

CTTCTACCCGCTGGTGAAGGAGCGACTCCCAGCCTTGCTGCTGAGAAC
ACCGTGCTTTCCAGTTGCTCACCAGCAGCATGAAGCCTGGGAAT
CGACGGTCTGTGTCGGTTCTCAGGAGATCAGTCCCCGAGAGC
CAGACACAAAATGTGGGCAAGATTCTGCGCAACAGGAACTAGACCCC
GAAGGGCGAGGCCACACGGTAAATCAGACCTCACTTTCCAATGTAAG
AGGTTTACATGCCTTTG
Supplementary figure 3-1: Cardiac structures are similarly clustered by microRNA and mRNA profiles of dog (A) and Cynomolgus (B), accordingly to their histological characteristics. Red circles: myocardial tissue (apex, left and right ventricle, septum, papillary muscle). Blue circles: left and right atrium. Grey circles: cardiac valves. A, apex. LA, left atrium. LV, left ventricle. PM, papillary muscle. RA, right atrium. RV, right ventricle. S, septum. V, valve.
Supplementary table 3-2: Rat cardiac structure enriched microRNAs

<table>
<thead>
<tr>
<th>Valves</th>
<th>miRNA</th>
<th>id</th>
<th>Sequence</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rno-let-7e</td>
<td>mirnaUID2686</td>
<td>TGAGGTAGGAGGTGTTATAGTT</td>
<td>17.94</td>
</tr>
<tr>
<td></td>
<td>rno-miR-3554</td>
<td>mirnaUID1040</td>
<td>CTATGCCAGCATCTTGCCCT</td>
<td>17.93</td>
</tr>
<tr>
<td></td>
<td>rno-miR-204</td>
<td>mirnaUID0307</td>
<td>TTCCCTTTGTCATCTATGCT</td>
<td>17.68</td>
</tr>
<tr>
<td></td>
<td>rno-miR-10b</td>
<td>mirnaUID2476</td>
<td>TACCCCTGTAGAACCGAATTTGTG</td>
<td>7.31</td>
</tr>
<tr>
<td></td>
<td>rno-miR-497,mmu-miR-497</td>
<td>mirnaUID0236</td>
<td>CAGCAGCACACTGTGTTGTTGTA</td>
<td>6.42</td>
</tr>
<tr>
<td></td>
<td>mmu-miR-5109</td>
<td>mirnaUID0403</td>
<td>TGTTGCGGACGGAGGAATCCGA</td>
<td>6.42</td>
</tr>
<tr>
<td></td>
<td>rno-miR-199a-3p,mmu-miR-199a-3p,mmu-miR-199b</td>
<td>mirnaUID2023</td>
<td>ACAGTGTCTGACATTGGTTA</td>
<td>5.14</td>
</tr>
<tr>
<td></td>
<td>rno-miR-140*,mmu-miR-140*</td>
<td>mirnaUID2487</td>
<td>TACCACAGGGTGAACCGACGG</td>
<td>4.90</td>
</tr>
<tr>
<td></td>
<td>rno-miR-434,mmu-miR-434-3p</td>
<td>mirnaUID0606</td>
<td>TTTGAACCATCACTCGACCTC</td>
<td>4.84</td>
</tr>
<tr>
<td></td>
<td>rno-miR-31</td>
<td>mirnaUID1686</td>
<td>AGGCAAGATGCTGCGATAGCTGT</td>
<td>3.71</td>
</tr>
<tr>
<td></td>
<td>rno-miR-23b</td>
<td>mirnaUID0633</td>
<td>ATCACATTGCCAGGGATTACC</td>
<td>3.59</td>
</tr>
<tr>
<td></td>
<td>rno-let-7b</td>
<td>mirnaUID1072</td>
<td>TGAGGTAGTAGTTGTTGTGGTT</td>
<td>3.21</td>
</tr>
<tr>
<td></td>
<td>rno-miR-423*,mmu-miR-423-5p</td>
<td>mirnaUID2095</td>
<td>TGAGGGGCAGAGAGGAGACTTTT</td>
<td>3.14</td>
</tr>
<tr>
<td></td>
<td>rno-miR-320</td>
<td>mirnaUID0965</td>
<td>AAAAGCTGGGGTGAGAGGGCCGA</td>
<td>3.07</td>
</tr>
<tr>
<td></td>
<td>rno-miR-125a-5p</td>
<td>mirnaUID0109</td>
<td>TCCCTGAGACCTTAAACCTGTGA</td>
<td>3.01</td>
</tr>
<tr>
<td></td>
<td>rno-miR-3596c</td>
<td>mirnaUID1636</td>
<td>ACTATAAACCTCTACTCTCA</td>
<td>2.94</td>
</tr>
<tr>
<td></td>
<td>rno-let-7d*</td>
<td>mirnaUID1929</td>
<td>CTATACGACCTGCTGCTTTTCT</td>
<td>2.78</td>
</tr>
<tr>
<td></td>
<td>rno-miR-3588</td>
<td>mirnaUID2671</td>
<td>TCACAAAGTTAGGTTCTACCGGA</td>
<td>2.76</td>
</tr>
<tr>
<td></td>
<td>rno-let-7c</td>
<td>mirnaUID1210</td>
<td>TGAGGTAGTAGTTGTTGTATGTT</td>
<td>2.72</td>
</tr>
<tr>
<td></td>
<td>rno-miR-3543</td>
<td>mirnaUID2716</td>
<td>CAGGAGTCGAGTGAGGTTCTAAA</td>
<td>2.51</td>
</tr>
<tr>
<td></td>
<td>rno-miR-99b</td>
<td>mirnaUID0532</td>
<td>CACCCGTAGAACCGACCTTGC</td>
<td>2.51</td>
</tr>
<tr>
<td></td>
<td>rno-miR-125b-5p</td>
<td>mirnaUID2699</td>
<td>TCCCTGAGACCTAACTTGTA</td>
<td>2.29</td>
</tr>
<tr>
<td></td>
<td>mmu-miR-744</td>
<td>mirnaUID0939</td>
<td>TGCAGGGGCTAGGGCTAACAGCA</td>
<td>2.29</td>
</tr>
<tr>
<td></td>
<td>rno-miR-127</td>
<td>mirnaUID0088</td>
<td>TCGGATCCGTCTAGGCTTGTTGCT</td>
<td>2.29</td>
</tr>
<tr>
<td></td>
<td>rno-miR-3585-5p</td>
<td>mirnaUID1381</td>
<td>TTCACAAAGGCTGTTCTTCAT</td>
<td>2.17</td>
</tr>
<tr>
<td>MiRNA</td>
<td>id</td>
<td>Sequence</td>
<td>Fold enrichment</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>rno-miR-30e</td>
<td>mirnaUID0677</td>
<td>TGTAAACATCCTTGACTGGAAG</td>
<td>30.37</td>
<td></td>
</tr>
<tr>
<td>rno-miR-30e*</td>
<td>mirnaUID1498</td>
<td>CTTTCAGTCGGATGTTCACAGC</td>
<td>14.42</td>
<td></td>
</tr>
<tr>
<td>rno-miR-133a*,mmu-miR-133a*</td>
<td>mirnaUID2046</td>
<td>AGCTGGTAAATGGGAACCAAT</td>
<td>3.76</td>
<td></td>
</tr>
<tr>
<td>rno-miR-499</td>
<td>mirnaUID1007</td>
<td>TTAAGACCTTGAGTGGTTTT</td>
<td>3.73</td>
<td></td>
</tr>
<tr>
<td>rno-miR-133a,mmu-miR-133a</td>
<td>mirnaUID1006</td>
<td>TTTGGTCCCCCTCAACCAGCTG</td>
<td>2.78</td>
<td></td>
</tr>
<tr>
<td>rno-miR-3567</td>
<td>mirnaUID1032</td>
<td>TACCAAAAGTAATAATGGCTG</td>
<td>2.78</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-1a</td>
<td>mirnaUID0152</td>
<td>TGGAATGTAAGAAGATGGATAT</td>
<td>2.70</td>
<td></td>
</tr>
<tr>
<td>rno-miR-133b</td>
<td>mirnaUID2652</td>
<td>TTTGGTCCCCCTCAACCAGCTA</td>
<td>2.68</td>
<td></td>
</tr>
<tr>
<td>rno-miR-150</td>
<td>mirnaUID1542</td>
<td>TCTCCCAACCTTGACCAGTG</td>
<td>2.44</td>
<td></td>
</tr>
<tr>
<td>rno-miR-208b-3p,mmu-miR-208b</td>
<td>mirnaUID0997</td>
<td>ATAAAGCGAAAGAAAGGTTCG</td>
<td>2.44</td>
<td></td>
</tr>
<tr>
<td>rno-miR-450a</td>
<td>mirnaUID2119</td>
<td>TTTTGCGATGTGGTTCATATG</td>
<td>2.40</td>
<td></td>
</tr>
<tr>
<td>rno-miR-3582</td>
<td>mirnaUID1365</td>
<td>CAGCTGGTTGAAGGGACCAA</td>
<td>2.35</td>
<td></td>
</tr>
<tr>
<td>mmu-miR-149</td>
<td>mirnaUID2194</td>
<td>TCTGGCTCCGTTGCTCCTCCTCC</td>
<td>2.07</td>
<td></td>
</tr>
<tr>
<td>rno-miR-143,mmu-miR-143</td>
<td>mirnaUID0897</td>
<td>TGAGATGAAAGCAGAGAAAAAGG</td>
<td>2.04</td>
<td></td>
</tr>
<tr>
<td>rno-miR-322,mmu-miR-322</td>
<td>mirnaUID0573</td>
<td>CAGCAGCAATTCATGATGGG</td>
<td>2.03</td>
<td></td>
</tr>
</tbody>
</table>

**Myocardium**

<table>
<thead>
<tr>
<th>MiRNA</th>
<th>id</th>
<th>Sequence</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>rno-miR-328a,mmu-miR-328</td>
<td>mirnaUID1067</td>
<td>CTGGCCCTCCTGCCCCCTGGCT</td>
<td>2.05</td>
</tr>
</tbody>
</table>

**Atria**

<table>
<thead>
<tr>
<th>MiRNA</th>
<th>id</th>
<th>Sequence</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>rno-miR-31</td>
<td>mirnaUID1686</td>
<td>AGGCAAGATGCTGGCATAGGGT</td>
<td>7.41</td>
</tr>
<tr>
<td>rno-miR-3554</td>
<td>mirnaUID1040</td>
<td>CTATGCCAGCATTGCGGCT</td>
<td>7.41</td>
</tr>
<tr>
<td>rno-miR-127</td>
<td>mirnaUID0088</td>
<td>TCGGATCCGTTGAGCTTGGCT</td>
<td>3.95</td>
</tr>
<tr>
<td>rno-miR-490,mmu-miR-490-3p</td>
<td>mirnaUID0503</td>
<td>CAACCTGGAGGACTCCATGCTG</td>
<td>3.02</td>
</tr>
<tr>
<td>rno-miR-434,mmu-miR-434-3p</td>
<td>mirnaUID0606</td>
<td>TTTGAACCATCAGACTCTCCCT</td>
<td>2.95</td>
</tr>
</tbody>
</table>
### Supplementary table 3-3: Monkey cardiac structure enriched microRNAs

<table>
<thead>
<tr>
<th>miRNA</th>
<th>id</th>
<th>Sequence</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>mml-miR-320, hsa-miR-320a, hsa-miR-320d</td>
<td>mirnaUID0965</td>
<td>AAAAGCTGGGTTGAGAGGCGA</td>
<td>50.76</td>
</tr>
<tr>
<td>hsa-miR-320b</td>
<td>mirnaUID0343</td>
<td>AAAAGCTGGGTTGAGAGGCGA</td>
<td>40.96</td>
</tr>
<tr>
<td>mml-miR-214</td>
<td>mirnaUID0512</td>
<td>ACAGCAGGCACAGACAGCGAGT</td>
<td>37.44</td>
</tr>
<tr>
<td>hsa-miR-3120-5p</td>
<td>mirnaUID0899</td>
<td>CCGTCTCTGCTGCTGTACA</td>
<td>31.12</td>
</tr>
<tr>
<td>mml-miR-197</td>
<td>mirnaUID0938</td>
<td>TTCACACCTTCTCCACCCAGC</td>
<td>22.56</td>
</tr>
<tr>
<td>mml-miR-92b</td>
<td>mirnaUID0054</td>
<td>TATTCAGTCCGAGGCTGTTG</td>
<td>20.74</td>
</tr>
<tr>
<td>mml-let-7b</td>
<td>mirnaUID1072</td>
<td>TGGAGTGTAGGTTGTTTGTT</td>
<td>11.88</td>
</tr>
<tr>
<td>hsa-miR-574-3p</td>
<td>mirnaUID2267</td>
<td>CACGCTCATGCACAACCCACA</td>
<td>9.14</td>
</tr>
<tr>
<td>mml-miR-140-3p</td>
<td>mirnaUID2487</td>
<td>TACCCAGGGTGAACCACCGG</td>
<td>9.12</td>
</tr>
<tr>
<td>mml-miR-134, hsa-miR-134</td>
<td>mirnaUID1573</td>
<td>TGGTACAGGTTGACCAGGAGG</td>
<td>8.65</td>
</tr>
<tr>
<td>mml-miR-125b</td>
<td>mirnaUID2699</td>
<td>TCCCTGAGACCTAACTTGTA</td>
<td>8.44</td>
</tr>
<tr>
<td>hsa-miR-1296</td>
<td>mirnaUID0319</td>
<td>TTAGGGCCCCGCTCCACCTCCTCC</td>
<td>7.86</td>
</tr>
<tr>
<td>mml-miR-204</td>
<td>mirnaUID0307</td>
<td>TTTGCCCTGCTCACTCTATGCCT</td>
<td>7.83</td>
</tr>
<tr>
<td>mml-let-7c</td>
<td>mirnaUID1210</td>
<td>TGGAGTGTAGGTTGTTTGTTGTT</td>
<td>6.06</td>
</tr>
<tr>
<td>hsa-miR-328</td>
<td>mirnaUID1067</td>
<td>CTGGCCCTCTCTGCTCCCTTCCGT</td>
<td>5.69</td>
</tr>
<tr>
<td>mml-miR-125b-1*</td>
<td>mirnaUID2553</td>
<td>ACGGGGTTAGGCTTGTGGGAGCT</td>
<td>5.36</td>
</tr>
<tr>
<td>mml-miR-34a</td>
<td>mirnaUID1747</td>
<td>TGGCAGTGTCTTTAGCTGGTTGT</td>
<td>5.34</td>
</tr>
<tr>
<td>hsa-miR-744</td>
<td>mirnaUID0939</td>
<td>TGGCGGGCTAGGGCTAACAGCA</td>
<td>4.90</td>
</tr>
<tr>
<td>mml-miR-127, hsa-miR-127-3p</td>
<td>mirnaUID0088</td>
<td>TCGGATCCGTCTGAGCTGGCT</td>
<td>4.77</td>
</tr>
<tr>
<td>hsa-let-7b*</td>
<td>mirnaUID2339</td>
<td>CTATACAACTACTGCTCTCC</td>
<td>4.72</td>
</tr>
<tr>
<td>mml-miR-423-5p</td>
<td>mirnaUID2095</td>
<td>TGGAGGGCCAGAGCGAGACTTTT</td>
<td>4.52</td>
</tr>
<tr>
<td>mml-miR-193b</td>
<td>mirnaUID1124</td>
<td>AACTGCGCCCTCAAGTTGCCCCGT</td>
<td>4.41</td>
</tr>
<tr>
<td>mml-miR-100</td>
<td>mirnaUID0973</td>
<td>AACCCGTAGATCCGAACTTTGT</td>
<td>4.07</td>
</tr>
<tr>
<td>mml-miR-140-5p</td>
<td>mirnaUID0183</td>
<td>CAGTGGGTCTTACCTTGTAG</td>
<td>3.99</td>
</tr>
<tr>
<td>hsa-let-7d*</td>
<td>mirnaUID1929</td>
<td>CTATACGACCTCGCTCTTTTCT</td>
<td>3.66</td>
</tr>
<tr>
<td>mml-miR-409-3p</td>
<td>mirnaUID2437</td>
<td>GAATGTTGCTCGTGTTGAC</td>
<td>3.60</td>
</tr>
<tr>
<td>mml-miR-99b</td>
<td>mirnaUID0532</td>
<td>CACCCGTAGAACCGACCTTGC</td>
<td>3.06</td>
</tr>
<tr>
<td>hsa-miR-335*</td>
<td>mirnaUID1199</td>
<td>TTTTTTATTATTCAGCTTGCACC</td>
<td>2.98</td>
</tr>
<tr>
<td>mml-miR-125a-5p</td>
<td>mirnaUID0109</td>
<td>TCCCTGAGACCCCTTTAACCCTGTGA</td>
<td>2.75</td>
</tr>
<tr>
<td>mml-miR-181d</td>
<td>mirnaUID1317</td>
<td>AACATTCTTGTTTCTCGGTGTTG</td>
<td>2.66</td>
</tr>
<tr>
<td>hsa-miR-106b*</td>
<td>mirnaUID2147</td>
<td>CCGCAGCTTGCGTACTTGGCTG</td>
<td>2.60</td>
</tr>
<tr>
<td>mml-miR-152</td>
<td>mirnaUID1339</td>
<td>TCGATGCTAGACAGAACTTTG</td>
<td>2.45</td>
</tr>
<tr>
<td>miRNA</td>
<td>id</td>
<td>Sequence</td>
<td>Fold enrichment</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>mml-miR-199a-3p, hsa-miR-199b-3p</td>
<td>mirnaUID2023</td>
<td>ACAGTAGTCTGCACATTGGTTA</td>
<td>2.43</td>
</tr>
<tr>
<td>mml-miR-423-3p</td>
<td>mirnaUID0925</td>
<td>AGCTCGGTCTGAGGGCCCTCACTCTCAGT</td>
<td>2.40</td>
</tr>
<tr>
<td>hsa-miR-3184</td>
<td>mirnaUID2607</td>
<td>TGAGGGGCCCTCAGACGGGTTT</td>
<td>2.40</td>
</tr>
<tr>
<td>mml-miR-23a</td>
<td>mirnaUID2468</td>
<td>ATCCAGGTGGAGGGATTTC</td>
<td>2.32</td>
</tr>
<tr>
<td>hsa-miR-125b-2*</td>
<td>mirnaUID2235</td>
<td>TCACAGTGCTCCTCTGGGAC</td>
<td>2.26</td>
</tr>
<tr>
<td>hsa-miR-3120-3p</td>
<td>mirnaUID0801</td>
<td>CACAGCAAGTGAGCAGGGCA</td>
<td>2.24</td>
</tr>
<tr>
<td>hsa-miR-214*</td>
<td>mirnaUID1165</td>
<td>TGCTGTCTACCTTGCTGTGC</td>
<td>2.23</td>
</tr>
<tr>
<td>mml-miR-130a</td>
<td>mirnaUID1062</td>
<td>CAGTGCAATGGTTAAAGGGCAT</td>
<td>2.17</td>
</tr>
<tr>
<td>mml-miR-92a</td>
<td>mirnaUID0699</td>
<td>TATTGCACTTGGCCGCTGT</td>
<td>2.16</td>
</tr>
<tr>
<td>mml-miR-145, hsa-miR-145</td>
<td>mirnaUID1820</td>
<td>GTCCAGTTTTCCAGGAATCCCTT</td>
<td>2.10</td>
</tr>
<tr>
<td>mml-miR-199a, mml-miR-199a-5p</td>
<td>mirnaUID2233</td>
<td>CCCAGTGTTCAGACTACCTGTC</td>
<td>2.08</td>
</tr>
<tr>
<td>mml-miR-28, hsa-miR-28-5p</td>
<td>mirnaUID2058</td>
<td>AAGGAGCTCACAGTCTATTTGAG</td>
<td>2.04</td>
</tr>
<tr>
<td>mml-miR-181b</td>
<td>mirnaUID0653</td>
<td>AACTTCATGCTGCTCGGTGTTT</td>
<td>2.03</td>
</tr>
<tr>
<td>mml-let-7a, hsa-let-7a</td>
<td>mirnaUID2005</td>
<td>TGAGGTAGATGGTTGTATTTG</td>
<td>2.02</td>
</tr>
<tr>
<td>mml-miR-191</td>
<td>mirnaUID0921</td>
<td>CAACGGAATCCCAAAAGGCAGCTG</td>
<td>2.01</td>
</tr>
</tbody>
</table>

### Myocardium

<table>
<thead>
<tr>
<th>miRNA</th>
<th>id</th>
<th>Sequence</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-499a-3p</td>
<td>mirnaUID0074</td>
<td>AACATCACTGCAAGTCTTAACA</td>
<td>12.05</td>
</tr>
<tr>
<td>mml-miR-499-5p</td>
<td>mirnaUID1007</td>
<td>TTAAGACTTTGCTGAGTTTT</td>
<td>11.96</td>
</tr>
<tr>
<td>mml-miR-208b</td>
<td>mirnaUID0997</td>
<td>AATAAGACGAACAAAAAGGGTTT</td>
<td>10.88</td>
</tr>
<tr>
<td>mml-miR-363</td>
<td>mirnaUID2513</td>
<td>AATTTGACCGGTATCCCTAGTTA</td>
<td>10.08</td>
</tr>
<tr>
<td>hsa-miR-378d</td>
<td>mirnaUID0020</td>
<td>ACTGGAATTGGATCGAAGAAA</td>
<td>6.63</td>
</tr>
<tr>
<td>mml-miR-133a</td>
<td>mirnaUID0646</td>
<td>TTGCCCTCCATCACCAGCTG</td>
<td>6.04</td>
</tr>
<tr>
<td>mml-miR-30e</td>
<td>mirnaUID0677</td>
<td>TGAAACATCCCTGGACTGGAAG</td>
<td>5.87</td>
</tr>
<tr>
<td>mml-miR-10b</td>
<td>mirnaUID2476</td>
<td>TACCCCTGTAAGACCCAATTGTTG</td>
<td>5.37</td>
</tr>
<tr>
<td>mml-miR-133c, hsa-miR-133a</td>
<td>mirnaUID0106</td>
<td>TTGGTCCCCCTCAACCAGCTG</td>
<td>5.21</td>
</tr>
<tr>
<td>hsa-miR-30d*</td>
<td>mirnaUID0175</td>
<td>CTTTCAGTCAGATGTGTTGCTGC</td>
<td>4.93</td>
</tr>
<tr>
<td>hsa-miR-30e*</td>
<td>mirnaUID1498</td>
<td>CTTTCAGTCAGATGTTTACACGC</td>
<td>4.64</td>
</tr>
<tr>
<td>hsa-miR-145*</td>
<td>mirnaUID0432</td>
<td>ATTCCTGGAAATTACTGTCTTG</td>
<td>4.63</td>
</tr>
<tr>
<td>mml-miR-133b</td>
<td>mirnaUID2652</td>
<td>TTGGGTCCCCCTCAACCAGCTA</td>
<td>4.55</td>
</tr>
<tr>
<td>mml-miR-143</td>
<td>mirnaUID0897</td>
<td>TGAGATGAGCAGCAGGTACCTCA</td>
<td>4.33</td>
</tr>
<tr>
<td>mml-miR-29b</td>
<td>mirnaUID0341</td>
<td>TAGCACCATTGAAATCAGTG</td>
<td>4.21</td>
</tr>
<tr>
<td>miRNA ID</td>
<td>Accession ID</td>
<td>Target Sequence</td>
<td>Score</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------</td>
<td>---------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>mml-miR-29c</td>
<td>mirnaUID2148</td>
<td>TAGCACCATTGAAATCGGTTA</td>
<td>4.11</td>
</tr>
<tr>
<td>mml-miR-22</td>
<td>mirnaUID2497</td>
<td>AAGCTGCCAGTTGAAGAACTGT</td>
<td>4.06</td>
</tr>
<tr>
<td>mml-miR-30a-5p, hsa-miR-30a</td>
<td>mirnaUID0712</td>
<td>TGTAACATCTCCTGACTGGAAGC</td>
<td>3.63</td>
</tr>
<tr>
<td>mml-miR-30b, mml-miR-30c, hsa-miR-30b</td>
<td>mirnaUID2059</td>
<td>TGTAACATCCTACACTCTCAGCT</td>
<td>3.50</td>
</tr>
<tr>
<td>hsa-miR-30c-1*</td>
<td>mirnaUID0178</td>
<td>CTGGGAGAGGGTTTTACTCC</td>
<td>3.36</td>
</tr>
<tr>
<td>mml-miR-1, hsa-miR-1</td>
<td>mirnaUID0152</td>
<td>TGGAATGAAAGAATGATATGTAT</td>
<td>3.23</td>
</tr>
<tr>
<td>mml-miR-301a</td>
<td>mirnaUID2381</td>
<td>CAGTGCAATAGTATTGCTAAGGC</td>
<td>3.21</td>
</tr>
<tr>
<td>hsa-miR-378i</td>
<td>mirnaUID1256</td>
<td>ACTGGACTAGGATGACTGAGG</td>
<td>3.14</td>
</tr>
<tr>
<td>mml-miR-338-3p</td>
<td>mirnaUID1371</td>
<td>TCCAGCATCAGTGGATTTGTTGA</td>
<td>3.08</td>
</tr>
<tr>
<td>hsa-miR-3065-5p</td>
<td>mirnaUID1514</td>
<td>TCAACAAAATCAGTGACTGGA</td>
<td>3.08</td>
</tr>
<tr>
<td>mml-miR-378, hsa-miR-378c</td>
<td>mirnaUID0205</td>
<td>ACTGGACTTGGAGTGCAAGAGTGG</td>
<td>2.97</td>
</tr>
<tr>
<td>mml-miR-142-5p</td>
<td>mirnaUID0690</td>
<td>CATAAAGTAGAAAGCAGACTACT</td>
<td>2.93</td>
</tr>
<tr>
<td>mml-miR-27b</td>
<td>mirnaUID2565</td>
<td>TTCAACAGTGTTAGGTTCTG</td>
<td>2.91</td>
</tr>
<tr>
<td>mml-miR-340</td>
<td>mirnaUID0680</td>
<td>TTATAAAGCAATGAGACTGATT</td>
<td>2.72</td>
</tr>
<tr>
<td>mml-miR-451</td>
<td>mirnaUID2416</td>
<td>AAACCGTTACCATTACTGAGTT</td>
<td>2.53</td>
</tr>
<tr>
<td>hsa-miR-126*</td>
<td>mirnaUID1796</td>
<td>CATTATTACTTTTGGTACGCG</td>
<td>2.45</td>
</tr>
<tr>
<td>mml-miR-107</td>
<td>mirnaUID1208</td>
<td>AGCAGCATTGTACAGGGCTATCA</td>
<td>2.43</td>
</tr>
<tr>
<td>mml-miR-150</td>
<td>mirnaUID1542</td>
<td>TCTCACAACCTTGTACCAGTG</td>
<td>2.43</td>
</tr>
<tr>
<td>mml-miR-221</td>
<td>mirnaUID2188</td>
<td>AGCTACATTGTCTGCTGGGTTC</td>
<td>2.41</td>
</tr>
<tr>
<td>mml-miR-30d</td>
<td>mirnaUID0941</td>
<td>TGTAACATCAGCAGTGGAAGCT</td>
<td>2.32</td>
</tr>
<tr>
<td>mml-miR-101</td>
<td>mirnaUID1884</td>
<td>TACAGTACTGTGATAACTGAAG</td>
<td>2.22</td>
</tr>
<tr>
<td>mml-let-7f</td>
<td>mirnaUID1332</td>
<td>TGAGGATGATGATGTATAGTT</td>
<td>2.21</td>
</tr>
<tr>
<td>mml-miR-126, hsa-miR-126</td>
<td>mirnaUID0048</td>
<td>TCGTACCGTGAGTAATAATGCG</td>
<td>2.20</td>
</tr>
<tr>
<td>mml-miR-148b</td>
<td>mirnaUID1084</td>
<td>TCAGTGCATACAGAAGCCTTGT</td>
<td>2.14</td>
</tr>
<tr>
<td>mml-miR-30a-3p, hsa-miR-30a*</td>
<td>mirnaUID1016</td>
<td>CTTTCAGTCGGATGTGGTGAGC</td>
<td>2.12</td>
</tr>
<tr>
<td>mml-miR-222</td>
<td>mirnaUID1145</td>
<td>AGCTACATCGTGCTGTGGAAT</td>
<td>2.03</td>
</tr>
</tbody>
</table>
## Supplementary table 3-4: Canine cardiac structure enriched microRNAs

<table>
<thead>
<tr>
<th>miRNA</th>
<th>id</th>
<th>Sequence</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valves</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cfa-miR-204, hsa-miR-204</td>
<td>mirnaUID0307</td>
<td>TTTCCCTTTGTCTCATCTATGCCT</td>
<td>8.17</td>
</tr>
<tr>
<td>cfa-miR-127, hsa-miR-127-3p</td>
<td>mirnaUID0088</td>
<td>TCGGATCCCGTCTGAGCTTGCT</td>
<td>4.29</td>
</tr>
<tr>
<td>cfa-miR-328, hsa-miR-328</td>
<td>mirnaUID1067</td>
<td>CTGCCCCTCCTCTGCCCTTCCGT</td>
<td>3.52</td>
</tr>
<tr>
<td>hsa-miR-744</td>
<td>mirnaUID0939</td>
<td>TCGGGGCTAGGGCTAACAGCA</td>
<td>3.32</td>
</tr>
<tr>
<td>cfa-miR-199, hsa-miR-199a-3p, hsa-miR-199b-3p</td>
<td>mirnaUID2023</td>
<td>ACAGTAGTCTGCACATGGTTA</td>
<td>3.15</td>
</tr>
<tr>
<td>cfa-miR-320, hsa-miR-320a, hsa-miR-320d</td>
<td>mirnaUID0965</td>
<td>AAAAGCTGGGTTAGAGGCGGA</td>
<td>3.07</td>
</tr>
<tr>
<td>cfa-let-7c, hsa-let-7c</td>
<td>mirnaUID1210</td>
<td>TGAGGTAGTAGGGTTGTATGGT</td>
<td>2.71</td>
</tr>
<tr>
<td>cfa-miR-99b, hsa-miR-99b</td>
<td>mirnaUID0532</td>
<td>CACCCGTAAGACCGACCTTGCG</td>
<td>2.40</td>
</tr>
<tr>
<td>cfa-let-7e, hsa-let-7e</td>
<td>mirnaUID2686</td>
<td>TGAGGTAGGGCTTTGTATAGGT</td>
<td>2.27</td>
</tr>
<tr>
<td>hsa-miR-151-3p</td>
<td>mirnaUID1826</td>
<td>CTAGACTGAAGCTCCTTGAGG</td>
<td>2.25</td>
</tr>
<tr>
<td>cfa-miR-149, hsa-miR-149</td>
<td>mirnaUID2194</td>
<td>TCTGGCTCCGTGTCCTCCTCCC</td>
<td>2.21</td>
</tr>
<tr>
<td>cfa-miR-181b, hsa-miR-181b</td>
<td>mirnaUID0653</td>
<td>AACATTGATGTGCTTGCTGTT</td>
<td>2.18</td>
</tr>
<tr>
<td>cfa-miR-125b, hsa-miR-125b</td>
<td>mirnaUID2699</td>
<td>TCCCTGAGACCCCTAACTTGTA</td>
<td>2.18</td>
</tr>
<tr>
<td>cfa-miR-152, hsa-miR-152</td>
<td>mirnaUID1339</td>
<td>TCAGTGACATGAACAGTCTTGG</td>
<td>2.07</td>
</tr>
<tr>
<td><strong>Myocardium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cfa-miR-208b</td>
<td>mirnaUID0997</td>
<td>ATAAGACGAAACAAAGGGTTGTG</td>
<td>70.0304</td>
</tr>
<tr>
<td>cfa-miR-31, hsa-miR-31</td>
<td>mirnaUID1686</td>
<td>AGGCAAGATGCTGGCATAGCTGTG</td>
<td>17.620426</td>
</tr>
<tr>
<td>cfa-miR-499, hsa-miR-499-5p</td>
<td>mirnaUID1007</td>
<td>TTAAGACTTGAGTGATGTTT</td>
<td>17.01442</td>
</tr>
<tr>
<td>miRNA</td>
<td>ID</td>
<td>Sequence</td>
<td>Score</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td>-------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>hsa-miR-499a-3p</td>
<td>mimaUID0074</td>
<td>AACATCAGTAAGTCTAAACA</td>
<td>16.83687</td>
</tr>
<tr>
<td>cfa-miR-1,hsa-miR-1</td>
<td>mimaUID0152</td>
<td>TGGAATGTAAGAAGATGTAT</td>
<td>9.188781</td>
</tr>
<tr>
<td>hsa-miR-378i</td>
<td>mimaUID1256</td>
<td>ACTGGACATGGAGTCAGAAGG</td>
<td>5.7802687</td>
</tr>
<tr>
<td>hsa-miR-378d</td>
<td>mimaUID0020</td>
<td>ACTGGACCTGGAGTCAGAAA</td>
<td>4.8989153</td>
</tr>
<tr>
<td>cfa-miR-378,hsa-miR-378c</td>
<td>mimaUID0205</td>
<td>ACTGGACCTGGAGTCAGAAGG</td>
<td>4.191974</td>
</tr>
<tr>
<td>hsa-miR-133a</td>
<td>mimaUID0106</td>
<td>TTTGGTCCCCCTCAACCAGCTG</td>
<td>4.075601</td>
</tr>
<tr>
<td>cfa-miR-133a,cfa-miR-133c</td>
<td>mimaUID0013</td>
<td>TTGGTCCCCCTCAACCAGCTG</td>
<td>4.07559</td>
</tr>
<tr>
<td>cfa-miR-30b,cfa-miR-30c,hsa-miR-30b,hsa-miR-30c</td>
<td>mimaUID2059</td>
<td>TGTAACATCCCTACACTCTAGCAGT</td>
<td>3.9003046</td>
</tr>
<tr>
<td>cfa-miR-126,hsa-miR-126*</td>
<td>mimaUID1796</td>
<td>CATTATTACTTTTGTTACTGCG</td>
<td>3.619509</td>
</tr>
<tr>
<td>hsa-miR-126</td>
<td>mimaUID0048</td>
<td>TCGTACGTGTTAATAATGCG</td>
<td>3.5997996</td>
</tr>
<tr>
<td>hsa-miR-486-5p</td>
<td>mimaUID1023</td>
<td>TCCTGTAATGGCTGCCCAGG</td>
<td>3.3498151</td>
</tr>
<tr>
<td>cfa-miR-363,hsa-miR-363</td>
<td>mimaUID2513</td>
<td>AATTGCACGACTCCTACACTCTAGC</td>
<td>3.2826152</td>
</tr>
<tr>
<td>hsa-miR-486-3p</td>
<td>mimaUID2078</td>
<td>CGGGGCAGCTCAGTCAGGAT</td>
<td>3.1971457</td>
</tr>
<tr>
<td>cfa-miR-133b</td>
<td>mimaUID2652</td>
<td>TTGGTCCCCCTCAACCAGCTA</td>
<td>3.1729188</td>
</tr>
<tr>
<td>hsa-miR-30d*</td>
<td>mimaUID0175</td>
<td>CTTCCAGTCAGATGGTTGCTG</td>
<td>3.1622963</td>
</tr>
<tr>
<td>cfa-miR-30d,hsa-miR-30d</td>
<td>mimaUID0941</td>
<td>TGTAACATCCCGAGCTGGAAGCT</td>
<td>2.9301157</td>
</tr>
<tr>
<td>cfa-miR-10b,hsa-miR-10b</td>
<td>mimaUID2476</td>
<td>TACCCCTGTAAGCCAATTGTTG</td>
<td>2.885671</td>
</tr>
<tr>
<td>cfa-miR-30e,hsa-miR-30e*</td>
<td>mimaUID1498</td>
<td>CTTCAGTCGATGTTTACAGC</td>
<td>2.8295717</td>
</tr>
<tr>
<td>hsa-miR-30e</td>
<td>mimaUID0677</td>
<td>TGTAACATCCTTGACTGGAAG</td>
<td>2.8032448</td>
</tr>
<tr>
<td>cfa-miR-30a,hsa-miR-30a</td>
<td>mimaUID0712</td>
<td>TGTAACATCCTGACTGGAAGC</td>
<td>2.5368807</td>
</tr>
<tr>
<td>cfa-miR-144,hsa-miR-144</td>
<td>mimaUID1312</td>
<td>TACAGTATAGAGATGTCAGT</td>
<td>2.46647</td>
</tr>
<tr>
<td>miRNA</td>
<td>id</td>
<td>Sequence</td>
<td>Fold enrichment</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------</td>
<td>---------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>cfa-miR-184,hsa-miR-184</td>
<td>mirnaUID1958</td>
<td>TGGACGGGAGAAGCTGATAAGGGT</td>
<td>41.79</td>
</tr>
<tr>
<td>cfa-miR-208a</td>
<td>mirnaUID2674</td>
<td>ATAAAGACGAGCAAAAAAGCTTGT</td>
<td>31.20</td>
</tr>
<tr>
<td>cfa-miR-490,hsa-miR-490-3p</td>
<td>mirnaUID0503</td>
<td>CAACCTGGAGGACTCCATGCTG</td>
<td>4.09</td>
</tr>
<tr>
<td>cfa-miR-221,hsa-miR-221</td>
<td>mirnaUID2188</td>
<td>AGCTACATTGTCTGCTGGTTTC</td>
<td>2.47</td>
</tr>
<tr>
<td>cfa-miR-222,hsa-miR-222</td>
<td>mirnaUID1145</td>
<td>AGCTACATCTGGCTACTGGGT</td>
<td>2.38</td>
</tr>
<tr>
<td>cfa-miR-204,hsa-miR-204</td>
<td>mirnaUID0307</td>
<td>TTCCCTTTGTCTCCTATGCTC</td>
<td>2.32</td>
</tr>
</tbody>
</table>

**Supplementary table 3-5: Normalized miRNA seq reads for mir-1, miR-125b-5p, miR-204 and miR-208b in rat myocardium or valves.**

<table>
<thead>
<tr>
<th>Rat miRNA</th>
<th>Valve seq reads</th>
<th>Myocardium seq reads</th>
<th>Average Ct</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Valves</td>
<td>Myocardium</td>
<td>Valve seq</td>
</tr>
<tr>
<td>mmu-miR-1a</td>
<td>141</td>
<td>1223</td>
<td>15</td>
</tr>
<tr>
<td>miR-125b-5p</td>
<td>17256</td>
<td>2506</td>
<td>17</td>
</tr>
<tr>
<td>miR-204</td>
<td>4482</td>
<td>244</td>
<td>18</td>
</tr>
<tr>
<td>miR-208b</td>
<td>814</td>
<td>11250</td>
<td>30</td>
</tr>
</tbody>
</table>
Supplementary figure 3-2: Correlation of 4 cardiac disease relevant genes with putative targeting microRNA in canine. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 normalized intensity for the indicated probe set. Black curve represents log2 scaled and normalized microRNA read counts. Three replicates are plotted for each structure.
Supplementary figure 3-3: Correlation 4 cardiac disease relevant genes with putative targeting microRNA in Cyno monkey. Timp3 and miR-1 (A), Rbm24 and miR-125b-5p (B), Tgfbr2 and miR-204 (C), Csnk2a2 and miR-208b (D). Green curve represents log2 normalized intensity for the indicated probe set. Black curve represents log2 scaled and normalized microRNA read counts. Three replicates are plotted for each structure.
Supplementary figure 3-4: Robustness of microRNA seq and validation with qPCR. Data obtained with miRNAseq or TLDA cards are compared for each rat cardiac sample. $r_s = \text{Spearman’s rank correlation}$, $r = \text{Pearson’s correlation}$. 
Supplementary figure 3-6: Gene ontology analysis of all Targetscan putative targets of structure-enriched conserved microRNA targets. Targets of conserved myocardial enriched microRNAs (A). Targets of conserved valves enriched microRNAs (B).
Supplementary figure 3-7: Cloning of 3’ UTRs of Timp3, Csnk2a2, Rbm24, Rbm38, Tgfbr2 and Akap2 in pmiR-GLO. Yellow arrows indicate ORFs. Grey arrows identify the region surrounding the microRNA Targetscan targeting site cloned in pmiR-GLO.
Chapter 4: Concluding discussion

4.1 Brief summary of results

In the context of toxicogenomics, it would be desirable to be able to interpret the results of microRNAs profiling upon xenobiotics administration in terms of “functional signatures”, similarly to what is possible today with mRNAs expression. However in order to do this, much more information is needed on the real microRNAs “targetome”, and on microRNAs relative distribution across the tissues of the model species.

In this thesis we generated data that can support further elucidation of the molecular mechanisms of cardiac function and drug-induced cardiomyopathy. First, we identified a microRNAs signature altered by an anti-tumoral agent known for its cardiotoxicity (doxorubicin), and proposed a link with concomitant transcriptome variation, and we could identify a novel direct microRNAs-mRNAs interaction (miR-34/Sipa1). Second, we have uncovered the spatial distribution of microRNAs and mRNAs in 8 cardiac structures of rat, dog and Cynomolgus monkey, with a level of detail never achieved before in these model species. A subset of microRNAs with a patterned expression across cardiac structures was further characterized and 3 novel targets relevant for cardiac biology were validated (Timp3, Rbm24, Csnk2a2).

Ideally, our findings will contribute to develop more predictive safety models for drug development, especially for cardiac toxicity.

4.2 MicroRNAs toxicity/pharmacodynamics indicators in the tissue

We identified for the first time the microRNAs dysregulated \textit{in vivo} by DOX in the rat heart. Notably, 2 of them (miR-216b and miR-367) were increased earlier than first signs of cardiotoxicity. Importantly the myomiR miR-208b was
increased concomitantly with its genomic host gene, Myh7, underpinning the occurrence of a dose/time dependent cardiac remodeling. However, since a consistent number of DOX-induced microRNAs were not previously characterized, it was difficult to suggest their implication in pathological events associated to DOX in the heart. In particular, we could not find evidence of a correlation between the DOX-induced microRNAs with autophagy or fibrosis (data not shown and Supplementary figure 2-5), two mechanisms that can contribute to DOX-induced cardiac toxicity (Kobayashi et al., 2010). In first place, there were no clear signs of autophagy induction from the gene expression in vivo, and we did not observe any concomitant increase of DOX-induced microRNAs in neonatal rat ventricular myocytes treated with DOX (data not shown). However, it is possible that the signals of the autophagy gene signature would be diluted, as only a few myocytes displayed lesions compatible with autophagy. Importantly, the use of a non-cardiotoxic Top2 inhibitor (etoposide, EPS) suggests that the increase of miR-215, mir-216b, miR-208b, mIR-34c and miR-367 is DOX specific. We could not exclude that these microRNAs could be implicated in other toxic events implicated with DOX cardiotoxicity, such as mitochondrial stress (Thompson et al., 2009).

Nevertheless, consistently with the anti-proliferative effect of DOX, a subset of the dysregulated microRNAs were related to cell proliferation, including the 4 upregulated onco-suppressors (miR-215, miR-216b, miR-31 and miR-708), the 2 p53 transcriptional responders (miR-34c and miR-215) and 1 down-regulated onco-miR (miR-221) (Supplementary table 2-5).

Therefore, although we could not elucidate a critical toxic pathway that directly involved the microRNAs (with the exception of mir-208b over-expression that most likely is a consequence of its host gene up-regulation), those microRNAs that were related to arrest of cell proliferation could be potential pharmacodynamics endpoints for anti-proliferative drugs for example.
4.3 Heterogeneity of heart tissue and cross-species heart atlas

Tissues and organs are heterogeneous, and it is often debatable how tissues should be sampled in order to capture relevant molecular changes. In addition to the well studied ischemic diseases, cardiovascular liabilities relevant to drug safety include dilated cardiomyopathy, arrhythmias, contractile toxicity, valvular and secondary toxicity leading to heart failure (Stummann et al., 2009). Other than ventricle walls, also atrial walls, cardiac valves, papillary muscles and septum can be involved in cardiac pathologies of different etiology. However little is known about the molecular mechanisms implicated in remodeling and diseases affecting these areas. This has particular relevance in the case of drug-induced valvular toxicity, which is often assessed neither during histopathological readouts, nor with toxicogenomics.

We addressed the cardiac heterogeneity issue by combining microRNAs sequencing and gene expression microarrays from 8 distinct cardiac structures and generated a large amount of data highly relevant to the preclinical cardiac safety assessment for rat, dog and Cynomolgus monkey, three species widely used in pharmacological research, but not much as basic research models, and therefore still poorly annotated.

It was evident that each cardiac zone can be differentiated by the pattern of expression of both mRNAs and microRNAs. Structures mainly composed of cardiomyocytes (ventricles, apex, septum and papillary muscles) of course were very similar, while atria and valves were markedly distinct. In a word, when generating the expression profiles of generic heart samples, the cardiomyocytes “fingerprint” is predominant, and we would recommend defining the highly expressed mRNAs or microRNAs as “cardiomyocytes” specific, rather then “heart” specific.
Figure 4-1: Percentual representation of selected gene lists in 8 cardiac structures of the heart. LA=left atrium, RA= right atrium. Six gene lists were manually curated and contained in total 222 Affymetrix probe sets.

In conclusion, our data sets will allow researchers to obtain more accurate cardiac samples and to detect dissection abnormalities by looking at the percentual composition of structure enriched genes or microRNAs, as exemplified in Figure 4-1.

Gene/microRNAs structure signatures can help to understand whether an increase/decrease of a certain transcript in a complex tissue is reflecting a real increase of the average cellular content of the transcripts, or rather an over-/under-representation of a specific cell type/structure due to the applied stimulus.

4.4 Cardiac microRNAs-mRNAs regulatory circuits and pathways

One challenge of microRNAs research is to characterize their function by defining the real targets, among all the predicted ones. Systematic identification of functional microRNAs targets and their co-distribution across tissues/organs/cell types is crucial to elucidate microRNAs-controlled regulatory circuitries. At present, it is not yet possible to associate alteration in specific microRNAs expression to pathways and biological processes (GO analysis) altered upon drug administration, since most the function of the microRNAs is defined by their “targetome”. Extensive comparison between microRNAs and
mRNAs expression will open new avenues for the identification of microRNAs implicated in specific pathways.

Typically, the effect of microRNAs on their target genes is observed by introducing a perturbation in the system (in vitro or in vivo), such as a mutation or pharmacological treatment with an active compound, and we also used pharmacological treatment in the DOX study (see Chapter 2). However we speculated it would be possible to functionalize microRNAs also at the steady state by comparing different tissues. This would identify mainly key microRNAs-mRNAs interactions key to maintain the tissue identity, as discussed in Chapter 3 and briefly below.

4.4.1 Effect of DOX on cardiac remodeling in vivo

We described for the first time that Sipa1 was a direct target of miR-34 family and of miR-34c in particular. This finding is most likely related to the pharmacological effect of DOX, since Sipa1 has been described as pro-metastatic gene (Park et al., 2005), and miR-34 family as onco-suppressors (Ichimura et al., 2010).

A subset of microRNAs involved in fibrosis was monitored by single assay qPCR across the study conditions, with and without DZR co-administration. However only miR-208b was increased by DOX, and brought down to baseline levels by DZR (Supplementary figure 2-5).

DOX was shown to induce autophagy in cardiomyocytes (Kobayashi et al., 2010) and we found clues of miR-34c activity on autophagic regulator Ambra1 in H9c2 cells treated with DOX (Supplementary figure 2-6B), although the observed effect is most probably indirect.

4.4.2 Anti-correlation of microRNAs with target mRNAs at the steady state

The second strategy we employed to identify and validate microRNAs targets was the comparison of heterogeneous, but still highly similar samples. Matched
mRNAs and microRNAs expression from 8 cardiac structures from 3 mammalian species suggested a number of microRNAs/mRNAs anti-correlations interesting for heart physiology and diseases. Direct inhibition of the transcript mediated by the microRNAs was confirmed for 4 candidate genes by reporter assays.

Unexpectedly, one interesting finding was that each of the 2 targeting sites predicted for miR-1/miR-206 family in Timp3 3’UTR were extremely specific for either miR-1 (as shown in Chapter 3) or miR-206 (as shown by Limana et al.). MiR-206 is normally not expressed in the mammalian heart, but was found up-regulated in presence of fibrosis (Limana et al., 2011), while miR-1 is normally down-regulated. The importance of the microRNAs mediated control of this gene was further reinforced by the reportedly high potency of both miR-1 and miR-206 in the Timp3-3’ UTR reporter assay, and the different sites of action argues against the belief that members of the same family should share the same targets.

Further functional studies will be needed to elucidate the role in cardiac physiology of the 3 other miRNA/mRNAs couple described in our work (mir-125b-5p/Rbm24, miR-204/Tgfbr2, mir-208b/Csnk2a2).
Chapter 5: Final remarks and future directions

5.1 MicroRNAs as “early” biomarkers of toxicity in the tissue

In principle, variation of specific microRNAs expression induced by external stimuli (including xenobiotics) can potentially precede downstream molecular alterations of the transcriptome. Therefore microRNAs could be early pharmacodynamics/toxicity biomarkers in the tissue, even earlier than tissue biomarkers (Figure 5-1). This can be exemplified by our finding that miR-1 was able to strongly down-regulate Timp3, a key gene in extra-cellular matrix remodeling and cardiac fibrosis, suggesting that a decrease in miR-1 could be prodromal to an increase in Timp3 associated to a fibrotic process. Furthermore, an important aspect is that microRNAs involved in a specific process (i.e. cell proliferation) may not necessarily be dysregulated by perturbation of that same process (either pharmacological or genetic), as suggested by Jentzsch et al. who identified, via a cardiomyocytes hypertrophy screening, microRNAs that were never found altered in hypertrophy models (Jentzsch et al., 2011).

5.2 MicroRNAs as source of circulating biomarkers of tissue lesions

MicroRNAs are increasingly regarded as promising non-invasive damage biomarkers and these data sets are a resource for circulating indicators of cardiac lesions at the preclinical level. Furthermore, since microRNAs sequences and distribution are usually conserved, observations common to the 3 species could be highly relevant to the human. Our cardiac atlas constitutes a repository for selection of translatable circulating microRNAs for cardiac structure lesions in human.
5.3 Non-canonical regulatory circuits and transcriptional regulation of microRNAs

Increasing interest is growing around specific cases in which microRNAs control of expression extends to RNA-RNA interactions, or in which pseudo-genes modulate microRNAs activity (Poliseno et al., 2010; Sumazin et al., 2011). Open questions remain regarding the regulation of microRNAs expression, and our miRNA seq data sets could be a starting ground for elucidating transcriptional regulation mechanisms.

![Figure 5-1: microRNAs may be earlier predictors of gene expression in toxicogenomics evaluation of drug-induced tissue injury.](image)

However, the scarce genomic annotation of the pre-clinical species used for pharmaceutical research advocates for better annotation, since many choices regarding the patients are done based on the information extracted from these models.


